AU723349B2 - Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases - Google Patents

Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases Download PDF

Info

Publication number
AU723349B2
AU723349B2 AU13525/97A AU1352597A AU723349B2 AU 723349 B2 AU723349 B2 AU 723349B2 AU 13525/97 A AU13525/97 A AU 13525/97A AU 1352597 A AU1352597 A AU 1352597A AU 723349 B2 AU723349 B2 AU 723349B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
group
receptor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU13525/97A
Other versions
AU1352597A (en
Inventor
Linda D Artman
Manuel F. Balandrin
Robert M. Barmore
Eric G Del Mar
Scott T. Moe
Alan L Mueller
Daryl L. Smith
Bradford C. Van Wagenen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Publication of AU1352597A publication Critical patent/AU1352597A/en
Application granted granted Critical
Publication of AU723349B2 publication Critical patent/AU723349B2/en
Priority to AU71810/00A priority Critical patent/AU770292B2/en
Priority to AU2004202114A priority patent/AU2004202114A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/55—Diphenylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Description

1 Description Compounds Active at a Novel Site on Receptor-Operated Calcium Channels Useful for Treatment of Neurological Disorders and Diseases This is a continuation-in-part of co-pending International Patent Application No.
PCT/US96/10201, filed June 7, 1996, which is a continuation-in-part of co-pending application U.S. Serial No. 08/485,038, filed June 7, 1995, which is a continuation-in-part of co-pending International Patent Application No. PCT/US94/12293, filed October 26, 1994, designating the United States, which is a continuation-in-part of co-pending application U.S. Serial No. 08/288,688, filed August 9, 1994, now abandoned, which was a continuation-in-part of co-pending International Patent Application No. PCT/US94/01462, filed February 8, 1994, which is a continuation-in-part of U.S. Serial No. 08/014,813, filed February 8, 1993, now abandoned, all of which are hereby incorporated by reference herein in their entirety.
Field of the Invention 1i This invention relates to compounds useful as neuroprotectants, anticonvulsants, anxiolytics, analgesics, muscle relaxants or adjuvants to general anesthetics. The invention relates as well to methods useful for the treatment of neurological disorders and diseases, including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac arrest or 20 neonatal distress, •*go o*o* oo *oo oo [I:\DAYLIB\libaa]08021.DOC:kww WO 97/46511 PCTIUS96/20697 2 epilepsy, anxiety, and neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis (ALS). The invention relates as well to methods of screening for compounds active at a novel site on receptor-operated calcium channels, and thereby possessing therapeutic utility as neuroprotectants, anticonvulsants, anxiolytics, analgesics, muscle relaxants or adjuvants to general anesthetics, and/or possessing potential therapeutic utility for the treatment of neurological disorders and diseases as described above.
Background of the Invention The following is a description of relevant art, none of which is admitted to be prior art to the claims.
Glutamate is the major excitatory neurotransmitter in the mammalian brain. Glutamate binds or interacts with one or more glutamate receptors which can be differentiated pharmacologically into several subtypes. In the mammalian central nervous system (CNS) there are three main subtypes of ionotropic glutamate receptors, defined pharmacologically by the selective agonists N-methyl-D-aspartate (NMDA), kainate and a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA). The NMDA receptor has been implicated in a variety of neurological pathologies including stroke, head trauma,, spinal cord injury, epilepsy, anxiety, and neurodegenerative diseases such as Alzheimer's Disease (Watkins and Collingridge, The NMDA Receptor, Oxford: WO 97/46511 PCT/US96/20697 3 IRL Press, 1989). A role for NMDA receptors in nociception and analgesia has been postulated as well (Dickenson, A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol.
Sci. 11: 307, 1990). More recently, AMPA receptors have been widely studied for their possible contributions to such neurological pathologies (Fisher and Bogousslavsky, Evolving toward effective therapy for acute ischemic stroke. J. Amer. Med. Assoc. 270: 360, 1993; Yamaguchi et al., Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models.
Epilepsy Res. 15: 179, 1993).
When activated by glutamate, the endogenous neurotransmitter, the NMDA receptor permits the influx of extracellular calcium (Ca 2 and sodium through an associated ion channel. The NMDA receptor allows considerably more influx of Ca 2 than do kainate or AMPA receptors (but see below), and is an example of a receptor-operated Ca 2 channel. Normally, the channel is opened only briefly, allowing a localized and transient increase in the concentration of intracellular Ca 2 ([Ca' 2 which, in turn, alters the functional activity of the cell. However, prolonged increases in [Ca 2 ]i, resulting from chronic stimulation of the NMDA receptor, are toxic to the cell and lead to cell death. The chronic elevation in [Ca 2 resulting from stimulation of NMDA receptors, is said to be a primary cause of neuronal degeneration following a stroke (Choi, Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623, 1988). Overstimulation of NMDA WO 97/46511 PCT/US96/20697 4 receptors is also said to be involved in the pathogenesis of some forms of epilepsy (Dingledine et al., Excitatory amino acid receptors in epilepsy.
Trends Pharmacol. Sci. 11: 334, 1990), anxiety (Wiley and Balster, Preclinical evaluation of N-methyl-D-aspartate antagonists for antianxiety effects: A review. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? NPP Books, Ann Arbor, Michigan, pp.
801-815, 1992), neurodegenerative diseases (Meldrum and Garthwaite, Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11: 379, 1990), and hyperalgesic states (Dickenson, A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol. Sci. 11: 307, 1990).
The activity of the NMDA receptor-ionophore complex is regulated by a variety of modulatory sites that can be targeted by selective antagonists.
Competitive antagonists, such as the phosphonate act at the glutamate binding site, whereas noncompetitive antagonists, such as phencyclidine (PCP), MK-801 or magnesium (Mg 2 act within the associated ion channel (ionophore). There is also a glycine binding site that can be blocked selectively with compounds such as 7-chlorokynurenic acid. There is evidence suggesting that glycine acts as a co-agonist, so that both glutamate and glycine are necessary to fully elicit NMDA receptor-mediated responses. Other potential sites for modulation of NMDA receptor function include a zinc (Zn 2 binding site and a sigma ligand binding site.
Additionally, endogenous polyamines such as spermine are WO 97/46511 PCT/US96/20697 believed to bind to a specific site and so potentiate NMDA receptor function (Ransom and Stec, Cooperative modulation of P[H]MK-801 binding to the NMDA receptor-ion channel complex by glutamate, glycine and polyamines.
J. Neurochem. 51: 830, 1988). The potentiating effect of polyamines on NMDA receptor function may be mediated via a specific receptor site for polyamines; polyamines demonstrating agonist, antagonist, and inverse agonist activity have been described (Reynolds, Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor. Europ. J. Pharmacol. 177: 215, 1990; Williams et al., Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. Neuron 5: 199, 1990). Radioligand binding studies have demonstrated additionally that higher concentrations of polyamines inhibit NMDA receptor function (Reynolds and Miller, Ifenprodil is a novel type of NMDA receptor antagonist: Interaction with polyamines. Molec. Pharmacol. 36: 758, 1989; Williams et al., Effects of polyamines on the binding of 3 H]MK-801 to the NMDA receptor: Pharmacological evidence for the existence of a polyamine recognition site. Molec. Pharmacol. 36: 575, 1989; Sacaan and Johnson, Characterization of the stimulatory and inhibitory effects of polyamines on 3 H]TCP binding to the NMDA receptor-ionophore complex.
Molec. Pharmacol. 37: 572, 1990). This inhibitory effect .of polyamines on NMDA receptors is probably a nonspecific effect not mediated via the polyamine receptor) because patch clamp electro-physiological studies have demonstrated that this inhibition is WO 97/46511 PCTUS96/20697 6 produced by compounds previously shown to act at the polyamine receptor as either agonists or antagonists (Donevan et al., Arcaine Blocks N-Methyl-D-Aspartate Receptor Responses by an Open Channel Mechanism: Whole-Cell and Single-Channel Recording Studies in Cultured Hippocampal Neurons. Molec. Pharmacol. 41: 727, 1992; Rock and Macdonald, Spermine and Related Polyamines Produce a Voltage-Dependent Reduction of NMDA Receptor Single-Channel Conductance. Molec. Pharmacol.
42: 157, 1992).
Recent studies have demonstrated the molecular diversity of glutamate receptors (reviewed by Nakanishi, Molecular Diversity of Glutamate Receptors and Implications for Brain Function. Science 258: 597, 1992). At least five distinct NMDA receptor subunits (NMDAR1 and NMDAR2A through NMDAR2D), each encoded by a distinct gene, have been identified to date. Also, in NMDAR1, alternative splicing gives rise to at least six additional isoforms. It appears that NMDAR1 is a necessary subunit, and that combination of NMDAR1 with different members of NMDAR2 forms the fully functional NMDA receptor-ionophore complex. The NMDA receptor-ionophore complex, thus, can be defined as a hetero-oligomeric structure composed of at least NMDAR1 and NMDAR2 subunits; the existence of additional, as yet undiscovered, subunits is not excluded by this definition. NMDAR1 has been shown to possess binding sites for glutamate, glycine, Mg 2 MK-801, and Zn 2 The binding sites for sigma ligands and polyamines have not yet been localized on NMDA receptor subunits, although ifenprodil recently has been reported to be more potent WO 97/46511 PCT/US96/20697 7 at the NMDAR2B subunit than at the NMDAR2A subunit (Williams, Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol.
Pharmacol. 44: 851, 1993).
Several distinct subtypes of AMPA and kainate receptors have been cloned as well (reviewed by Nakanishi, Molecular diversity of glutamate receptors and implications for brain function. Science 258: 597, 1992). Of particular relevance are the AMPA receptors designated GluR1, GluR2, GluR3, and GluR4 (also termed GluRA through GluRD), each of which exists in one of two forms, termed flip and flop, which arise by RNA alternative splicing. GluR1, GluR3 and GluR4, when expressed as homomeric or heteromeric receptors, are permeable to Ca 2 and are therefore examples of receptor-operated Ca 2 channels. Expression of GluR2 alone or in combination with the other subunits gives rise to a receptor which is largely impermeable to Ca 2 As most native AMPA receptors studied in situ are not Ca2+-permeable (discussed above), it is believed that such receptors in situ possess at least one GluR2 subunit.
Furthermore, it is hypothesized that the GluR2 subunit is functionally distinct by virtue of the fact that it contains an arginine residue within the putative pore-forming transmembrane region II; GluR1, GluR3 and GluR4 all contain a glutamine residue in this critical region (termed the Q/R site, where Q and R are the single letter designations for glutamine and arginine, respectively). The activity of the AMPA receptor is WO 97/46511 PCT/US96/20697 8 regulated by a number of modulatory sites that can be targeted by selective antagonists (Honore et al., Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241: 701, 1988; Donevan and Rogawski, GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10: 51, 1993).
Competitive antagonists such as NBQX act at the glutamate binding site, whereas compounds such as GYKI 52466 appear to act noncompetitively at an associated allosteric site.
Compounds that act as competitive or noncompetitive antagonists at the NMDA receptor are said to be effective in preventing neuronal cell death in various in vitro neurotoxicity assays (Meldrum and Garthwaite, Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11: 379, 1990) and in in vivo models of stroke (Scatton, Therapeutic potential of NMDA receptor antagonists in ischemic cerebrovascular disease in Drug Strategies in the Prevention and Treatment of Stroke, IBC Technical Services Ltd., 1990). Such compounds are also effective anticonvulsants (Meldrum, Excitatory amino acid neurotransmission in epilepsy and anticonvulsant therapy in Excitatory Amino Acids. Meldrum, Moroni, Simon, and Woods New York: Raven Press, p. 655, 1991), anxiolytics (Wiley and Balster, Preclinical evaluation of N-methyl-D-aspartate antagonists for antianxiety effects: A review. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? NPP Books, Ann Arbor, Michigan, pp.
WO 97/46511 PCTfUS96/20697 9 801-815, 1992), and analgesics (Dickenson, A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol. Sci. 11: 307, 1990), and certain NMDA receptor antagonists may lessen dementia associated with Alzheimer's Disease (Hughes, Merz' novel approach to the treatment of dementia. Script No. 1666: 24, 1991).
Similarly, AMPA receptor antagonists have come under intense scrutiny as potential therapeutic agents for the treatment of such neurological disorders and diseases. AMPA receptor antagonists have been shown to possess neuroprotectant (Fisher and Bogousslavsky, Evolving toward effective therapy for acute ischemic stroke. J. Amer. Med. Assoc. 270: 360, 1993) and anticonvulsant (Yamaguchi et al., Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15: 179, 1993) activity in animal models of ischemic stroke and epilepsy, respectively.
The nicotinic cholinergic receptor present in the mammalian CNS is another example of a receptor-operated Ca2+ channel (Deneris et al., Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol.
Sci. 12: 34, 1991). Several distinct receptor subunits have been cloned, and these subunits can be expressed, in Xenopus oocytes for example, to form functional receptors with their associated cation channels. It is hypothesized that such receptor-ionophore complexes are heteropentameric structures. The possible role of WO 97/46511 PCT/US96/20697 nicotinic receptor-operated Ca 2 channels in the pathology of neurological disorders and diseases such as ischemic stroke, epilepsy and neurodegenerative diseases has been largely unexplored.
It has been demonstrated previously that certain spider and wasp venoms contain arylalkylamine toxins (also called polyamine toxins, arylamine toxins, acylpolyamine toxins or polyamine amide toxins) with activity against glutamate receptors in the mammalian CNS (for reviews see Jackson and Usherwood, Spider toxins as tools for dissecting elements of excitatory amino acid transmission. Trends Neurosci. 11: 278, 1988; Jackson and Parks, Spider Toxins: Recent Applications In Neurobiology. Annu. Rev. Neurosci. 12: 405, 1989; Saccomano et al., Polyamine spider toxins: Unique pharmacological tools. Annu. Rep. Med. Chem. 24: 287, 1989; Usherwood and Blagbrough, Spider Toxins Affecting Glutamate Receptors: Polyamines in Therapeutic Neurochemistry. Pharmacol. Therap. 52: 245, 1991; Kawai, Neuroactive Toxins of Spider Venoms. J. Toxicol.
Toxin Rev. 10: 131, 1991). Arylalkylamine toxins were initially reported to be selective antagonists of the AMPA/kainate subtypes of glutamate receptors in the mammalian CNS (Kawai et al., Effect of a spider toxin on glutaminergic synapses in the mammalian brain. Biomed.
Res. 3: 353, 1982; Saito et al., Spider Toxin (JSTX) blocks glutamate synapse in hippocampal pyramidal neurons. Brain Res. 346: 397, 1985; Saito et al., Effects of a spider toxin (JSTX) on hippocampal CA1 neurons in vitro. Brain Res. 481: 16, 1989; Akaike et al., Spider toxin blocks excitatory amino acid responses WO 97/46511 PCT/US96/20697 11 in isolated hippocampal pyramidal neurons. Neurosci.
Lett. 79: 326, 1987; Ashe et al., Argiotoxin-636 blocks excitatory synaptic transmission in rat hippocampal CA1 pyramidal neurons. Brain Res. 480: 234, 1989; Jones et al., Philanthotoxin blocks quisqualate-induced, AMPA-induced and kainate-induced, but not NMDA-induced excitation of rat brainstem neurones in vivo. Br. J.
Pharmacol. 101: 968, 1990). Subsequent studies have demonstrated that while certain arylalkylamine toxins are both nonpotent and nonselective at various glutamate receptors, other arylalkylamines are both very potent and selective at antagonizing responses mediated by NMDA receptor activation in the mammalian CNS (Mueller et al., Effects of polyamine spider toxins on NMDA receptor-mediated transmission in rat hippocampus in vitro. Soc. Neurosci. Abst. 15: 945, 1989; Mueller et al., Arylamine spider toxins antagonize NMDA receptor-mediated synaptic transmission in rat hippocampal slices. Synapse 9: -244, 1991; Parks et al., Polyamine spider toxins block NMDA receptor-mediated increases in cytosolic calcium in cerebellar granule neurons. Soc. Neurosci. Abst. 15: 1169, 1989; Parks et al., Arylamine toxins from funnel-web spider (Agelenopsis aperta) venom antagonize N-methyl-Daspartate receptor function in mammalian brain. J.
Biol. Chem. 266: 21523, 1991; Priestley et al., Antagonism of responses to excitatory amino acids on rat cortical neurones by the spider toxin, argiotoxin-636.
Br. J. Pharmacol. 97: 1315, 1989; Draguhn et al., Argiotoxin-636 inhibits NMDA-activated ion channels expressed in Xenopus oocytes. Neurosci. Lett. 132: 187, WO 97/46511 PCT/US96/20697 12 1991; Kiskin et al., A highly potent and selective N-methyl-D-aspartate receptor antagonist from the venom of the Agelenopsis aperta spider. Neuroscience 51: 11, 1992; Brackley et al., Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins. J. Pharmacol. Exptl.
Therap. 266: 1573, 1993; Williams, Effects of Agelenopsis aperta toxins on the N-methyl-D-aspartate receptor: Polyamine-like and high-affinity antagonist actions. J. Pharmacol. Exptl. Therap. 266: 231, 1993) Inhibition of nicotinic cholinergic receptors by the arylalkylamine toxin philanthotoxin has also been reported (Rozental et al., Allosteric inhibition of nicotinic acetylcholine receptors of vertebrates and insects by philanthotoxin. J. Pharmacol. Exptl. Therap.
249: 123, 1989).
Parks et al. (Arylamine toxins from funnel-web spider (Agelenopsis aperta) venom antagonize N-methyl-D-aspartate receptor function in mammalian brain. J. Biol. Chem. 266: 21523, 1991), describe arylalkylamine spider toxins a-agatoxins) which antagonize NMDA receptor function in mammalian brain.
The authors discuss the mechanism of action of arylalkylamine toxins, and indicate that an NMDA receptor-operated ion channel is the probable site of action of the a-agatoxins, and most probably other spider venom arylalkylamines. They state: The discovery that endogenous polyamines in the vertebrate brain modulate the function of NMDA receptors suggests that the arylamine toxins may produce their PCTIUS96/20697 WO 97/46511 13 antagonism via a polyamine-binding site on glutamate receptors.
Brackley et al. studied the effects of spermine and philanthotoxin 433 on the responses evoked by application of excitatory amino acids in Xenopus oocytes injected with mRNA from rat or chick brain.
These authors reported that, at concentrations below those that antagonize glutamate receptor function, both spermine and philanthotoxin potentiate the effects of excitatory amino acids and some other neurotransmitters.
On the basis of these and other data, Brackley et al. concluded that the arylamine toxins may, by binding nonspecifically to the membranes of excitable cells, reduce membrane fluidity and alter receptor function. The validity of this intriguing idea for NMDA receptor function is not well supported by two recent binding studies.
Reynolds reported that argiotoxin 636 inhibits the binding of [3H]MK-801 to rat brain membranes in a manner that is insensitive to glutamate, glycine, or spermidine.
This author concluded that argiotoxin 636 exerts a novel inhibitory effect on the NMDA receptor complex by binding to one of the Mg 2+ sites located within the NMDA-gated ion channel. Binding data reported by Williams et al.
also support the conclusion that argiotoxin 636 does not act primarily at the polyamine modulatory site on the NMDA receptor, but rather acts directly to produce an activity-dependent block of the ion channel. It is already known that compounds such as phencyclidine and ketamine can block WO 97/46511 PCT/US96/20697 14 the ion channels associated with both arthropod muscle glutamate receptors and mammalian NMDA receptors. Thus, it seems possible that vertebrate and invertebrate glutamate receptors share additional binding sites for allosteric modulators of receptor function, perhaps related to divalent cation-binding sites. Clearly, considerable additional work will be needed to determine if the arylamines define such a novel regulatory site.
Usherwood and Blagbrough (Spider Toxins Affecting Glutamate Receptors: Polyamines in Therapeutic Neurochemistry. Pharmacol. Therap. 52: 245, 1991) describe a proposed intracellular binding site for arylalkylamine toxins (polyamine amide toxins) located within the membrane potential field referred to as the QUIS-R channel selectivity filter. The authors postulate that the binding site for polyamine amide toxins may occur close to the internal entrance of the channel gated by the QUIS-R of locust muscle. The authors also note that one such toxin, argiotoxin-636, selectively antagonizes the NMDA receptor in cultured rat cortical neurons.
Gullak et al. (CNS binding sites of the novel NMDA antagonist Arg-636. Soc. Neurosci. Abst. 15: 1168, 1989), describe argiotoxin-63 6 (Arg-636) as a polyamine (arylalkylamine) toxin component of a spider venom.
This toxin is said to block NMDA-induced elevation of cGMP in a noncompetitive fashion. The authors state that: 125 I]Arg-636 bound to rat forebrain WO 97/46511 PCTIUS96/20697 membranes with Kd and Bmax values of 11.25 AM and 28.95 pmol/mg protein specific). The ability of other known polyamines and recently discovered polyamines from Agelenopsis aperta to inhibit binding paralleled neuroactivity as functional NMDA antagonists. No other compounds tested were able to block specific binding.
The authors then stated that polyamines (arylalkylamines) may antagonize responses to NMDA by interacting with membrane ion channels.
Seymour and Mena (In vivo NMDA antagonist activity of the polyamine spider venom component, argiotoxin-636. Soc. Neurosci. Abst. 15: 1168, 1989) describe studies that are said to show that argiotoxin-636 does not significantly affect locomotor activity at doses that are effective against audiogenic seizures in DBA/2 mice, and that it significantly antagonizes NMDA-induced seizures with a minimal effective dose of 32 mg/kg given subcutaneously Herold and Yaksh (Anesthesia and muscle relaxation with intrathecal injections of AR636 and AG489, two acylpolyamine spider toxins, in rats.
Anesthesiology 77: 507, 1992) describe studies that are said to show that the arylalkylamine argiotoxin-636 (AR636), but not agatoxin-489 (AG489), produces muscle relaxation and anesthesia following intrathecal administration in rats.
Williams (Effects of Agelenopsis aperta toxins on the N-methyl-D-aspartate receptor: Polyamine-like and high-affinity antagonist actions, J. Pharmacol. Exptl.
WO 97/46511 PCTIUS96/20697 16 Therap. 266: 231, 1993) reports that the a-agatoxins (arylalkylamines) Agel-489 and Agel-505 enhance the binding of 3 H]MK-801 to NMDA receptors on membranes prepared from rat brain by an action at the stimulatory polyamine receptor; polyamine receptor agonists occluded the stimulatory effects of Agel-489 and Agel-505 and polyamine receptor antagonists inhibited the stimulatory effect of Agel-505. Higher concentrations of Agel-489 and Agel-505, and argiotoxin-636 at all concentrations tested, had inhibitory effects on the binding of H]MK-801. In Xenopus oocytes voltage-clamped at mV, Agel-505 inhibited responses to NMDA with an ICso of 13 nM; this effect of Agel-505 occurred at concentrations approximately 10,000-fold lower than those that affected [3H]MK-801 binding. Responses to kainate were inhibited only 11% by 30 nM Agel-505. The antagonism of NMDA-induced currents by Agel-505 was strongly voltage-dependent, consistent with an open-channel blocking effect of the toxin. Williams states: Although c-agatoxins can interact at the positive allosteric polyamine site on the NMDA receptor, stimulatory effects produced by this interaction may be masked in functional assays due to a separate action of the toxins as high-affinity, noncompetitive antagonists of the receptor.
Brackley et al. (Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins, J. Pharmacol. Exp. Therap.
266: 1573, 1993) report that the polyamine-containing WO 97/46511 PCTIUS96/20697 17 toxins (arylalkylamines) philanthotoxin-343 (PhTX-343) and argiotoxin-636 (Arg-636) produce reversible, noncompetitive, partly voltage-dependent antagonism of kainate- and NMDA-induced currents in Xenopus oocytes injected with rat brain RNA. Arg-636 was demonstrated to be selective for NMDA-induced responses (IC 0 0.04 MM) compared to kainate-induced responses (ICs 0.07 MM), while PhTX-343 was selective for kainate-induced responses (ICs, 0.12 uM) compared to NMDA-induced responses (IC 50 2.5 Arg-636 more potently antagonized responses to NMDA in Xenopus oocytes expressing cloned NMDAR1 subunits (IC, 5 0.09 uM) than responses to kainate in oocytes expressing either cloned GluRl (IC 50 3.4 4M) or GluR1+GluR2 subunits (IC, 0 300 PhTX-343, on the other hand, was equipotent at antagonizing NMDAR1 (ICs 5 2.19 MM) and GluRl (ICs, 2.8 4M), but much less potent against GluR1+GluR2 subunits (IC, 5 270 MM).
Raditsch et al. (Subunit-specific block of cloned NMDA receptors by argiotoxin-636. FEBS Lett.
324: 63, 1993) report that Arg-636 more potently antagonizes responses in Xenopus oocytes expressing NMDAR1+NMDAR2A subunits (IC 50 9 nM) or NMDAR1+NMDAR2B subunits (IC 50 2.5 nM) than NMDAR1+NMDAR2C subunits (ICs 5 460 nM), even though all of the receptor subunits contain an asparagine residue in the putative pore-forming transmembrane region II (the Q/R site, as discussed above). The authors state that the large difference in Arg-636 sensitivity between NMDAR1+NMDAR2A and NMDAR1+NMDAR2C channels "must be conferred by other structural determinants." WO 97/46511 PCT/US96/20697 18 Herlitz et al. (Argiotoxin detects molecular differences in AMPA receptor channels. Neuron 10: 1131, 1993) report that Arg-636 antagonizes subtypes of AMPA receptors in a voltage- and use-dependent manner consistent with open-channel blockade. Arg-636 potently antagonizes Ca2-permeable AMPA receptors comprised of GluRAi (Ki 0.35 uM), GluRCi (Ki 0.23 MM), or GluRDi subunits 0.43 uM), while being essentially ineffective against Ca 2 *-impermeable GluRBi subunits at concentrations up to 10 gM.
Other data reported by these investigators strongly suggest that the Q/R site in the putative pore-forming transmembrane region II is of primary importance in determining Arg-636 potency and Ca 2 permeability.
Blaschke et al. (A single amino acid determines the subunit-specific spider toxin block of a-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels. Proc. Natl. Acad. Sci. USA 90: 6528, 1993) report that the arylalkylamine JSTX-3 potently antagonizes responses to kainate in Xenopus oocytes expressing GluRl (ICs 5 0.04 gM) or GluR3 (ICs 5 0.03 subunits, but that expressed receptors in which a GluR2 subunit is present are essentially unaffected by the toxin. Site-directed mutagenesis studies strongly implicate the Q/R site as the primary site influencing toxin potency.
Nakanishi et al. (Bioorganic studies of transmitter receptors with philanthotoxin analogs. Pure Appl. Chem., in press) have synthesized a number of highly potent photoaffinity labeled philanthotoxin WO 97/46511 PCTIS96/20697 19 (PhTX) analogs. Such analogs have been studied on expressed nicotinic cholinergic receptors as a model system for receptor-operated calcium channels. These investigators suggest that these PhTX analogs block the ion channel with the hydrophobic headpiece of the toxin binding to a site near the cytoplasmic surface while the polyamine tail extends into the ion channel from the cytoplasmic side.
Summary of the Invention Applicant has examined the structural diversity and biological activity of arylalkylamines (sometimes referred to as arylamine toxins, polyamine toxins, acylpolyamine toxins or polyamine amide toxins) in spider and wasp venoms, and determined that some of the arylalkylamines present in these venoms act as potent noncompetitive antagonists of glutamate receptor-operated Ca 2 channels in the mammalian CNS.
Although these arylalkylamine compounds contain within their structure a polyamine moiety, they are unlike other known simple polyamines in possessing extremely potent and specific effects on certain types of receptor-operated Ca 2 channels.
Using native arylalkylamines as lead structures, a number of analogs were synthesized and tested. Initial findings on arylalkylamines isolated and purified from venom were confirmed utilizing synthetic arylalkylamines. These compounds are small molecules (mol. wt. <800) with demonstrated efficacy in in vivo models of stroke and epilepsy. The NMDA receptor-ionophore complex was used as a model of WO 97/46511 PCT/US96/20697 receptor-operated Ca 2 channels. Selected arylalkylamines were shown to block NMDA receptor-mediated responses by a novel mechanism.
Moreover, the unique behavioral pharmacological profile of these compounds suggests that they are unlikely to cause the PCP-like psychotomimetic activity and cognitive deficits that characterize other inhibitors of the NMDA receptor. Finally, the arylalkylamines are unique amongst NMDA receptor antagonists in that they are able to antagonize certain subtypes of cloned and expressed AMPA receptors, namely, those permeable to Ca 2 The arylalkylamines, therefore, are the only known class of compounds able to antagonize glutamate receptor-mediated increases in cytosolic Ca 2 regardless of the pharmacological definition of receptor subtype.
Additionally, the arylalkylamines inhibit another receptor-operated Ca 2 channel, the nicotinic cholinergic receptor. Given that excessive and prolonged increases in cytosolic Ca 2 have been implicated in the etiology of several neurological disorders and diseases, such arylalkylamines are valuable small molecule leads for the development of novel therapeutics for various neurological disorders and diseases.
Applicant has determined that the selected arylalkylamines bind with high affinity at a novel site on the NMDA receptor-ionophore complex which has heretofore been unidentified, and that said arylalkylamines do not bind with high affinity at any of the known sites (glutamate binding site, glycine binding site, MK-801 binding site, Mg 2 binding site, Zn 2 binding site, polyamine binding site, sigma binding site) on WO 97/46511 PCTIS96/20697 21 said NMDA receptor-ionophore complex. This determination has allowed applicant to develop methods and protocols by which useful compounds can be identified which provide both therapeutically useful compounds and lead compounds for the development of other therapeutically useful compounds. These compounds can be identified by screening for compounds that bind at this novel arylalkylamine binding site, and by determining whether such a compound has the required biological, pharmacological and physiological properties.
The method includes the step of identifying a compound which binds to the receptor-operated Ca 2 channel at that site bound by the arylalkylamine compounds referred to herein as Compound 1, Compound 2 or Compound 3, and having the structures shown below.
ocom H H H H N H O o o NH Compound 1
NH,
H
Compound 2 WO 97/46511 PCT/US96/20697 22 0
H
N N N N
N
NH
2 SH H H H Fe Compound 3 By "therapeutically useful compound" is meant a compound that is potentially useful in the treatment of a disorder or disease state. A compound uncovered by the screening method is characterized as having potential therapeutic utility in treatment because clinical tests have not yet been conducted to determine actual therapeutic utility.
By "neurological disorder or disease" is meant a disorder or disease of the nervous system including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, and neurodegenerative disease. Also meant by "neurological disorder or disease" are those disease states and conditions in which a neuroprotectant, anticonvulsant, anxiolytic, analgesic, muscle relaxant and/or adjunct in general anesthesia may be indicated, useful, recommended or prescribed.
By "neurodegenerative disease" is meant diseases including, but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, and WO 97/46511 PCTIUS96/20697 23 amyotrophic lateral sclerosis (ALS).
By "neuroprotectant" is meant a compound capable of preventing the neuronal damage or death associated with a neurological disorder or disease.
By "anticonvulsant" is meant a compound capable of reducing convulsions produced by conditions such as simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery.
By "anxiolytic" is meant a compound capable of relieving the feelings of apprehension, uncertainty and fear that are characteristic of anxiety.
By "analgesic" is meant a compound capable of relieving pain by altering perception of nociceptive stimuli without producing anesthesia or loss of consciousness.
By "muscle relaxant" is meant a compound that reduces muscular tension.
By "adjunct in general anesthesia" is meant a compound useful in conjunction with anesthetic agents in producing the loss of ability to perceive pain associated with the loss of consciousness.
By "potent" or "active" is meant that the compound has activity at receptor-operated calcium channels, including NMDA receptors, Ca 2 -permeable AMPA receptors, and nicotinic cholinergic receptors, with an
IC
0 s value less than 10 M, more preferably less than 100 nM, and even more preferably less than 1 nM.
By "selective" is meant that the compound is WO 97/46511 PCTUS96/20697 24 potent at receptor-operated calcium channels as defined above, but is less potent by greater than 10-fold, more preferably 50-fold, and even more preferably 100-fold, at other neurotransmitter receptors, neurotransmitter receptor-operated ion channels, or voltage-dependent ion channels.
By "biochemical and electrophysiological assays of receptor-operated calcium channel function" is meant assays designed to detect by biochemical or electrophysiological means the functional activity of receptor-operated calcium channels. Examples of such assays include, but are not limited to, the fura-2 fluorimetric assay for cytosolic calcium in cultured rat cerebellar granule cells (see Example 1 and Example 2), patch clamp electrophysiolocial assays (see Example 3 and Example 27), rat hippocampal slice synaptic transmission assays (see Example radioligand binding assays (see Example 4, Example 24, Example 25, and Example 26), and in vitro neuroprotectant assays (see Example 6).
By "efficacy" is meant that a statistically significant level of the desired activity is detectable with a chosen compound; by "significant" is meant a statistical significance at the p 0.05 level.
By "neuroprotectant activity" is meant efficacy in treatment of neurological disorders or diseases including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxiainduced nerve cell damage, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress, WO 97/46511 PCTIUS96/20697 neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, and neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis (ALS) (see Examples 7 and 8, below).
By "anticonvulsant activity" is meant efficacy in reducing convulsions produced by conditions such as simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery (see Examples 9 and 10, below).
By "anxiolytic activity" is meant that a compound reduces the feelings of apprehension, uncertainty and fear that are characteristic of anxiety.
By "analgesic activity" is meant that a compound produces the absence of pain in response to a stimulus that would normally be painful. Such activity would be useful in clinical conditions of acute and chronic pain including, but not limited to the following: preemptive preoperative analgesia; peripheral neuropathies such as occur with diabetes mellitus and multiple sclerosis; phantom limb pain; causalgia; neuralgias such as occur with herpes zoster; central pain such as that seen with spinal cord lesions; hyperalgesia; and allodynia.
By "causalgia" is meant a painful disorder associated with injury of peripheral nerves.
By "neuralgia" is meant pain in the distribution of a nerve or nerves.
WO 97/46511 PCTIUS96/20697 26 By "central pain" is meant pain associated with a lesion of the central nervous system.
By "hyperalgesia" is meant an increased response to a stimulus that is normally painful.
By "allodynia" is meant pain due to a stimulus that does not normally provoke pain (see Examples 11 through 14, below).
By "induction of long-term potentiation in rat hippocampal slices" is meant the ability of tetanic electrical stimulation of afferent Schaffer collateral fibers to elicit long-term increases in the strength of synaptic transmission at the Schaffer collateral-CAl pyramidal cell pathway in rat hippocampal slices maintained in vitro (see Example 19).
By "therapeutic dose" is meant an amount of a compound that relieves to some extent one or more symptoms of the disease or condition of the patient.
Additionally, by "therapeutic dose" is meant an amount that returns to normal, either partially or completely, physiological or biochemical parameters associated with or causative of the disease or condition. Generally, it is an amount between about 1 nmole and 1 Amole of the compound, dependent on its ECs 0 (ICs 0 in the case of an antagonist) and on the age, size, and disease associated with the patient.
By "impair cognition" is meant the ability to impair the acquisition of memory or the performance of a learned task (see Example 20). Also by "impair congnition" is meant the ability to interfere with normal rational thought processes and reasoning.
By "disrupt motor function" is meant the WO 97/46511 PCTJUS96/20697 27 ability to significantly alter locomotor activity (see Example 15) or elicit significant ataxia, loss of the righting reflex, sedation or muscle relaxation (see Example 16).
By "locomotor activity" is meant the ability to perform normal ambulatory movements.
By "loss of the righting reflex" is meant the ability of an animal, typically a rodent, to right itself after being placed in a supine position.
By "neuronal vacuolization" is meant the production of vacuoles in neurons of the cingulate cortex or retrosplenial cortex (see Example 18).
By "cardiovascular activity is meant the ability to elicit significant changes in parameters including, but not limited to, mean arterial blood pressure and heart rate (see Examples 21 and 22).
By "hyperexcitability" is meant an enhanced susceptibility to an excitatory stimulus.
Hyperexcitability is often manifested as a significant increase in locomotor activity in rodents administered a drug (see Example By "sedation" is meant a calmative effect, or the allaying of activity and excitement. Sedation is often manifested as a significant decrease in locomotor activity in rodents administered a drug (see Example By "PCP-like abuse potential" is meant the potential of a drug to be wrongfully used, as in the recreational use of PCP "angel dust") by man. It is believed that PCP-like abuse potential can be predicted by the ability of a drug to generalize to PCP WO 97/46511 PCT/US96/20697 28 in rodents trained to discriminate PCP from saline (see Example 17.) By "generalization to PCP" is meant that a compound is perceived as being PCP in rodents trained to discriminate PCP from saline (see Example 17).
By "PCP-like psychotomimetic activity" is meant the ability of a drug to elicit in man a behavioral syndrome resembling acute psychosis, including visual hallucinations, paranoia, agitation, and confusion. It is believed that PCP-like psychotomimetic activity can be predicted in rodents by the ability of a drug to produce PCP-like stereotypic behaviors including ataxia, head weaving, hyperexcitability, and generalization to PCP in rodents trained to discriminate PCP from saline (see Example Example 16, and Example 17).
By "ataxia" is meant a deficit in muscular coordination.
By "head weaving" is meant the stereotypic behavior elicited in rodents by PCP in which the head is repeatedly moved slowly and broadly from side to side.
By "pharmaceutical composition" is meant a therapeutically effective amount of a compound of the present invention in a pharmaceutically acceptable carrier, a formulation to which the compound can be added to dissolve or otherwise facilitate administration of the compound. Examples of pharmaceutically acceptable carriers include water, saline, and physiologically buffered saline. Such a pharmaceutical composition is provided in a suitable dose. Such compositions are generally those which are WO 97/46511 PCTIS96/20697 29 approved for use in treatment of a specified disorder by the FDA or its equivalent in non-U.S. countries.
In a related aspect, the invention features a method for treating a neurological disease or disorder, comprising the step of administering a pharmaceutical composition comprising a compound which binds to a receptor-operated calcium channel at the site bound by one of the arylalkylamines Compound 1, Compound 2 and Compound 3, said compound being a potent and selective noncompetitive antagonist at such a receptor-operated calcium channel, and having one or more of the following pharmacological and physiological properties: efficacy in in vitro biochemical and electrophysiological assays of receptor-operated calcium channel function, in vivo anticonvulsant activity, in vivo neuroprotectant activity, in vivo anxiolytic activity, and in vivo analgesic activity; said compound also possessing one or more of the following pharmacological effects: the compound does not interfere with the induction of long-term potentiation in rat hippocampal slices, and, at a therapeutic dose, does not impair cognition, does not disrupt motor performance, does not produce neuronal vacuolization, has minimal cardiovascular activity, does not produce sedation or hyperexcitability, has minimal PCP-like abuse potential, and has minimal PCP-like psychotomimetic activity. By "minimal" is meant that any side effect of the drug is tolerated by an average individual, and thus that the drug can be used for therapy of the target disease. Such side effects are well known in the art and are routinely regarded by the FDA as minimal when it approves a drug for a target WO 97/46511 PCTIUS96/20697 disease.
Treatment involves the steps of first identifying a patient that suffers from a neurological disease or disorder by standard clinical methodology and then treating such a patient with a composition of the present invention.
In a further aspect, the invention features compounds useful for treating a patient having a neurological disease or disorder wherein said compound is a polyamine-type compound or an analog thereof a polyheteroatomic molecule) having the formula
R
I
R
I
R
1
R
1 I Ar- (C)m-CO-NR 1 [ZR- k-N
R
2
R
2
R
2
R
2 wherein Ar is an appropriately substituted aromatic ring, ring system or other hydrophob'ic entity; Ar can be an aromatic carbocyclic aryl groups such as phenyl and bicyclic carbocyclic aryl ring systems such as naphthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, and indenyl), heteroaromatic indolyl, dihydroindolyl, quinolinyl and isoquinolinyl, and their respective 1,2,3,4-tetrahydro- and 2-oxo- derivatives), alicyclic (cycloaliphatic), or heteroalicyclic ring or ring system (mono-, bi-, or tricyclic), having 5- to 7-membered ring(s) optionally substituted with 1 to 5 substituents independently selected from lower alkyl of 1 to 5 carbon atoms, lower haloalkyl of 1 to 5 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 WO 97/46511 PCTIJS96/20697 31 to 5 carbon atoms, halogen, nitro, amino, lower alkylamino of 1 to 5 carbon atoms, amido, lower alkylamido of 1 to 5 carbon atoms, cyano, hydroxyl, sulfhydryl, lower acyl of 2 to 4 carbon atoms, sulfonamido, lower alkylsulfonamido of 1 to 5 carbon atoms, lower alkylsulfoxide of 1 to 5 carbon atoms, lower hydroxyalkyl of 1 to 5 carbon atoms, lower alkylketo of 1 to 5 carbon atoms, or lower thioalkyl of 1 to 5 carbon atoms, each m is an integer from 0 to 3, inclusive, eack k is an integer from 1 to 10, inclusive, each j is the same or different and is an integer from 1 to 12, inclusive, each RI and R 2 independently is selected from the group consisting of hydrogen, lower alkyl of 1 to carbon atoms, lower alkylamino of 1 to 5 carbon atoms, lower alkylamido of 1 to 5 carbon atoms, lower mono-, di-, or trifluoroalkyl of 1 to 5 carbon atoms, hydroxy, amidino, guanidino, or typical common amino acid side chain or with an associated carbon atom R 1 and R 2 taken together form a carbonyl, and each Z is selected from the group consisting of nitrogen, oxygen, sulfur, amido, sulfonamido, and carbon.
WO 97/46511 PCTIUS96/20697 32 Preferred aromatic headgroups include, but are not limited to, the following: r r 00CH 3
Y
Headgroup B T -Y
OH
Headgroup
C
Headqroup A
H
2
N
Headgroup D Headgroup E ___Headgroup F
R
K OR Headgroup WO 97/46511 PCTUS96/20697 33 where Y
R
i
R
1
R
1
R
I I I Ar- m-CO-NR
I
j k-N I I I R2
R
2
R
2
R
2 Preferably the claims claiming a compound exclude known compounds whose chemical structures are enabled.
In further preferred embodiments, the compound is selected from the group of Compounds 4 through 18, where such compounds have the formulae: F
NH
2 F H Compound 4
OCH
3 0
NH
HH
NH
2 -I 0
NH
2
NH
2 Compound
OCH
3 0 0 NH 0 NH2 H N 2 Compound 6
OCH
3 0 0 NH s 0 H N NH2N
SCH
3
NH
2
H
CH
3 Compound 7 PCTIUS96/20697 WO 97/46511 0 N NH 2 11 NH2 compound 8 F J KNK~N.NH 2 Compound 9 OH 0 NH 14 H N2 H
NH
2 Compound Compound 11
NH
2 Compound 12 N. 0 ~0 N- NH 2 Compound 13
NH
2 Compound 14 WO 97/46511 PCTIUS96/20697
OH
O ~O0 NH 2 0 Br Compound BrO O NH 2 Compound 16 -1 0 NH r^ 0, f0 NH 2 Compound 17
OCH
3
H
VO O NH 2 Compound 18 Applicant has also determined (see Example 23 below) that simplified arylalkylamines (see below) are potent, noncompetitive antagonists of the NMDA receptor-ionophore complex. The simplified arylalkylamines are distinct from the arylalkylamines exemplified by Compounds 4-18 as described above. For example, such compounds bind to the site labeled by 3 H]MK-801 at concentrations ranging approximately 1 to 400-fold higher than those which antagonize NMDA receptor-mediated function. Such simplified arylalkylamines possess one or more of the following additional biological properties: significant neuroprotectant activity, significant anticonvulsant 36 activity, significant analgesic activity, no PCP-like stereotypic behavior in rodents (hyperexcitability and head weaving) at effective neuroprotectant, anticonvulsant and analgesic doses, no generlization to PCP in a PCP discrimination assay at effective neuroprotectant, anticonvulsant and analgesic doses, no neuronal vacuolization at effective neuroprotectant, anticonvulsant and analgesic doses, significantly less potent activity against voltage-sensitive calcium channels, and minimal hypotensive activity at effective neuroprotectant, anticonvulsant and analgesic doses. Such compounds may, however, inhibit the induction of LTP in rat hippocampal slices and may produce motor impairment at neuroprotectant, anticonvulsant and analgesic doses.
There is therefore disclosed herein the following compounds: SA compound of the formula: 4 R R 2
NH
2 R7 R2 (X)mwherein: X is independently selected from the group consisting of-Br, -Cl, -CF 3 alkyl, 15 -OH, -OCF 3 -O-alkyl, and -0-acyl; RI is independently selected from the group consisting of-H, lower alkyl and -0-acyl;
R
2 is independently selected from the group consisting of alkyl, and hydroxyalkyl, or both R 2 s together are imino;
R
4 is phenoxy which is optionally substituted with -Cl, -Br, -CF 3 alkyl, -OH, S 20 -OCF 3 -O-alkyl or -0-acyl; provided that when X is H, then R 4 is substituted with meta-fluoro, meta-chloro, orthomethyl, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.
A compound of the formula:
R
1 R4 R R2 Ni2
R
2 wherein: A? wherein: [I:DAYLIB\libaa08021 .DOC:kww 37 X is independently selected from the group consisting of-Br, -Cl, -CF3, alkyl, -OH, -OCF 3 O-alkyl, and -0-acyl; Ri is independently selected from the group consisting of--H, lower alkyl and -O-acyl;
R
2 is independently selected from the group consisting of-H, alkyl, and hydroxyalkyl, or both R 2 S together are imino;
R
4 is phenoxy which is optionally substituted with -Cl, -Br, -CF3, alkyl, -OH,
-OCF
3 -0-alkyl or -0-acyl; provided that when X is H, then R 4 is substituted with meta-fluoro, meta-chloro, orthomethyl, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.
A complex of the formula:
.NHR
3 p p p p p p p wherein 15 X is independently selected from the group consisting of-F, Cl, -Br, -CF 3 alkyl, -OH, -OCF 3 -0-alkyl, and -0-acyl;
R
1 is independently selected from the group consisting of lower alkyl, and alkyl;
R
2 is independently selected from the group consisting of lower alkyl, and hydroxyalkyl, or both R 2 s together are imino; 20 R 3 is selected from the group consisting of methyl and ethyl;
R
4 is phenoxy which is optionally substituted with -Cl, -Br, -CF3, alkyl, -OH,
-OCF
3 -O-alkyl or -0-acyl; provided that when X is para-fluoro, R4 is not meta-CF 3 -substituted phenoxy; and m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.
A compound of the formula:
NHR
3 [I:\DAYLIB\libaa]08021 .DOC:kww wherein: (X)m is selected from the group consisting of meta-fluoro, meta-chloro, ortho-O-lower alkyl, ortho-methyl, ortho-fluoro, ortho-chloro, meta-O-lower alkyl, meta-methyl, ortho- OH, and meta-OH; R1 is H; R2 is H;
R
3 is selected from the group consisting of methyl and ethyl;
R
4 is phenoxy which is optionally substituted with Cl, -Br, -CF 3 alkyl, OH, -OCF 3 -O-alkyl, or -O-acyl; and pharmaceutically acceptable salts and complexes thereof.
A compound of the formula
R
1 R 2 0O (X)mwherein: X is independently selected from the group consisting of--H, -Br, -Cl, -CF3, 1is alkyl, -OH, -OCF 3 -O-alkyl, -0-acyl;
R
1 is independently selected from the group consisting of-H, alkyl, hydroxyalkyl, -OH, O-alkyl, and -0-acyl; :bo: R 2 is independently selected from the group consisting of alkyl, and hydroxyalkyl, or both R 2 s together are imino; 20 R 3 is independently selected from the group consisting of-H, methyl, and ethyl;
R
4 is phenylthio which is optionally substituted with -Cl, -Br, -CF3, alkyl, OH, -OCF 3 -0-alkyl, or -0-acyl; and m is independently an integer from 0 to 5; and pharmaceutically acceptable salts and complexes thereof.
Also disclosed herein is a method of treating a patient having a neurological disease or disorder, the method comprising administering to the patient a compound as described above or pharmaceutically acceptable salts or complexes thereof.
By "patient" is meant any animal that has a cell with an NMDA receptor. Preferably, the animal is a mammal. Most preferably, the animal is a human.
By "alkyl" is meant a branched or unbranched hydrocarbon chain containing between S1 and 6, preferably between 1 and 4, carbon atoms, such as, methyl, ethyl, n-propyl, [I:\DAYLIBIibaa080 2 l 1.DOC:kww 39 iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, 2-methylpentyl, cyclopropylmethyl, allyl, and cyclobutylmethyl.
By "lower alkyl" is meant a branched or unbranched hydrocarbon chain containing between 1 and 4 carbon atoms, of which examples are listed herein.
By "hydroxyalkyl" is meant an alkyl group as defined above, substituted with a hydroxyl group.
By "alkylphenyl is meant an alkyl group as defined above, substituted with a phenyl group.
By "acyl" is meant where R is H or alkyl is defined above, such as, e.g., formyl, acetyl, propionyl, or butyryl; or, R is -O-alkyl such as in alkyl carbonates or R is N-alkyl such as in alkyl carbamates.
By "cycloalkyl" is meant a branched or unbranched cyclic hydrocarbon chain containing between 3 and 12 carbon atoms.
0 *5 0* *o *00 0 [I:\DAYLIB\Iibaa]08021 .DOC:kww I0 PAGES 40 TO 46 HAVE BEEN LEFT INTENTIONALLY BLANK 9, 9 9* 9 9 9. 9* 9 9 99.9 9 999.
9 .99.
9 9 9 *999 9 999 9.9.
p 9 [I:\DAYLIB\Iibaa]08021 .DOC:kww 47 In preferred aspects, the administered compound is selected from the group consisting of Compound 128, 129, 130, 131, 132, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,212, 213,214 and 215.
In preferred embodiments, the methods of treatment include administration of a compound selected from Compounds 19 through 215, or pharmaceutically acceptable salts and complexes thereof. Preferably, the a go* [I:\DAYLIB\libaa]08021 .DOC:kww WO 97/46511 PCT/US96/20697 48 compound has an ICS0, 10 AM at an NMDA receptor, more preferably 2.5 iM, and most preferably 0.5 AM at an NMDA receptor.
In further preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound 19, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 97, 98, 100, 101, 102, 103, 105, 106, 107, 108, 109, 111, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 (potential prodrug), 139, 141, 142, 143, 144, 145,, 146, 147, 148, 149, and 150, and pharmaceutically acceptable salts and complexes thereof.
These compounds have an IC, 0 10/m at an NMDA receptor.
In more preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound 19, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 66, 69, 70, 75, 76, 81, 82, 83, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 100, 101, 102, 103, 105, 106, 108, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 128, 129, 130, 131, 132, 133, 135, 136, 137, 138 (potential prodrug), 139, 142, 144, 145, 146, 147, 148, 149, and 150, and pharmaceutically acceptable salts WO 97/46511 PCT/US96/20697 49 and complexes thereof. These compounds have an IC, 0 /M at an NMDA receptor In other embodiments, the compound is selected from the group consisting of Compound 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 82, 83, 88, 89, 90, 92, 93, 94, 95, 96, 101, 102, 103, 105, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 129, 130, 131, 135, 136, 137, 138, 139, 142, 144, 145, 148, 149, and 150, and pharmaceutically acceptable salts and complexes thereof.
In particularly preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound 19, 20, 21, 22, 23, 24, 25, 27, 28, 30, 31, 32, 33, 38, 39, 43, 44, 46, 47, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 82, 83, 89, 90, 91, 93, 94, 95, 96, 97, 103, 111, 118, 119, 120, 122, 126, 135, 136, 137, 138 (potential prodrug), 142, 144, 145, 147, 148, 149, and 150, and pharmaceutically acceptable salts and complexes thereof. These compounds have an
IC,
0 0.5 AM at an NMDA receptor.
In more preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound 20, 24, 25, 33, 50, 60, 66, 69, 103, 111, 118, 119, 120, 122, 136, 137, 138 (potential prodrug), 142, 144, 145, 148, 149, and 150, and pharmaceutically acceptable salts and complexes thereof.
In particularly preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound WO 97/46511 PCTIUS96/20697 33, 50, 60, 119, and 144, and pharmaceutically acceptable salts and complexes thereof.
In other particularly preferred embodiments, the methods of treatment include administration of a compound selected from the group consisting of Compound 33, 50, 60, 119, and 144, and pharmaceutically acceptable salts and complexes thereof.
In preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 181, 182, 183, 184, 185, 186, 187, and pharmaceutically acceptable salts and complexes thereof. These compounds have an IC5 0 10AuM at an NMDA receptor.
In further preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 181, 185, 186, and pharmaceutically acceptable salts and complexes thereof.
These compounds have an ICs0 10M at an NMDA receptor.
In other more preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 181, 183, 184, 185, 186, 187, and pharmaceutically acceptable WO 97/46511 PCTIUS96/20697 51 salts and complexes thereof. These compounds have an
IC
50 2.5 AM at an NMDA receptor.
In further preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 181, 185, 186, and pharmaceutically acceptable salts and complexes thereof.
These compounds have an IC5 0 2.5 yM at an NMDA receptor.
In other particularly preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 156, 157, 158, 159, 161, 163, 164, 165, 167, 168, 169, 170, 171, 181, 186 and pharmaceutically acceptable salts and complexes thereof.
These compounds have an IC5 0 0.5 LM at an NMDA receptor.
In further preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 167, 168, 169, 170, 171, 181, 186 and pharmaceutically acceptable salts and complexes thereof. These compounds have an IC5 0 0.5 AM at an NMDA receptor.
In other preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder comprising WO 97/46511 PCTIUS96/20697 52 administering a compound selected from the group consisting of Compounds 151 215, and pharmaceutically acceptable salts and complexes thereof.
In more preferred aspects, the invention provides a method for treating a patient having a neurological disease or disorder comprising administering a compound selected from the group consisting of Compound 151, 152, 153, 154, 155, 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 181, 185, 186, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and pharmaceutically acceptable salts and complexes thereof.
The present invention provides simplified arylalkylamines comprising the compounds of Formulas I-IX and all preferred aspects of Formulas I-IX as set out above.
Examples of such simplified arylalkylamines include, but are not limited to, Compounds 19 215, whose structures are provided below. Preferably, the compound has an IC, 0 10 AM at an NMDA receptor. More preferably, the compound has an IC 50 5 AM, more preferably 2.5 MM, and most preferably 0.5 FM at an NMDA receptor.
In preferred embodiments, the compound is selected from the group consisting of Compound 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 78, 79, 82, 83, 84, 88, 89, 90, 92, 93, 94, 95, 96, 98, 101, WO97/46511 PCT/US96/20697 53 102, 103, 105, 107, 108, 109, 111, 115, 116, 118, 119, 120, 121, 122, 124, 125, 126, 127, 129, 130, 131, 134, 135, 136, 137, 138 (potential prodrug), 139, 141, 142, 143, 144, 145, 148, 149, and 150. These compounds have an IC 50 10 AM at an NMDA receptor.
In other embodiments, the compound is selected from the group consisting of Compound 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 82, 83, 88, 89, 90, 92, 93, 94, 95, 96, 101, 102, 103, 105, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 129, 130, 131, 135, 136, 137, 138, 139, 142, 144, 145, 148, 149, and 150.
In more preferred embodiments, the compound is selected from the group consisting of Compound 21, 22, 23, 24, 25, 27, 28, 29, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 82, 83, 88, 89, 90, 92, 93, 94, 95, 96, 101, 102, 103, 105, 108, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 129, 130, 131, 135, 136, 137, 138 (potential prodrug), 139, 142, 144, 145, 148, 149, and 150. These compounds have an IC 0 f 2.5 aM at an NMDA receptor.
In particularly preferred embodiments, the compound is selected from the group consisting of Compound 21, 22, 23, 24, 25, 27, 28, 33, 38, 39, 43, 44, 46, 47, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 82, 83, 89, 90, 93, 94, 95, 96, 103, 111, 118, 119, 120, 122, 126, 135, 136, 137, 138 (potential prodrug), 142, 144, 145, 148, 149, and 150.
These compounds have an IC, 0 0.5 AM at an NMDA receptor.
WO 97/46511 PCTUS96/20697 54 In preferred embodiments, the compound is selected from the group consisting of Compound 24, 33, 50, 60, 66, 69, 103, 111, 118, 119, 120, 122, 136, 137, 138, 142, 144, 145, 148, 149, and 150.
In particularly preferred embodiments, the compound is selected from the group consisting of Compound 20, 33, 50, 60, 119, and 144.
In more particularly preferred embodiments, the compound is selected from the group consisting of Compound 33, 50, 60, 119, and 144.
In other preferred aspects, the compound is selected from the group consisting of Compound 151, 152, 153, 154, 155, 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 181, 185, 186, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and pharmaceutically acceptable salts and complexes thereof.
In other preferred aspects, the compound is selected from the group consisting of Compound 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 181, 185, 186, and pharmaceutically acceptable salts and complexes thereof. These compounds have an IC., 10 AM at an NMDA receptor.
In more preferred aspects, the compound is selected from the group consisting of Compound 157, 158, 159, 163, 164, 167, 168, 169, 170, 171, 181, 185, 186, and pharmaceutically acceptable salts and complexes thereof. These compounds have an IC.
0 2.5 AM at an NMDA receptor.
WO 97/46511 PCTIUS96/20697 In most preferred aspects, the compound is selected from the group consisting of Compound 157, 158, 159, 163, 164, 167, 168, 169, 170, 171, 181, 186, and pharmaceutically acceptable salts and complexes thereof.
These compounds have an IC 50 0.5 AM at an NMDA receptor.
Excluded from the composition of matter aspect of the present invention are known compounds whose chemical structures are covered by the generic formulae presented above.
Also provided in an aspect of the invention are pharmaceutical compositions useful for treating a patient having a neurological disease or disorder. The pharmaceutical compositions are provided in a pharmaceutically acceptable carrier and appropriate dose. The pharmaceutical compositions may be in the form of pharmaceutically acceptable salts and complexes, as is known to those skilled in the art.
The pharmaceutical compositions comprise the compounds of Formulas I-IX and all preferred aspects of Formulas I-IX as set out above.
Preferred pharmaceutical compositions comprise Compounds 19 215. Preferably, the compound has an IC 50 AM at an NMDA receptor. More preferably the compound has an IC 50 5 AM, more preferably 2.5 AM, and most preferably 0.5 AM at an NMDA receptor.
In further preferred embodiments, the pharmaceutical composition comprises a compound selected from the group consisting of Compound 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, WO 97/46511 WO 9746511PCTIUS96/20697 56 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 75, 76, 77, 78, 79, 81, 82, 83, 84, 86, 87, 88, .89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 100, 101, 102, 103, 105, 106, 107, 108, 109, 111, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 (potential prodrug) 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, and 150. These compounds have an IC5 0 10AM at an NNDA receptor.
Preferably, the compound is selected from the group consisting of 21, 22, 23, 24, 25, 26, 27, 28, 29, 33, 34, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 78, 79, 82, 83, 84, 88, 89, 92, 93, 94, 95, 96, 98, 101, 102, 103, 105, 107, 108, 109, 111, 115, 116, 118, 119, 120, 121, 122, 124, 125, 126, 127, 129, 130, 131, 134, 135, 136, 137, 138 (potential prodrug) 139, 141, 142, 143, 144, 145, 148, 149, and 150.
In other embodiments, the compound is selected from the group consisting of 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 69, 76, 82, 83, 88, 89, 90, 92, 93, 94, 95, 96, 101, 102, 103, 105, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 129, 130, 131, 135, 136, 137, 138, 139, 142, 144, 145, 148, 149, and 150.
In more preferred embodiments, the pharmaceutical composition comprises a compound selected from the group consisting of Compound 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58, 59, 60, 6'1, 62, 63, 64, 65, 66, 69, WO 97/46511 PCT/US96/20697 57 76, 81, 82, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 100, 101, 102, 103, 105, 106, 108, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 128, 129, 130, 131, 132, 133, 135, 136, 137, 138 (potential prodrug), 139, 142, 144, 145, 146, 148, 149, and 150.
These compounds have an ICs 0 2.5 iM at an NMDA receptor.
Preferably, the compound is selected from the group consisting of 21, 22, 23, 24, 25, 27, 28, 29, 33, 34, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 76, 82, 83, 88, 89, 90, 92, 93, 94, 96, 101, 102, 103, 105, 108, 109, 111, 115, 118, 119, 120, 121, 122, 125, 126, 127, 129, 130, 131, 135, 136, 137, 138 (potential prodrug), 139, 142, 144, 145, 148, 149, and 150.
In particularly preferred embodiments, the pharmaceutical composition comprises a compound is selected from the group consisting of Compound 20, 21, 22, 23, 24, 25, 27, 28, 30, 31, 32, 33, 38, 39, 43, 44, 46, 47, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 82, 83, 89, 90, 91, 93, 94, 96, 97, 103, 111, 118, 119, 120, 122, 126, 135, 136, 137, 138 (potential prodrug), 142, 144, 145, 148, 149, and 150. These compounds have an IC 50 0.5 gM at an NMDA receptor.
Preferably, the compound is selected from the group consisting of 21, 22, 23, 24, 25, 27, 28, 33, 38, 39, 43, 44, 46, 47, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 69, 82, 83, 89, 90, 93, 94, 95, 96, 103, 111, 118, 119, 120, 122, 126, 135, 136, WO 97/46511 PCTIUS96/20697 58 137, 138 (potential prodrug), 142, 144, 145, 148, 149, and 150.
In more preferred embodiments, the pharmaceutical composition comprises a compound selected from the group consisting of Compound 20, 24, 25, 33, 60, 66, 69, 103, 111, 118, 119, 120, 122, 136, 137, 138, 142, 144, 145, 148, 149, and 150.
Preferably, the compound is selected from the group consisting of Compound 24, 25, 33, 50, 60, 66, 69, 103, 111, 118, 119, 120, 122, 136, 137, 138, 142, 144, 145, 148, 149, and 150.
In most particularly preferred embodiments, the pharmaceutical composition comprises a compound selected from the group consisting of Compound 20, 33, 50, 60, 119, and 144.
Preferably, the compound is selected from the group consisting of 33, 50, 60, 119, and 144.
In other preferred aspects, the pharmaceutical composition comprises a compound selected from the group consisting of compound 151, 152, 153, 154, 155, 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 181, 185, 186, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and pharmaceutically acceptable salts and complexes thereof, and a pharmaceutically acceptable carrier.
In other preferred aspects the pharmaceutical composition comprises a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 181, 185, 186, and WO 97/46511 PCT1US96/20697 59 pharmaceutically acceptable salts and complexes thereof, and a pharmaceutically acceptable carrier. These compounds have an IC, 0 10 1M at an NMDA receptor.
In more preferred aspects, the pharmaceutical composition comprises a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 166, 167, 168, 169, 170, 171, 181, 185, 186, and pharmaceutically acceptable salts and complexes thereof, and a pharmaceutically acceptable carrier. These compounds have an IC 50 2.5 gM at an NMDA receptor.
In most preferred aspects, the pharmaceutical composition comprises a compound which is selected from the group consisting of Compound 157, 158, 159, 163, 164, 167, 168, 169, 170, 171, 181, 186, and pharmaceutically acceptable salts and complexes thereof, and a pharmaceutically acceptable carrier. These compounds have an IC, 0 s 0.5 gM at an NMDA receptor.
Structural modifications can be made to compounds such as 20 or 60 which do not add materially to the structure-activity relationships (SAR) illustrated here. For example, successful bioisosteric replacement or substitution of optionally substituted phenyl groups, such as those occurring in Compounds or 60, can be accomplished with other lipophilic or semi-polar aromatic naphthyl, naphthoxy, benzyl, phenoxy, phenylthio), aliphatic (alkyl, e.g., isopropyl), cycloaliphatic (cycloalkyl, e.g., cyclohexyl), heterocyclic pyridyl, furanyl, thiofuranyl (thiophenyl)], or other functional groups or systems, as is well known in the art, will afford clinically useful compounds (structural homologs, WO 97/46511 PCT/US96/20697 analogs, and/or congeners) with similar biopharmaceutical properties and activity at the NMDA receptor cf. Compounds 37, 75, 79, 83, 89, 119- 122, 125, 126, 128, 130, 132, 137, 144, and 145). For example, such replacements or substitutions have been used to great effect in the development of SAR among other groups of highly clinically and commercially successful synthetic pharmaceutical agents such as the classical H,-antihistamines, anticholinergics (antimuscarinics; anti-Parkinsonians), antidepressants (including tricyclic compounds), and opioid analgesics [See, Foye et al. Principles of Medicinal Chemistry, 4th ed., Lea and Febiger/Williams and Wilkins, Philadelphia, PA, 1995, pp. 233, 265, 281-282, 340-341, 418-427, and 430; Prous, The Year's Drug News, Therapeutic Targets 1995 Edition, Prous Science Publishers, Barcelona, Spain, 1995, pp. 13, 55-56, 58-59, 74, 89, 144-145, 152, 296- 297, and 317]. Similarly, bioisosteric replacement or substitution of the methylene or methine groups in the propyl backbone of compounds such as 20 or 60 with, oxygen, sulfur, or nitrogen, will afford clinically useful NMDA receptor-active compounds with similarly useful biopharmaceutical properties, such as Compound 88 (a modified "classical H,-antihistamine-type" structure), which can be further optimized for activity at the NMDA receptor by preparing, the corresponding compound(s) containing, (bis) (3fluorophenyl) group(s), as taught by the present invention. The propyl backbone of compounds such as and 60 may also be modified successfully by the WO 97/46511 PCT/US96/20697 61 incorporation of ring systems (as in Compounds 102 and 111) and/or unsaturation a double bond, as in Compounds 81, 106, 109, and 139) to afford further clinically useful NMDA receptor-active compounds of the present invention (cf. compounds cited above) In a related aspect, the invention features a method for making a therapeutic agent comprising the steps of screening for said agent by determining whether said agent is active on a receptor-operated calcium channel, and synthesizing said therapeutic agent in an amount sufficient to provide said agent in a therapeutically effective amount to a patient. Said screening may be performed by methods known to those of ordinary skill in the art, and may, for example be performed by the methods set out herein. Those skilled in the art are also familiar with methods used to synthesize therapeutic agents in amounts sufficient to be provided in a therapeutically effective amount.
In a preferred aspect, said receptor-operated calcium channel is an NMDA receptor. In a more preferred aspect, said method further comprises the step of adding a pharmaceutically acceptable carrier to said agent. In a further preferred aspect said therapeutic agent comprises a compound of Formula I, as set out herein. In a further preferred aspect said therapeutic agent comprises a compound of Formula II, III, IV, V, VI, VII, VIII, or IX, as set out herein. In particularly preferred aspects, said therapeutic agent comprises a compound having a structure selected from the group consisting of Formulas I-IX, and all preferred aspects of said formulas as set out herein. In further WO 97/46511 PCTfUS96/20697 62 preferred aspects, said therapeutic agent is selected from the group consisting of Compounds 19-215. In a particularly preferred aspect, said therapeutic agent is provided to a patient having a neurological disease or disorder. In a related aspect, said screening comprises the step of identifying a compound which binds to said receptor-operated calcium channel at a site bound by one of the arylalkylamines Compound 1, Compound 2, and Compound 3.
PCTIUS96/20697 WO 97/46511 63 K- NH 2
NH
2 PCTIUS96/20697 WO 97/46511
NH
2
NH
2 F -NH 2
CH
3 Compound 57 Comnound 55 Compound 56
CH
3 F
NH
2
F
Compound 58
H
NCH
3 Compound 59 Comnound 60 Compound 59 Compound WO 97/46511 PCT1US96/20697 .C-2mound 7 6 PCTIUS96/20697 WO 97/46511 WO 97/46511 PCT/US96/20697 67 WO 97/46511 PCTfUS96/20697 WO 97/46511 PCTIUS96/20697 69 PCTIUS96/20697 WO 97/46511 Compound 151 Compound 154 Compound 155 Compound 156 Compound 157 Compound 158 Compound 160 WO 97/46511 PCTIUS96/20697 Compound 163 Compound 166 Compound 169 F
NN
2
OCH
3 Compound 172 Compound 170 Compound 171 Compound 173 Compound 174 I Compound 175 Compound 177 PCT1US96/20697 WO 97/46511 Compound 178 N"
H
NI-I
Compound 179
H
NCH
3 Compound 180 O~ H2 Compound 183 Co
N
mp
NH
nd Compound 181 Compound 184 Compound 185 N H 2
H
3
CO
H
3
CO
Compound 189
N
NH
2
L
Compound 187 Compound 188 Compound 191 Cmon 9 Compound 192 WO 97/46511 PCT1US96/20697
F
:11r-NH 2
F
NH
2
F
Compound 193 NH2 Compound 196 Compound 194 Compound 195 Compound 197 Compound 198 Compound 199 Compound 200 Compound 201 Compound 202 Compoud 202Compound 203 Compound 204 PCT/US96/20697 WO 97/46511 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
WO 97/46511 PCT/US96/20697 Description of the Preferred Embodiments The following is a detailed description of the methods and tests by which therapeutically useful compounds can be identified and utilized for the treatment of neurological disorders and diseases. The tests are exemplified by use of Compound 1, Compound 2 or Compound 3, but other compounds which have similar biological activity in these assays can also be used (as discovered) to improve on the tests. Lead compounds such as Compound 1, Compound 2 or Compound 3 can be used for molecular modeling using standard procedures, or existing or novel compounds in natural product libraries can be screened by the methods described below.
One key method is the means by which compounds can be quickly screened with standard radioligand binding techniques (a radiolabeled arylalkylamine binding assay) to identify those which bind at the same site on receptor-operated Ca 2 channels as Compound 1, Compound 2 or Compound 3. Data from such radioligand binding studies will also confirm that said compounds do not inhibit [H]arylalkylamine binding via an action at the known sites on receptor-operated Ca 2 channels (such as the glutamate binding site, glycine binding site, MK-801 binding site, Zn2+ binding site, Mg 2 binding site, sigma binding site, or polyamine binding site on the NMDA receptor-ionophore complex). This screening test allows vast numbers of potentially useful compounds to be identified and screened for activity in the other assays. Those skilled in the art will recognize that other rapid assays for detection of binding to the WO 97/46511 PCT/US96/20697 76 arylalkylamine site on receptor-operated Ca 2 channels can be devised and used in this invention.
Additional testing utilizes electrophysiological (patch clamp) methodology to extend the results obtained with the above-mentioned radioligand binding assay. Such results will confirm that compounds binding to the arylalkylamine site are functional, noncompetitive antagonists of receptor-operated Ca 2 channels with the following properties in common with the arylalkylamines themselves: open-channel block manifested as use-dependent block, and voltage-dependent onset and reversal from block. Such results will also confirm that said compounds do not have their primary activity at the previously described sites on receptor-operated Ca 2 channels (such as the glutamate binding site, glycine binding site, MK-801 binding site, Zn 2 binding site, Mg 2 binding site, sigma binding site, or polyamine binding site on the NMDA receptor-ionophore complex).
In addition, recombinant DNA technology can be used to make such testing even more rapid. For example, using standard procedures, the gene(s) encoding the novel arylalkylamine binding site receptor) can be identified and cloned. This can be accomplished in one of several ways. For example, an arylalkylamine affinity column can be prepared, and solubilized membranes from cells or tissues containing the arylalkylamine receptor passed over the column. The receptor molecules bind to the column and are thus isolated. Partial amino acid sequence information is then obtained which allows for the isolation of the gene WO 97/46511 PCTIUS96/20697 77 encoding the receptor. Alternatively, cDNA expression libraries are prepared and subfractions of the library are tested for their ability to impart arylalkylamine receptors on cells which do not normally express such receptors CHO cells, mouse L cells, HEK 293 cells, or Xenopus oocytes). In this way, the library fraction containing the clone encoding the receptor is identified. Sequential subfractionation of active library fractions and assay eventually results in a single clone encoding the arylalkylamine receptor.
Similarly, hybrid-arrest or hybrid-depletion cloning can be used. Xenopus oocytes are injected with mRNA from an appropriate tissue or cell source human brain tissue). Expression of the arylalkylamine receptor is detected as, for example, an NMDA- or glutamate-stimulated influx of calcium which can be blocked by Compound 1, Compound 2 or Compound 3. cDNA clones are tested for their ability to block expression of this receptor when cDNA or cRNA are hybridized to the mRNA of choice, prior to injection into Xenopus oocytes.
The clone responsible for this effect is then isolated by the process described above. Once the receptor gene is isolated, standard techniques are used to identify the polypeptide or portion(s) thereof which is (are) sufficient for binding arylalkylamines (the arylalkylamine binding domain[s]). Further, using standard procedures, the entire receptor or arylalkylamine binding domain(s) can be expressed by recombinant technology. Said receptor or binding domain(s) can be isolated and used as a biochemical reagent such that, rather than using a competitive assay WO97/46511 PCT/US96/20697 78 exemplified below, a simple direct binding assay can be used. That is, a screen is set up for compounds which bind at the novel arylalkylamine receptor. In this way large numbers of compounds can be simultaneously screened, by passage through.a column containing the novel arylalkylamine receptor or arylalkylamine binding domain, and analysis performed on compounds which bind to the column.
Additional testing utilizes the combination of molecular biological techniques (expression of cloned NMDA, AMPA or nicotinic cholinergic receptors) and patch clamp electrophysiological techniques. Specifically, arylalkyl-amine analogs can be rapidly screened for potency at cloned and expressed subunits of the above-mentioned receptor-ionophore complexes.
Site-directed mutagenesis can be utilized in an effort to identify which amino acid residues may be important in determining arylalkylamine potency.
Assays for Potent and Selective Antagonists of Receptor-Operated Calcium Channels in the Mammalian CNS Desired properties of a drug include: high affinity and selectivity for receptor-operated Ca 2 channels, such as those present in NMDA, AMPA and nicotinic cholinergic receptor-ionophore complexes (compared to responses mediated via other neurotransmitter receptors, neurotransmitter receptor-operated ion channels, or voltage-dependent ion channels) and a noncompetitive antagonism of said receptor-operated Ca 2 channels.
WO 97/46511 PCT/US96/20697 79 The NMDA receptor-ionophore complex is utilized as an example of a receptor-operated Ca 2 channel. Activation of the NMDA receptor opens a cation-selective channel that allows the influx of extracellular Ca 2 and Na', resulting in increases in [Ca 2 and depolarization of the cell membrane.
Measurements of [Ca 2 were used as primary assays for detecting the activity of arylalkylamine compounds on NMDA receptors. Purified arylalkylamines, synthetic aryl-alkylamines, and synthetic analogs of arylalkylamines were examined for activity in in vitro assays capable of measuring glutamate receptor activity.
Selected for detailed study were the arylalkylamines present in the venom of various spider species. The arylalkylamines present in these venoms are structurally distinct but have the basic structure of the class represented by Compounds 1 through 3. Other more simplified synthetic analogs generally consist of suitably substituted aromatic chromophoric groups attached to an alkyl(poly)amine moiety (see Compounds 19 through 215 below).
A primary assay that provides a functional index of glutamate receptor activity and that allows high-throughput screening was developed. Primary cultures of rat cerebellar granule cells loaded with the fluorimetric indicator fura-2 were used to measure changes in [Ca 2 elicited by NMDA and its coagonist glycine. This assay provides an extremely sensitive and precise index of NMDA receptor activity. Increases in [Ca2+]i evoked by NMDA are dependent on the presence of glycine, and are blocked by extracellular Mg 2 or WO 97/46511 PCT/US96/20697 antagonists acting at the glutamate, glycine, or MK-801 binding sites. Increases in [Ca 2 elicited by NMDA/glycine are readily distinguished from those resulting from depolarization by their refractoriness to inhibition by blockers of voltage-sensitive Ca 2 channels. The fidelity with which measurements of [Ca 2 'i corroborate results obtained by electrophysiological and ligand-binding studies suggests that such measurements mirror closely activation of the NMDA receptor-ionophore complex.
Example 1: Potent noncompetitive inhibition of NMDA receptor function Preferential inhibitory effects of arylalkylamines on NMDA receptor-mediated increases in [Ca 2 i in cultured rat cerebellar granule cells were measured. Increases in [Ca 2 iwere elicited by the addition of NMDA/glycine (50 pM/1 kM) in the presence or absence of different concentrations of each test compound. The IC,, values were derived for each test compound using from 2 to 8 separate experiments per test compound, and the standard error level was less than of the mean value for each compound.
All of the arylalkylamines tested blocked increases in [Ca 2 in cerebellar granule cells elicited by NMDA/glycine. Certain arylalkylamines similar in structure to Compound 1 or Compound 2 were nearly as potent as MK-801 (ICs 5 34 nM) which is the most potent compound in the literature known to preferentially block NMDA receptors. Compound 3 had an ICs 2 nM, that is, 17-fold more potent than MK-801. Many of the WO 97/46511 PCT/US96/20697 81 arylalkylamines tested were more potent than competitive antagonists such as AP5 (IC 0 15 4M). The inhibitory effects of the arylalkylamines were not overcome by increasing the concentrations of NMDA or glycine. That is, no change was observed in the EC, 0 for either NMDA or glycine. The arylalkylamines are thus noncompetitive antagonists at the NMDA receptor-ionophore complex, and act neither at the glutamate nor the glycine binding sites.
Example 2: Activity against Kainate and AMPA receptor function Measurements of [Ca 2 ]i in cerebellar granule cells can also be used to monitor activation of the native kainate or AMPA receptors present in this tissue.
Although the increases in [Ca 2 ']ievoked by these agonists are of a lesser magnitude than those evoked by NMDA/glycine, such responses are robust and can be used to precisely assess the specificity of action of arylalkylamines on pharmacologically defined glutamate receptor subtypes. Comparative measurements of [Ca 2 "]i revealed a clear distinction in the receptor selectivity of the arylalkylamines. Some, like JSTX-3 (Joro Spider toxin from the spider Nephila clavata), were more potent antagonists of responses elicited by kainate (100 iM) or AMPA (30 uM). On the other hand, arylalkylamines within the two structural classes defined by Compound 1 and by Compound 2 were found to inhibit preferentially responses evoked by NMDA (showing about a 100-fold difference in potency). Thus, arylalkylamines such as Compound 1 and Compound 2 are potent and selective WO 97/46511 PCT/US96/20697 82 inhibitors of NMDA receptor-mediated responses in cerebellar granule cells.
Example 3: Patch clamp electrophysiology studies Patch clamp electrophysiological studies on isolated cortical or hippocampal neurons from adult rat brain have provided additional insight into the mechanism of action of Compound 1, Compound 2 and Compound 3. These studies revealed potent and selective inhibitory effects of arylalkylamines on responses mediated by NMDA receptors. Thus, compounds such as Compound 1 blocked responses to NMDA at nanomolar concentrations without affecting the responses to kainate. These results, which show selective inhibitory effects of the arylalkylamines in cortical and hippocampal neurons, indicate that the arylalkylamines target NMDA receptors in different regions within the mammalian CNS. Moreover, it was found that the inhibitory effects of these compounds were use- and voltage-dependent. This strongly suggests that these compounds are blocking the open channel and, by this action, behave as noncompetitive NMDA receptor antagonists. Importantly, however, the arylalkylamines could be distinguished from both Mg 2 and MK-801, especially with respect to the voltage-dependence of their onset of action and reversibility of effect.
Example 4: Radioligand binding assays Radioligand binding studies have demonstrated that arylalkylamines such as Compound 1 and Compound 2 have a unique site of action. Although they act like WO 97/46511 PCTIUS96/20697 83 MK-801 in some respects (noncompetitive open-channel blockade, discussed above), they fail to displace 3 H]MK-801 binding at concentrations that completely block NMDA receptor-mediated responses. Assays such as these also demonstrate that the arylalkylamines do not bind with high affinity to the known MK-801, Mg 2 or polyamine binding sites on the NMDA receptor-ionophore complex. Neither do the arylalkylamines bind directly to either the glutamate, glycine or sigma binding sites at concentrations that block NMDA receptor-mediated responses. [3H]Compound 2 was synthesized as a radioligand for use in binding studies to further explore the mechanism of action of Compound 2 and particularly for use in a high-throughput screen to assess the activity of other analogs and to detect new lead structures. A similar approach was taken for [PH]Compound 5. It is clear that compounds like Compound 1 and Compound 2 target a site on the NMDA receptor-ionophore complex for which no other known compounds presently exist. The novel site of action of the arylalkylamines at the molecular level translates into pronounced therapeutic advantages at the behavioral level. As described below, the arylalkylamines possess a quite different behavioral profile from other noncompetitive antagonists of the NMDA receptor.
Example 5: Synaptic transmission studies The above findings demonstrate that certain arylalkylamines, specifically those related in structure to Compound 1 and Compound 2, act through a novel mechanism and site of action to potently and selectively WO 97/46511 PCT/US96/20697 84 inhibit NMDA receptor-mediated responses on neurons from several different brain areas. To further assess the selective inhibitory actions of the arylalkylamines, their effects on synaptic transmission mediated by NMDA or AMPA receptors were assessed.
Glutamate-mediated transmission at synapses of Schaffer collateral fibers and CA1 pyramidal cells was measured in slices of rat brain containing the hippocampus. This assay measures electrophysiologically the postsynaptic depolarization caused by the presynaptic release of glutamate, and can readily distinguish synaptic transmission mediated by NMDA or AMPA receptors. Arylalkylamines like Compound 1, Compound 2 and Compound 3 were again found to exert preferential inhibitory effects on NMDA receptor-mediated responses, and depressed responses mediated by AMPA receptors only at much higher concentrations. For example, Compound 1 had an IC, 0 for the NMDA receptor-mediated response of 20 4M, but an ICs, for the AMPA receptor-mediated response of 647 4M. These results show that arylalkylamines can selectively inhibit synaptic transmission mediated by NMDA receptors. Other naturally occurring arylalkylamines present in the venom of Agelenopsis aperta likewise exert potent and selective inhibitory effects on NMDA receptor-mediated responses in the rat hippocampus.
In the aggregate, then, the results of these various studies are complementary and together identify a structurally novel class of compounds with potent and selective inhibitory activity on NMDA receptors in the mammalian CNS. Additionally, these compounds target a WO 97/46511 PCT/US96/20697 unique site on the NMDA receptor-ionophore complex.
Compound 1, Compound 2 and Compound 3 were selected for additional study in a variety of in vitro and in vivo assays that model therapeutically important endpoints.
Neuroprotectant activity Desired properties of a neuroprotectant drug include the following. The drug can be administered by oral or injectable routes it is not significantly broken down in the stomach, intestine or vascular system and thus reaches the tissues to be treated in a therapeutically effective amount). Such drugs are easily tested in rodents to determine their bioavailability. The drug exhibits neuroprotectant activity efficacy) when given after an ischemic insult (stroke, asphyxia) or traumatic injury (head trauma, spinal cord injury). The drug is devoid of or has minimal side effects such as impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-like psychotomimetic activity.
Although glutamate is the physiological synaptic transmitter, chronic exposure to glutamate leads to neuronal cell death. Much of the neurodegeneration caused by glutamate appears to be mediated by NMDA receptors and results directly from chronically elevated levels of cytosolic Ca 2 There is now extensive experimental support for the view that NMDA and AMPA receptors play a major role in mediating the neuronal degeneration following a stroke and other WO 97/46511 PCT/US96/20697 86 ischemic/hypoxic events (Choi, Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623, 1988). Most of this evidence is based on the ability of competitive or noncompetitive antagonists of the NMDA or AMPA receptor to effectively block neuronal cell death in both in vitro and in vivo models of stroke. Compound 1, Compound 2 and Compound 4 were therefore examined for neuroprotectant effects in standard assays designed to detect such activity.
Example 6: Cortical neuron protection To assess the in vitro neuroprotectant effect of arylalkylamines, mouse cortical neurons grown in culture were exposed for 5 minutes to NMDA, and cell death after 24 hours was monitored by measuring the release of lactate dehydrogenase (LDH), a cytoplasmic enzyme that is released from dying cells (Choi et al., Glutamate neurotoxicity in cortical cell culture. J.
Neurosci. 7: 357, 1987). Exposure to NMDA killed about of the cortical neurons. Compound 1 or Compound 2, included along with NMDA, prevented cell death with IC 5 s values of 70 AM and 30 ruM, respectively. The effective concentrations of the arylalkylamines are higher than those of other noncompetitive NMDA receptor antagonists, but similar to those of competitive antagonists. The effective concentrations of NMDA receptor antagonists vary depending on the particular experimental conditions and the type of cell studied (cortical, hippocampal, striatal). This neuroprotectant effect likely results from the ability of these compounds to block the influx of extracellular Ca 2 triggered by the NMDA receptor.
WO 97/46511 PCTIUS96/20697 87 More rigorous testing to determine potential therapeutic efficacy involved in vivo stroke models. In these models, the blood supply is temporarily blocked by clamping the main arteries to the brain. Two in vivo models of this sort were used to determine the ability of Compound 1, Compound 2 and Compound 4 to prevent neuronal cell loss.
Example 7: Bilateral carotid artery occlusion The first assay was the bilateral common carotid artery occlusion model of forebrain ischemia performed in the gerbil (Karpiak et al., Animal models for the study of drugs in ischemic stroke. Ann. Rev.
Pharmacol. Toxicol. 29: 403, 1989; Ginsberg and Busto, Rodent models of cerebral ischemia. Stroke 20: 1627, 1989). Blood flow to the brain was interrupted for 7 minutes by clamping the carotid arteries. The test compounds were administered as a single dose given intraperitoneally 30 minutes after reinstating blood flow. During the course of these experiments, the core body temperature of the animals was maintained at 37 0 C to prevent any hypothermic reaction. It has been shown that many NMDA receptor antagonists cause hypothermia and this effect can account for much of the protective effect of these compounds. The brains were examined for neuronal cell death 4 days later by silver staining sections of the brain and quantifying death by morphometric analysis. Compound 2 (20 mg/kg) significantly (p 0.05) protected against neuronal cell death in all areas of the brain examined (region CA1 of hippocampus, striatum and neocortex). Doses as low as 1 WO 97/46511 PCTIUS96/20697 88 mg/kg afforded complete protection of the striatum. The degree of protection is comparable to that achieved with similar doses of the noncompetitive NMDA antagonist, MK-801.
In subsequent experiments, Compound 1 mg/kg) produced a 23% reduction in the amount of neuronal death in region CA1 of the gerbil hippocampus measured at 7 days post-ischemia, while Compound 4 mg/kg) provided 90% protection.
Example 8: Middle cerebral artery occlusion The middle cerebral artery model of stroke performed in the rat (Karpiak et al., Animal models for the study of drugs in ischemic stroke. Ann. Rev.
Pharmacol. Toxicol. 29: 403, 1989; Ginsberg and Busto, Rodent models of cerebral ischemia. Stroke 20: 1627, 1989) is different from the gerbil model because it results in a more restricted brain infarct, and thereby approximates a different kind of stroke (focal thrombotic stroke). In the first study using this stroke model, one cerebral artery was permanently occluded by surgical ligation. The test compounds were administered 30 minutes after the occlusion by a single intraperitoneal injection. During the course of these experiments, the core body temperature of the animals was maintained at 370C to prevent any hypothermic reaction. Brains were assessed histologically for neuronal cell loss 24 hours later.
Infarct volumes were calculated using the area of histological pallor from 10 slides and integrating the distance between each successive section. A single dose WO 97/46511 PCT/US96/20697 89 mg/kg) of Compound 1 was found to significantly (p 0.05) protect against neuronal cell loss equally as well as a maximally effective dose (10 mg/kg) of MK-801 (approximately 15% protection). Preliminary studies with Compound 2 (20 mg/kg) indicated a similar trend.
In the second study of focal cerebral ischemia in the rat, the middle cerebral artery was permanently occluded by passing a small piece of suture thread through the carotid artery to the region of the middle cerebral artery. Core body temperature was maintained at 37 0 C. Compound 4, 10 mg/kg i.p. administered immediately after the onset of the ischemic event, produced a statistically significant reduction in the volume of the brain infarct recorded 24 hr later.
In a third model of focal cerebral ischemia in the rat, an ischemic infarct was produced by a photothrombotic method using the dye Rose Bengal.
Compound 4, 10 mg/kg i.p. administered 30 min after the ischemic event, produced a 20% reduction in the volume of the infarct, similar to that seen with the noncompetitive NMDA receptor antagonist, MK-801.
In a fourth model of focal cerebral ischemia in the rat, the middle cerebral artery was temporarily occluded by passing a small piece of suture thread through the carotid artery to the region of the middle cerebral artery. The suture thread was withdrawn after an ischemic period of 2 hr. Core body temperature was maintained at 37 0 C. Compound 4 administered at 10 mg/kg i.p. immediately after the onset of the ischemic event, produced a statistically significant reduction in the volume of the brain infarct recorded 72 hr later.
WO 97/46511 PCT/US96/20697 Several important features of the lead compounds emerge from these in vivo results. First, and most importantly, Compound 1, Compound 2 and Compound 4 demonstrate neuroprotectant effects in several different in vivo models of stroke. The gerbil assay is a model for transient global cerebral ischemia and hypoxia such as cardiac arrest or perinatal hypoxia. The rat assays are models of permanent and temporary focal cerebral ischemia. The finding that Compound 1 and Compound 4 are neuroprotective in the permanent focal stroke models is surprising because the accessibility of the drug to the site of infarction is limited to the penumbral region which generally is not large. Nonetheless, Compound 1 and Compound 4 significantly (p 0.05) limited the extent of damage. Second, the compounds are effective when administered after the ischemic event.
This is important because there is believed to be a "window of opportunity" following an infarct during which drugs may effectively halt necrotic damage. How long this time is in humans has not been defined precisely, and will likely vary depending upon the type of infarct. The essential observation, however, is that these compounds can prevent the spread of neuronal cell death once the degenerative process has commenced.
Finally, Compounds 1, 2, and 4 are effective when administered parenterally, demonstrating that they penetrate the blood-brain barrier.
Anticonvulsant activity Desired properties of an anticonvulsant drug include: the drug can be administered by oral or WO 97/46511 PCT/US96/20697 91 injectable routes, the drug exhibits effective anticonvulsant activity against several seizure types, including, but not limited to, simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery; and the drug is devoid of or has minimal side effects such as impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-like psychotomimetic activity.
Glutamate is the major excitatory transmitter in the brain, and thus may play a major role in seizure activity, and contribute to the pathogenesis of epilepsy. Much of the evidence favoring a major role for glutamate receptors in epilepsy derives from pharmacological studies demonstrating that glutamate receptor agonists elicit seizures, and that NMDA and AMPA receptor antagonists are effective anticonvulsants when administered in vivo. There are numerous in vivo models involving different kinds of seizures and behavioral effects that are relevant for clinically distinct forms of epilepsy. It is thus prudent to test for effects in several models, because it may be an oversimplification to suppose that the same mechanism underlies all forms of seizure activity.
Example 9: Convulsant blocking activity In initial studies, the ability of arylalkylamines to block seizures induced by kainate, picrotoxin or bicuculline were examined. Each of these WO 97/46511 PCT/US96/20697 92 convulsants acts through a different mechanism and seizures elicited by kainate are qualitatively different from those elicited by picrotoxin or bicuculline. In these experiments, a fraction of Agelenopsis aperta venom containing several arylalkylamine toxins was administered intravenously (iv) 5 min before picrotoxin or bicuculline, and 5 min after kainate administration.
The arylalkylamines diminished the seizures induced by all three of these agents. The effects of picrotoxin or bicuculline were so severe that all 19 control animals died within 25 minutes. In contrast, there were no deaths in the 9 animals pretreated with the arylalkylamines. In fact, only about half the animals treated with the arylalkylamines showed any convulsions at all and those symptoms abated within an hour. These results demonstrate clear anticonvulsant effects of arylalkylamines and prompted further studies using purified arylalkylamines and their analogs.
Example 10: Seizure stimuli Three different seizure-inducing test paradigms were used initially in this second group of studies and arylalkylamines such as Compound 1 proved to be effective anticonvulsants in two such paradigms. The first two models used DBA/2 mice which are prone to audiogenic seizures. Seizures were elicited by sound (bell tone at 109 dBs) or the intraperitoneal (ip) administration of NMDA (56 mg/kg). The test substances were administered 15-30 min before the convulsant stimulus. The number of clonic seizures was recorded for 1 min following the audiogenic stimulus or for WO 97/46511 PCTIUS96/20697 93 min following the administration of NMDA. Compound 1, Compound 2, and several other arylalkylamines such as Compound 3 and Compound 4 depressed seizures evoked by either stimulus. For example, Compound 2 had an ED, 0 of 0.13 mg/kg s.c. for audiogenic stimulus and 0.083 mg/kg s.c. for NMDA stimulus. Similarly, the ECs, for Compound 4 in the audiogenic seizure model (0.08 mg/kg) approached that for MK-801 (0.02 mg/kg). In contrast, neither Compound 1 nor Compound 2 was effective at doses up to 50 mg/kg s.c. in reducing seizures in CF-1 mice elicited by i.p. NMDA.
In a second independent series of experiments, Compound 1 and Compound 4 were found to prevent seizures induced by sound in another genetically susceptible mouse model of reflex epilepsy (Frings mice) following intraperitoneal injection with IC, 0 values of 14.3 mg/kg and -15 mg/kg, respectively. These compounds were considerably more potent against audiogenic seizures in Frings mice following intracerebroventricular injection, with IC 50 values of 0.63 /g (Compound 1) and 4.77 ug (Compound Compound 1 was also found to be effective against seizures elicited by maximal electroshock in CF1 mice at a dose of 4 Ag i.c.v.
In further studies using the genetically susceptible mouse model of reflex epilepsy (Frings mice), Compound 9, Compound 12 and Compound 14, administered by i.c.v. injection, prevented sound-induced seizures with IC, 0 values of 4.77 4g, 12.2 Ag and 13.9 Mg, respectively.
These collective findings demonstrate that arylalkylamines such as Compound 1, Compound 2 and WO 97/46511 PCT/US96/20697 94 Compound 4 are effective in preventing epileptic (audiogenic) and nonepileptic (chemoconvulsant) seizures. This generalized pattern of activity suggests that arylalkylamines are clinically useful in controlling seizure activity. In addition, the potency of Compound 1, Compound 2 and especially Compound 4 in in vivo models of seizure activity shows that these compounds can have the therapeutically relevant effects when administrated parenterally in low doses, and are especially potent when administered directly into the cerebral ventricles.
Analgesic activity Desired properties of an analgesic drug include: the drug can be administered by oral or injectable routes, the drug exhibits analgesic activity, the drug is devoid of or has minimal side effects such as impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-like psychotomimetic activity.
Glutamate and NMDA receptor-mediated responses may play a role in certain kinds of pain perception (Dickenson, A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol.
Sci. 11: 302, 1990). The possible analgesic effects of Compound 1, Compound 2, Compound 3 and Compound 4 were therefore examined.
WO 97/46511 PCTIUS96/20697 Example 11: Writhing response test In the first series of experiments, the animals were administered an unpleasant stimulus (2-phenyl-l,4-benzoquinone, PBQ) which elicits a writhing response (abdominal stretching). Typically, the number of writhes occurring in a 5 min observation period is recorded. Classic analgesic drugs, such as morphine, are effective at decreasing the number of PBQ-elicited writhes (100% block of the writhing response at 4 mg/kg Nonsteroidal antiinflammatory agents are likewise effective in this model. Compound 1 (2 mg/kg), Compound 2 (2 mg/kg) and Compound 3 (1 mg/kg) depressed the writhing response by greater than 95% when administered s.c. or i.p. minutes before PBQ. These results demonstrate that Compound 1, Compound 2 and Compound 3 alleviate visceral pain.
In a similar series of studies, Compound 1 and Compound 4 were found to inhibit acetic acid-induced writhing in mice following i.p. injection with ICso values of 10 mg/kg and 1 mg/kg, respectively.
Example 12: Hot plate test Compound 1 was tested for analgesic activity in an additional assay. In this model of analgesic activity, mice were administered test substances s.c.
min before being placed on a hot plate (50 0 The time taken to lick the feet or 'jump off the plate is an index of analgesic activity, and effective analgesics increase the latency to licking or jumping. Morphine (5.6 mg/kg) increased the latency to jump by 765%.
WO 97/46511 PCT/US96/20697 96 Compound 1 was likewise effective in this assay and, at doses of 4 and 32 mg/kg, increased the latency to foot licking by 136% and the latency to jumping by 360%, respectively.
It is noteworthy that the analgesic effects of Compound 1 in the hot plate assay were not accompanied by a decreased performance in the inverted grid assay (see below). This shows that the increase in the latency to jump off the hot plate does not simply reflect impaired motor capabilities. Together, these data suggest that Compound 1 possesses significant analgesic activity.
In a later series of experiments, Compound 1 and Compound 4 were demonstrated to possess significant analgesic activity in rats when administered by the intrathecal route. In these experiments, a 52 0
C
hot plate was used as the nociceptive stimulus.
Compound 1 (0.3 3 nmol) and Compound 4 (0.3 3 nmol) produced dose- and time-dependent antinociceptive effects; these arylalkylamines were similar to morphine (0.3 3 nmol) in terms of potency and efficacy. The NMDA receptor antagonist, MK-801, on the other hand, was ineffective in this assay (3-30 nmol).
Example 13. Tail flick test In this standard assay, the thermal nociceptive stimulus was 52 0 C warm water with the latency to tail flick or withdrawal taken as the endpoint. Compound 1 (0.3 3 nmol) and Compound 4 (0.3 3 nmol) produced a dose- and time-dependent analgesic effect following i.th. administration. These WO 97/46511 PCT/US96/20697 97 arylalkylamines were similar to morphine (0.3 3 nmol) in terms of potency and efficacy. The NMDA receptor antagonist, MK-801, on the other hand, was ineffective in this assay (3-30 nmol).
Example 14. Formalin test Male Sprague-Dawley rats were habituated to an observation chamber for at least 1 hr before receiving an injection of dilute formalin in a volume of ul into the left rear paw. Behavioral responses were monitored immediately after s.c. injection of formalin into the dorsal surface of the paw by counting the number of flinches exhibited by the animal. Behaviors were monitored for at least 50 min after formalin injection and were recorded as early phase responses (0 10 min post-formalin) and late phase responses 50 min post-formalin). Compounds were injected intrathecally 10 min prior to formalin (pre-treatment) or 10 min after formalin (post-treatment) in a volume of 5 kl.
Intraplantal administration of formalin produced a typical biphasic response of flinching behavior, commonly described as the early and late phase responses. Intrathecal administration of Compound 1 (0.3 10 nmol) or Compound 4 (0.3 10 nmol) given as a pretreatment to formalin effectively inhibited both early- and late-phase flinching behaviors. This effect of pretreatment with the arylalkylamines was similar to that seen with pretreatment with morphine (1 10 nmol) or MK-801 (1 30 nmol).
WO 97/46511 PCT/US96/20697 98 Compound 1 (0.3 10 nmol i.th.) administered after the formalin produced some inhibition of late-phase flinching, though significance was achieved only at the 10 nmol dose. Compound 4 (0.3 10 nmol i.th.) administered after the formalin produced significant inhibition of late-phase flinching, with significance achieved at the 3 and 10 nmol doses. This analgesic profile of activity of the arylalkylamines is similar to that seen with post-formalin administration of morphine (1 10 nmol); post-formalin administration of MK-801 (1 30 nmol), however, failed to affect late-phase flinching.
Taken together, the results obtained with the hot plate, tail flick and formalin assays demonstrate that arylalkylamines such as Compound 1 and Compound 4 have significant analgesic activity in several rodent models of acute pain. The formalin assay additionally.
demonstrates that arylalkylamines are effective in an animal model of chronic pain. Importantly, the arylalkylamines possess significant analgesic activity when administered after the formalin stimulus. This profile of activity clearly distinguishes the arylalkylamines from standard NMDA receptor antagonists such as MK-801.
Side effects of arylalkylamines Given the important role NMDA receptors play in diverse brain functions, it is not surprising to find that antagonists of this receptor are typically associated with certain unwelcome side effects. In fact, it is this property that provides the major WO 97/46511 PCTIUS96/20697 99 obstacle to developing therapies that target NMDA receptors. The principal side effects, which characterize both competitive and noncompetitive antagonists, are a PCP-like psychotomimetic activity, impairment of motor performance, sedation or hyperexcitability, impairment of cognitive abilities, neuronal vacuolization, or cardiovascular effects (Willetts et al., The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11: 423, 1990; Olney et al., Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360, 1989). The psychotomimetic effect associated with inhibition of NMDA receptor-mediated responses is epitomized in the response to phencyclidine (PCP) or "angel dust" which acts at the MK-801 binding site. Impairment of cognitive ability is associated with the important role that NMDA receptors normally play in learning and memory.
Relatively less is known concerning the side effect profile of AMPA receptor antagonists. However, it is becoming clear that such compounds also elicit motor impairment, ataxia and profound sedation.
The activity of arylalkylamines was examined in animal models that index motor impairment, sedation and psychotomimetic activity as well as both in vitro and in vivo models of learning and memory.
PCP-like Psychotomimetic Activity In rodents, both competitive and noncompetitive antagonists of the NMDA receptor produce WO 97/46511 PCTIUS96/20697 100 a PCP-like stereotypic behavior characterized by hyperactivity, head-weaving, and ataxia (Willetts et al., The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11: 423, 1990; Snell and Johnson, In: Excitatory Amino Acids in Health and Disease, John Wiley Sons, p. 261, 1988). We investigated whether the arylalkylamines would elicit such behaviors. In addition, we investigated whether the arylalkylamines would substitute for PCP in rats trained to discriminate PCP from saline (Willetts et al., The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11: 423, 1990), and whether the arylalkylamines would elicit a PCP-like neuronal vacuolization (Olney et al., Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360, 1989).
Example 15: Locomotor activity The first assay simply monitors locomotor activity during the first hour following peripheral or administration of test substance. Mice received a dose of Compound 1 15 min before being placed into activity chambers. Activity was quantified by counting the number of breaks in a phototube grid in a 60 min period. In this assay, MK-801 (0.25 mg/kg p.o.) causes a 2- to 3-fold increase in locomotor activity.
However, Compound 1, even when tested at 32 mg/kg s.c., did not elicit hyperactivity and, in fact, tended to depress it. This result, using a purified arylalkylamine in mice, complements earlier results WO 97/46511 PCT/US96/20697 101 obtained in rats where the entire arylalkylamine-containing fraction from Agelenopsis aperta, when injected intravenously, did not elicit a PCP-like behavioral syndrome but seemed to produce a mild sedative effect.
Example 16: Motor impairment In the first assay for generalized motor impairment, Compound 1 was examined in the inverted grid assay. In this assay, animals are placed on a wire-holed grid suspended from a rotating metal bar which can be inverted. The animals are then scored for their ability to climb to the top or hang on to the grid. Animals with severe motor impairment fall off the grid. This assay provides an index of "behavioral disruption" that may result from ataxia, loss of the righting reflex, sedation, or muscle relaxation. In these tests, Compound 1, administered at 32 mg/kg s.c., did not lessen the ability of DBA/2 mice to right themselves when the grid was inverted (p 0.05).
Compound 2 was likewise without effect (p 0.05) on motor performance in DBA/2 mice when administered at a dose of 20 mg/kg s.c. These doses are considerably higher than those required to prevent sound-induced seizures in DBA/2 mice (see Example 10 above).
The second assay of acute motor impairment was the rotorod assay. In this assay, Frings and CF1 mice were injected with test compound and placed on a knurled rod which rotated at a speed of 6 rpm. The ability of the mice to maintain equilibrium for long periods of time was determined; those mice that were unable to WO 97/46511 PCT/US96/20697 102 maintain equilibrium on the rotorod for 1 min in each of 3 trials were considered impaired. Compound 1 produced acute motor impairment in Frings mice with a TD 5 o (that dose which produced motor toxicity in 50% of the test animals) of 16.8 mg/kg i.p. This dose is similar to that which prevents sound-induced seizures in Frings mice (see Example 10 above). There is a much clearer separation between effective and toxic doses of Compound 1 in Frings mice, however, when the Compound is administered i.c.v. In this case, no apparent motor toxicity was evident until the dose of Compound 1 exceeded 1.56 ug i.c.v. times the EDso of 0.63 ug) Finally, motor impairment in CF1 mice was noted with Compound 1 following i.c.v. administration of 4 ig.
Compound 4, Compound 9, Compound 12 and Compound 14 were administered to Frings mice by i.c.v.
injection, and acute motor impairment was measured. The TDso values for Compounds 9, 12 and 14 were 8-16 )g, 14.8 gg, 30.2 kg and 30.8 kg, respectively. These TD 5 o values were 2-3 times higher than the effective IC 5 s values for anticonvulsant potency (see Example above); a clear separation between effective and toxic doses was noted.
Example 17. PCP discrimination In this assay, rats who have been trained to lever press for food reinforcement must select which of two levers in their cages is correct. The only stimulus they have for selecting the correct lever is their ability to detect whether they received a PCP or vehicle injection. After about two months of training, rats WO 97/46511 PCT/US96/20697 103 become very good at discriminating PCP from vehicle injections and can then be tested with other drugs to determine if they are discriminated as PCP. When tested in this procedure, other drugs which are known to produce a PCP-like intoxication substitute for PCP.
These drugs include various PCP analogs such as ketamine and the noncompetitive NMDA receptor antagonist, MK-801.
Compound 1 (1 30 mg/kg did not substitute for PCP, and thus was completely devoid of PCP-like discriminative stimulus effects. At 30 mg/kg only 1 of the 7 animals tested responded at all on either lever. It is thus clear that a behaviorally effective dosage range of Compound 1 was evaluated. As the ability of test compounds to produce PCP-like effects in rats is believed to be predictive of their ability to produce PCP-like psychotomimetic activity and abuse liability in humans, these results strongly suggest that the arylalkylamines such as Compound 1 will lack such deleterious side effects in man.
Example 18 The administration of compounds such as PCP and MK-801 to rats produces a neurotoxic effect termed neuronal vacuolization. Following a single dose of such compounds, vacuoles are found in particular central neurons, especially those in the cingulate cortex and retrosplenial cortex. No such vacuolization was present in rats treated with Compound 1 at the single high dose of 100 mg/kg i.p.
Taken together, the results on locomotor activity, motor impairment, PCP discrimination and WO97/46511 PCT/US96/20697 104 neuronal vacuolization strongly suggest that arylalkylamines will be devoid of PCP-like side effects in man.
Cognitive impairment One of the major reasons for postulating a role of NMDA receptors in memory and learning derives from cellular studies on long-term potentiation (LTP) in the rat hippocampus. LTP is a long-lasting increase in the magnitude of synaptic responses produced by brief yet intense synaptic stimulation. Since the discovery of this phenomenon, it has become the preeminent cellular model of learning in the vertebrate brain (Teyler and Discenna, Long-term potentiation. Annu.
Rev. Neurosci. 10: 131, 1987). Transmission at synapses formed by Schaffer collaterals onto CA1 pyramidal cells is mediated by NMDA and AMPA receptors. Following a brief tetanizing stimulus, the magnitude of the population spike (a measure of synaptic transmission) is greatly increased and remains so for hours. It has been shown that all known competitive and noncompetitive antagonists of NMDA receptors block LTP in the rat hippocampus, whereas antagonists of non-NMDA receptors are without effect (Collingridge and Davis, In: The NMDA Receptor, IRL Press. p. 123, 1989). This supports a role of NMDA receptors in memory and learning.
WO 97/46511 PCTIUS96/20697 105 Example 19: LTP assay The effects of selected arylalkylamines and literature standards were examined for effects on LTP in slices of rat hippocampus. As anticipated, all the conventional competitive (AP5 and AP7) and noncompetitive (MK-801 and ifenprodil) NMDA receptor antagonists inhibited the induction of LTP in the hippocampus. Slices of rat hippocampus were superfused for 30-60 min with a test compound before delivering a tetanizing stimulus consisting of 3 trains, separated by 500 msec, of 100 Hz for 1 sec each. The response amplitude was monitored for an additional 15 minutes post-tetanus. The tetanizing stimulus caused a mean increase in the amplitude of the synaptic response. The induction of LTP was significantly blocked (p 0.05) by competitive (AP5, AP7) or noncompetitive (MK-801, ifenprodil) NMDA receptor antagonists. Quite surprisingly, none of the arylalkylamines tested (Compound 1, Compound 2, Compound 3 and others) blocked the induction of LTP (p 0.05), even when used at high concentrations (100-300 that caused some inhibition of the control response.
These results highlight yet another unique and important feature of arylalkylamines. Arylalkylamines are the first, and at present the only, class of compounds shown to be selective and potent antagonists of the NMDA receptor that do not block the induction of LTP. This likely reflects the novel mechanism and site of action of arylalkylamines and suggests that drugs which target the novel site on the NMDA receptor will similarly lack effects on LTP. As LTP is the primary WO 97/46511 PCTIJS96/20697 106 cellular model for learning and memory in the mammalian CNS, it additionally suggests that such drugs will lack deleterious effects on cognitive performance.
Example 20: Learning tests Preliminary experiments using one of the more potent synthetic arylalkylamine analogs, Compound 3, in an in vivo learning paradigm demonstrate that these drugs lack effects on cognitive performance. In this test, rats were trained to alternate turning in a T maze for a food reward. MK-801 was included for comparison.
Test compounds were administered i.p. 15 min before testing. Control animals made the correct choice about of the time. Increasing doses of MK-801 progressively decreased the number of correct choices and this decrement in behavior was accompanied by hyperactivity. In contrast, Compound 3 did not impair the ability of the animals to make the correct choices (p 0.05). At the highest doses tested, Compound 3 caused some decrease in locomotor activity, exactly the opposite effect observed with MK-801.
Although MK-801 decreased learning performance in parallel with increases in locomotor activity, other studies using different paradigms in rodents and primates have shown a clear dissociation between the effects on learning and locomotion. Thus, both competitive and noncompetitive NMDA receptor antagonists impair learning at doses which do not cause any overt change in motor behavior. This demonstrates that conventional NMDA receptor antagonists impair learning independently of other side effects. The results of the r v WO 97/46511 PCTIUS96/20697 107 T-maze assay demonstrate that Compound 3, and other arylalkylamines, do not impair learning even at doses that cause some decrease in locomotor activity.
One additional observation emerged from these learning tests. The animals' first response on the second day of testing was random and was therefore not dependent on the last response of the previous day's testing. Control animals thus correctly made the first choice about 50% of the time. MK-801 has no effect on this first choice. However, animals administered Compound 3 on the previous day made the first choice correctly considerably more often. Unlike control animals then, the animals treated with Compound 3 behaved as if they remembered the last choice of the previous day.
In a second series of experiments, the effect of Compound 4 on learning in the Morris water maze task was evaluated. In this test, a hidden platform was placed in a fixed location in a circular steel tank, and submerged 2 cm below the surface of the water. Each rat was given 3 trials per day with a 10 min intertrial interval for 5 days. A trial was initiated by placing the rat in the water, nose facing the wall of the tank, at one of three predetermined starting locations. The order of the start location was varied daily. Learning was measured as a decrease in time required to swim to the platform. If an animal failed to locate the platform within 60 sec after the start of the trial, the rat was hand-guided to it. The animals remained on the platform for 10 sec before being removed from the tank.
Ten min after the last training trial on day 5, the WO 97/46511 PCTIUS96/20697 108 animals received a probe test. The platform was removed for this 1 trial task and the animals were allowed to swim for 60 sec to assess the spatial bias for the platform location. Two measures were recorded from this task: latency to first crossing the area where the platform had been, and total number of crossings. A total of 5 injections of Compound 4 were given to each rat. In the first series of experiments, Compound 4 was administered at 10 mg/kg i.p. daily for 5 days. This treatment regimen impaired learning; however, these animals experienced significant weight loss and unusual behavioral signs ("shivering," motor impairment, difficulty in swimming) with repeated dosing of Compound 4. In a subsequent study, six animals received 1 mg/kg i.p. for the first 4 days of training, while two animals received 5 mg/kg i.p. during this period. On the last day of training, both groups received 10 mg/kg. Neither the 1 mg/kg nor the 5 mg/kg animals showed any impairment in learning the location of the hidden platform, nor did the final 10 mg/kg dose produce any impairment in the ability of the animal to perform the already learned task.
The results of these learning tasks are encouraging. They suggest that arylalkylamines lack the learning and memory deficits that typify other NMDA receptor antagonists. In fact, there is a suggestion that the arylalkylamines may even be nootropic (memory enhancers) WO 97/46511 PCT/US96/20697 109 Cardiovascular effects In vivo studies with certain arylalkylamines revealed a hypotensive effect of these compounds, especially at high doses. On the basis of these results, a systematic study of the effects of arylalkylamines on cardiovascular function was performed.
Example 21: Ca 2 channel inhibition We have discovered that some of the arylalkylamines are quite potent inhibitors of voltage-sensitive Ca 2 channels, specifically those sensitive to inhibition by dihydropyridines (L-type channels). Such effects on vascular smooth muscle would be expected to dilate blood vessels and cause a drop in blood pressure, thus producing hypotension.
The ability of arylalkylamines to inhibit dihydropyridine-sensitive Ca 2 channels was examined in cerebellar granule cells and a rat aortic smooth muscle cell line, A 7 r5 cells. In cerebellar granule cells, Compound 2 inhibited depolarization-induced increases in [Ca*]iat concentrations 100-fold higher than those required to block responses to NMDA (ICo 0 values of 24 pM and 161 nM, respectively). Overall, we have observed a wide range of potencies against voltage-sensitive Ca 2 channels that does not correlate with potency against NMDA receptors. This strongly suggests that further structure-activity work based on chemical modification of the arylalkylamine molecule will lead to the development of compounds that are very potent NMDA antagonists with low potency against voltage-sensitive Ca 2 channels. Indeed, Compound 1 (with an IC 0 s of 102 nM WO 97/46511 PCT/US96/20697 110 against NMDA receptor-mediated responses in cerebellar granule cells) is a relatively poor inhibitor of voltage-sensitive Ca 2 channels in cerebellar granule cells 257 MM) and is virtually without effect on voltage-sensitive Ca 2 influx in A,r5 cells (IC, 5 808 Arylalkylamines are not, however, indiscriminate blockers of voltage-sensitive Ca 2 channels. They do not, for example, affect voltage-sensitive Ca 2 channels in cerebellar Purkinje cells (P-type channels) or those channels thought to be involved in neurotransmitter release (N-channels). The arylalkylamines that do block voltage-sensitive Ca 2 channels appear to target specifically L-type Ca 2 channels. Moreover, as mentioned above, there is a high degree of structural specificity in this effect. For example, one arylalkylamine is 57 times more potent than another arylalkylamine in blocking Ca 2 influx through L-type channels, where the only structural difference between the compounds is the presence or absence of a hydroxyl group.
Example 22: In vivo cardiovascular studies The arylalkylamines Compound 1 and Compound 2 produce moderate drops (20-40 mm Hg) in mean arterial blood pressure (MABP) in anesthetized rats at doses which are effective in the in vivo stroke models (10-30 mg/kg The hypotensive effect of Compound 4 has been evaluated in greater detail. Compound 4 elicited a marked drop (40 mm Hg) in mean arterial pressure which persisted for approximately 90-120 min when administered WO97/46511 PCTIUS96/20697 111 at the dose of 10 mg/kg it was in this same group of rats that Compound 4 afforded significant neuroprotection in the suture model of middle cerebral artery occlusion (see Example 8 above). Similar results were obtained in the rat study in which Compound 4 demonstrated neuroprotectant activity in the Rose Bengal photothrombotic model of focal ischemic stroke (see Example 8 above). Further studies using the pithed rat preparation strongly suggest that the hypotensive activity of Compound 4 is a peripherally mediated effect. The hypotension and bradycardia produced by Compound 4 was maintained in rats pretreated with atropine, suggesting that these effects are not mediated by a cholinergic mechanism. Similarly, Compound 4 elicited hypotension and bradycardia in chemically sympathectomized rats (pretreated with a ganglionic blocker), suggesting that these effects are not mediated via the sympathetic nervous system.
On the basis of these findings, it is anticipated that chemical efforts will minimize the cardiovascular side effects by enhancing the uptake of arylalkylamine into the brain such that lower doses are required for neuroprotection, and increasing the selectivity (potency ratio) of arylalkylamines for receptor-operated Ca 2 channels over voltage-sensitive Ca 2 channels.
Example 23: Biological activity of Compound 19 and analogs Compounds 19 215 had high potencies against NMDA-induced increases in [Ca 2 i in rat cerebellar WO 97/46511 PCT/US96/20697 112 granule cells grown in culture (Table The inhibitory effect of Compound 19 on responses to NMDA was noncompetitive. Compounds 19 215 inhibited 3 H]MK-801 binding in membranes prepared from rat hippocampal and cortical tissue (Table 1).
Compound 19 possessed the following additional biological activities: significant (p 0.05 compared to control) anticonvulsant activity against maximal electroshock-induced seizures in mice following i.p.
administration (EDso 26.4 mg/kg and TDs 5 (rotorod) 43.8 mg/kg); significant anticonvulsant activity against maximal electroshock-induced seizures in mice following oral administration (EDso 35 mg/kg), but with motor impairment at 30 mg/kg; significant analgesic activity in the hot-plate and PBQ-induced writhing assays at 16 mg/kg no PCP-like stereotypic behavior (hyperexcitability and head weaving) at mg/kg i.p. in rats; no generalization to PCP in the PCP discrimination assay in rats at doses up to the behaviorally active dose of 30 mg/kg i.p. Compound 19 was significantly less potent in antagonizing increases in [Ca2*]i elicited by depolarizing concentrations of KC1 in rat cerebellar granule cells (IC 0 s 10.2 fiM), and was without effect on blood pressure when administered s.c.
in rats at doses up to 100 mg/kg. Compound 19, however, did block the induction of LTP in rat hippocampal slices when tested at 100 4M.
Compound 20 possessed the following additional biological activities: significant anticonvulsant activity against maximal electroshock-induced seizures in mice following i.p. administration (EDso 20.1 mg/kg WO 97/46511 PCT/US96/20697 113 and TD, 0 (rotorod) 20.6 mg/kg); no significant anticonvulsant activity against maximal electroshock-induced seizures in mice following oral administration at doses up to 30 mg/kg, but with motor impairment at 30 mg/kg; significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. (EDsO 2.1 mg/kg and TD 50 19.9 mg/kg) and oral (ED, 5 9.7 mg/kg and TD, 5 21.8 mg/kg) administration; significant anticonvulsant activity against maximal electroshock-induced seizures in rats following oral administration with an ED 0 value of 33.64 mg/kg and an TD 50 value of 55.87 mg/kg; an increase in seizure threshold as indexed by the i.v. Metrazol test in mice at the dose of 10 mg/kg significant neuroprotectant activity in a rat model of temporary focal ischemia (a 51% reduction in the infarct volume following the administration of two doses of 1 mg/kg the first given immediately after middle cerebral artery occlusion and the second given 6 hr later; a 43% reduction in the infarct volume following the administration of two doses of 1 mg/kg the first given 2 hr after middle cerebral artery occlusion at the time of reperfusion) and the second given 6 hr later); significant neuroprotectant activity (a 24% reduction in the infarct volume) in a rat model of permanent focal ischemia following the administration of 1 mg/kg i.p. at 30 min and again 4 hr post-occlusion; significant neuroprotectant activity (a 50% reduction in the infarct volume) in a rat photothrombotic model of focal ischemia following the administration of 10 mg/kg WO 97/46511 PCT/US96/20697 114 i.p. at 15 min, 3 hr, and again 6 hr post-occlusion; no significant analgesic activity at the dose of 25 mg/kg i.p. in the rat 52 0 C hot plate test or the rat 48 0 C tail flick test; significant analgesic activity, not blocked by the opiate receptor antagonist naloxone, in the rat formalin test at the dose of 10 mg/kg significant analgesic activity, not blocked by naloxone, against acetic acid-induced abdominal writhing in mice at the dose of 10 mg/kg no generalization to PCP in the PCP discrimination assay in rats at doses up to the behaviorally active dose of 10 mg/kg no neuronal vacuolization in rats when administered at doses of and 30 mg/kg no significant cardiovascular activity in anesthetized rats at doses up to 15 umoles/kg i.v. or 10 mg/kg no significant cardiovascular activity in conscious beagle dogs at doses of 0.3 or 1 mg/kg i.v. (60 sec bolus injection); transient increases in mean arterial pressure and heart rate in conscious beagle dogs at the dose of 3 mg/kg with larger magnitude and longer duration effects seen at the dose of 10 mg/kg i.v. (60 sec bolus injection); increased motor activity, agitation and anxiousness, slight tremors, licking of the mouth, whining,and urination in conscious beagle dogs at the dose of 3 mg/kg i.v. (60 sec bolus injection); dilated pupils, whole body tremors, incoordination, licking of the mouth, salivation, panting, rapid blinking of the eyes, whining, anxiousness, seizures, and death in conscious beagle dogs at the dose of 10 mg/kg i.v. sec bolus injection); no behavioral effects in conscious male NMRI mice at the doses of 2 and 4 mg/kg i.p.; WO 97/46511 PCT/US96/20697 115 excitation and increased reactivity to touch in conscious male NMRI mice at the dose of 8 mg/kg i.p.; excitation, Straub tail, tremor, stereotypies, hypothermia, and mydriasis in conscious male NMRI mice at the doses of 16 and 32 mg/kg convulsions and death in conscious male NMRI mice at the dose of 64 mg/kg convulsions and death in conscious male NMRI mice at the doses of 128 and 256 mg/kg i.p; no behavioral effects in conscious male Wistar rats at the dose of 2 mg/kg excitation, stereotypies, increased reactivity to touch, increased muscle tone, and tremor in conscious male Wistar rats at doses ranging from 4 to 16 mg/kg Straub tail, convulsions, and death in conscious male Wistar rats at the dose of 32 mg/kg i.v.
Compound 21 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 3.41 mg/kg and TD 5 s (motor impairment)= 15.3 mg/kg).
Compound 33 (an enantiomer of Compound 21) possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 4.6 mg/kg and TD 5 s (motor impairment) 27.8 mg/kg); significant anticonvulsant activity against maximal electroshock-induced seizures in rats following oral administration at the dose of mg/kg, with no motor toxicity apparent at this dose; WO 97/46511 PCT/US96/20697 116 significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg 30 min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; no significant analgesic activity at the dose of 25 mg/kg i.p. in the rat 52 0 C hot plate test or the rat 480C tail flick test; significant analgesic activity in a rat model of chronic neuropathic pain following i.th. administration of doses ranging from 15 to 80 kg; significant analgesic activity in a rat model of chronic neuropathic pain following i.p.
administration of doses of 3-10 mg/kg; no neuronal vacuolization when administered to rats at the dose of mg/kg no significant cardiovascular activity in anesthetized rats at doses up to 3 mg/kg no significant cardiovascular activity in conscious beagle dogs at the dose of 0.3 mg/kg i.v. (60 sec bolus injection); transient increases in mean arterial pressure in conscious beagle dogs at the dose of 1 mg/kg with larger magnitude and longer duration effects seen at the doses of 3 and 10 mg/kg i.v. (60 sec bolus injection); a transient increase in heart rate in conscious beagle dogs at the dose of 10 mg/kg i.v.
sec bolus injection); licking of the mouth in conscious beagle dogs at the dose of 3 mg/kg i.v.
(60 sec bolus injection); dilated pupils, whole body tremors, incoordination, licking of the mouth, salivation, and panting in conscious beagle dogs at the dose of 10 mg/kg i.v. (60 sec bolus injection); no significant drug-induced changes in the ECG in conscious beagle dogs at doses up to 10 mg/kg i.v. (60 sec bolus injection); no behavioral effects in conscious male NMRI WO 97/46511 PCTUS96/20697 117 mice at the doses of 2 and 4 mg/kg excitation, increased reactivity to touch, and hypothermia in conscious male NMRI mice at the dose of 8 mg/kg i.p.; excitation, Straub tail, tremor, jumping, stereotypies, hypothermia, and mydriasis in conscious male NMRI mice at the doses of 16 and 32 mg/kg convulsions in conscious male NMRI mice at the dose of 64 mg/kg i.p.; convulsions and death in conscious male NMRI mice at the doses of 128 and 256 mg/kg i.p.
Compound 34 (an enantiomer of Compound 21) possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 22 mg/kg and TDo 0 (motor impairment) between 10 and 15 mg/kg); hyperthermia in conscious male NMRI mice at the dose of 2 mg/kg no behavioral effects in conscious male NMRI mice at the dose of 4 mg/kg excitation, increased reactivity to touch, and hypothermia in conscious male NMRI mice at the dose of 8 mg/kg excitation, Straub tail, tremor, jumping, stereotypies, hypothermia, and mydriasis in conscious male NMRI mice at the doses of 16 and 32 mg/kg convulsions in conscious male NMRI mice at the dose of 64 mg/kg convulsions and death in conscious male NMRI mice at the doses of 128 and 256 mg/kg i.p.
Compound 22 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) WO97/46511 PCT/US96/20697 118 following i.p. (EDso 4.9 mg/kg and TDs 5 (inverted grid) 26.8 mg/kg) and oral (EDSo 5.1 mg/kg and LDs 18.3 mg/kg) administration; and no significant cardiovascular activity in anesthetized rats at doses up to 15 gmoles/kg (4.47 mg/kg) i.v.
Compound 50 (an enantiomer of Compound 22) possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 2.7 mg/kg and TD 50 (motor impairment) 17.4 mg/kg); significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following p.o. administration
(ED
5 o 9.0 mg/kg and TDs, (motor impairment) 18.9 mg/kg); significant anticonvulsant activity against maximal electroshock-induced seizures in rats following oral administration with ED, 0 28 mg/kg and TDso 20 mg/kg; significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg 30 min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; no significant analgesic activity at the dose of 25 mg/kg i.p. in the rat 52 0 C hot plate test or the rat 48 0 C tail flick test; and no significant cardiovascular activity in anesthetized rats at doses up to 5 mg/kg i.v.
Compound 51 (an enantiomer of Compound 22) possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible WO 97/46511 PCT/US96/20697 119 mouse model of reflex epilepsy (Frings mice) following i.p. administration (ED,s 9.1 mg/kg and TD,, (motor impairment) 13.6 mg/kg).
Compound 24 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration
(ED
50 5 mg/kg and TD, 0 (motor impairment) 16 mg/kg); significant anticonvulsant activity against maximal electroshock-induced seizures in rats following oral administration with ED, 0 46 mg/kg and TD, 5 51 mg/kg; no significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg 30 min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; and no significant cardiovascular activity in anesthetized rats at doses up to 10 mg/kg i.v.
Compound 25 possessed the following additional biological activities: significant anticonvulsant activity against maximal electroshock-induced seizures in mice following i.p. administration with an ED 0 12.47 mg/kg and a TD 50 32.18 mg/kg; significant anticonvulsant activity against maximal electroshock-induced seizures in rats following oral administration with an ED 5 46.43 mg/kg and a TD 50 between 163 and 326 mg/kg.
Compound 31 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) WO 97/46511 PCT/US96/20697 120 following i.p. administration
(ED
50 6 mg/kg and TD 5 s (motor impairment) between 10 and 20 mg/kg).
Compound 46 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 25 mg/kg and TDso (motor impairment) between 18 and 21 mg/kg); and no significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg 30 min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion.
Compound 57 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDso 1 mg/kg and TDso (motor impairment) between-6 and 8 mg/kg).
Compound 58 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDs 0 0.9 mg/kg and TDs (motor impairment) 14.5 mg/kg); no significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; and no significant cardiovascular activity in anesthetized rats at doses up to 2 mg/kg i.v.
WO 97/46511 PCT/US96/20697 121 Compound 59 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration
(ED
5 o 2.7 mg/kg and TDso (motor impairment) 7.8 mg/kg); a reduction in seizure threshold as indexed by the i.v. Metrazol test in mice at the dose of 11.7 mg/kg no significant neuroprotectant activity in a rat model of focal ischemic stroke following i.p. administration of 2 mg/kg min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; and no significant cardiovascular activity in anesthetized rats at doses up to 10 mg/kg i.v.
Compound 60 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (EDSo 4.4 mg/kg and TDs 0 (motor impairment) 9.2 mg/kg); significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following oral administration (EDso 10 mg/kg and TD 5 s (motor impairment) 25.6 mg/kg); significant anticonvulsant activity against maximal electroshock-induced seizures in mice following i.p. administration (EDs 5 8.17 mg/kg and TDs 0 (rotorod) 17.30 mg/kg); no effect on seizure threshold as indexed by the i.v. Metrazol test in mice at the doses of 1 and 4 mg/kg a reduction in seizure threshold as indexed by the i.v. Metrazol test in mice at the WO 97/46511 PCT/US96/20697 122 doses of 8 and 17 mg/kg significant neuroprotectant activity in a rat model of temporary focal ischemic stroke following i.p. administration of 2 mg/kg 30 min prior to vessel occlusion and 2 mg/kg 3 hr post-occlusion; significant neuroprotectant activity in a rat model of temporary focal ischemic stroke following i.p. or i.v. administration of 1 mg/kg 2 hr and again 8 hr post-occlusion; significant neuroprotectant activity in a rat model of temporary focal ischemic stroke following i.v. administration of 1 mg/kg 2 hr post-occlusion; no significant neuroprotectant activity in a rat photothrombotic model of focal ischemia following the administration of mg/kg i.p. at 15 min, 3 hr, and again 6 hr post-occlusion; no neuronal vacuolization when administered at doses of 20 mg/kg i.p. or 10 mg/kg i.v.; no significant cardiovascular activity in conscious beagle dogs at the dose of 0.3 mg/kg i.v. (60 sec bolus injection); transient increases in mean arterial pressure in conscious beagle dogs at the doses of 1 and 3 mg/kg with larger magnitude and longer duration effects seen at the dose of 10 mg/kg i.v. (60 sec bolus injection); transient increases in heart rate in conscious beagle dogs at the doses of 3 and 10 mg/kg i.v. (60 sec bolus injection); no significant changes in the ECG in conscious beagle dogs at doses ranging from 0.3 to 10 mg/kg i.v. (60 sec bolus injection); no significant behavioral effects in conscious beagle dogs at the doses of 0.3 and 1 mg/kg i.v. (60 sec bolus injection); a slight increase in respiratory rate in conscious beagle dogs at the dose of 3 mg/kg i.v.
WO97/46511 PCTIUS96/20697 123 sec bolus injection); dilated pupils, whole body tremors, salivation, and urination in conscious beagle dogs at the dose of 10 mg/kg i.v. (60 sec bolus injection); no significant behavioral effects in conscious male Wistar rats at doses up to 4 mg/kg i.v.; excitation, stereotypies, increased reactivity to touch, increased muscle tone, and tremor in conscious male Wistar rats at the dose of 8 mg/kg Straub tail, convulsions, and death in conscious male Wistar rats at the dose of 16 mg/kg i.v.
Compound 119 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration with an ED50 7.0 mg/kg and TD 50 (motor impairment) 26.3 mg/kg.
Compound 120 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible'mouse model of reflex epilepsy (Frings mice) following i.p. administration with an ED 50 4.77 mg/kg and TD 50 (motor impairment) between 20 and 30 mg/kg.
Compound 122 possessed the following additional biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflect epilepsy (Frings mice) following i.p. administration with an ED 50 4.7 mg/kg and TD 50 (motor impairment) 15.3 mg/kg.
WO 97/46511 PCTIUS96/20697 124 Compound 138 possessed the following additional biological activities: significant anticonvulsant activity against maximal electroshockinduced seizures in mice following i.p. administration with an ED 50 51.9 mg/kg and TD 50 (motor impairment) 100.7 mg/kg.
Compound 151 possessed the following additional biological activities: significant anticonvulsant activity against maximal electroshockinduced seizures in mice following i.p. administration with an ED 50 36.5 mg/kg and TD 50 (motor impairment) 108.4 mg/kg; a significant increase in seizure threshold as indexed by the i.v. Metrazol test in mice at the doses of 36.5 and 108 mg/kg i.p.
Compound 156 possessed the following additional biological activites: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflect epilepsy (Frings mice) following i.p. administration with an ED 50 5.0 mg/kg and TDso (motor impairment) 17.4 mg/kg.
Taken together, the results obtained with these simplified synthetic arylalkylamines suggest that such simplified molecules do not interact specifically with the arylalkylamine binding site on receptor-operated Ca 2 channels as do Compounds 1, 2 and 3. Specifically, Compounds 19 215 bind to the site labeled by [(H]MK-801 at concentrations ranging approximately 1 to 400-fold higher than those which antagonize the function of the NMDA receptor-ionophore complex. The fact that Compounds 19 215 at WO97/46511 PCT/US96/20697 125 therapeutic doses do not generally produce PCP-like stereotypic behavior, substitute for PCP in drug discrimination assays, or elicit neuronal vacuolization suggests, however, that such compounds might be useful either as lead compounds or drug candidates for neurological disorders and diseases. It has been reported that compounds which bind with low affinity (relative to MK-801) to the site labeled by 3 H]MK-801 might possess therapeutic utility and possess a more favorable side effect profile than that possessed by a high affinity antagonist such as MK-801 itself (Rogawski, Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14: 325, 1993). The low affinity of certain compounds within the group of Compounds 19 215 (relative to MK-801) for the site labeled by 3 H]MK-801 may place these compounds into this general class of low affinity noncompetitive antagonists.
Identification of a novel modulatory site on receptor-operated calcium channels Having identified arylalkylamines which have therapeutically useful properties as defined above, compounds can now be identified which act at the critical arylalkylamine binding site on receptor-operated Ca" 2 channels, such as those present within NMDA, AMPA and nicotinic cholinergic receptor-ionophore complexes.
Examples of suitable tests now follow: WO 97/46511 PCT/US96/20697 126 Example 24: Radioligand binding in rat cortex or cerebellum.
The following assay can be utilized as a high throughput assay to screen product libraries natural product libraries and compound files at major pharmaceutical companies) to identify new classes of compounds with activity at this unique arylalkylamine site. These new classes of compounds are then utilized as chemical lead structures for a drug development program targeting the arylalkylamine binding site on receptor-operated Ca 2 channels. The compounds identified by this assay offer a novel therapeutic approach to treatment of neurological disorders or diseases. Examples of such compounds include those provided in the generic chemical formulae above.
Routine experiments can be performed to identify those compounds having the desired activities.
Rat brain membranes are prepared according to the method of Williams et al. (Effects of polyamines on the binding of 3 H]MK-801 to the NMDA receptor: Pharmacological evidence for the existence of a polyamine recognition site. Molec. Pharmacol. 36: 575, 1989) with the following alterations: Male Sprague-Dawley rats (Harlan Laboratories) weighing 100-200 g are sacrificed by decapitation. The cortex or cerebellum from 20 rats are cleaned and dissected. The resulting brain tissue is homogenized at 40C with a polytron homogenizer at the lowest setting in 300 ml 0.32 M sucrose containing 5 mM K-EDTA (pH The homogenate is centrifuged for 10 min at 1,000 x g and the supernatant removed and centrifuged at 30,000 x g WO97/46511 PCTIUS96/20697 127 for 30 minutes. The resulting pellet is resuspended in 250 ml 5 mM K-EDTA (pH 7.0) stirred on ice for 15 min, and then centrifuged at 30,000 x g for 30 minutes. The pellet is resuspended in 300 ml 5 mM K-EDTA (pH 7.0) and incubated at 320C for 30 min. The suspension is then centrifuged at 100,000 x g for 30 min. Membranes are washed by resuspension in 500 ml 5 mM K-EDTA (pH incubated at 320C for 30 min, and centrifuged at 100,000 x g for 30 minutes. The wash procedure, including the 30 min incubation, is repeated. The final pellet is resuspended in 60 ml 5 mM K-EDTA (pH 7.0) and stored in aliquots at -800C. The extensive washing procedure utilized in this assay was designed in an effort to minimize the concentrations of glutamate and glycine (co-agonists at the NMDA receptor-ionophore complex) present in the membrane preparation.
To perform a binding assay with 3 H]arylalkylamine, aliquots of SPMs (Synaptic Plasma Membranes) are thawed, resuspended in 30 mls of 30 mM EPPS/lmM K-EDTA, pH 7.0, and centrifuged at 100,000 x g for 30 minutes. SPMs are resuspended in buffer A (30 mM EPPS/1 mM K-EDTA, pH The 3 H] arylalkylamine is added to this reaction mixture. Binding assays are carried out in polypropylene test tubes. The final incubation volume is 500 il. Nonspecific binding is determined in the presence of 100 AM nonradioactive arylalkylamine. Duplicate samples are incubated at 0°C for 1 hour. Assays are terminated by the addition of 3 ml of ice-cold buffer A, followed by filtration over glass-fiber filters (Schleicher Schuell No. 30) that are presoaked in 0.33% polyethyleneimine (PEI). The WO 97/46511 PCT/US96/20697 128 filters are washed with another 3 x 3 ml of buffer A, and radioactivity is determined by scintillation counting at an efficiency of 35-40% for 3
H.
In order to validate the above assay, the following experiments are also performed: The amount of nonspecific binding of the [3H]arylalkylamine to the filters is determined by passing 500 t1 of buffer A containing various concentrations of [3H]arylalkylamine through the presoaked glass-fiber filters. The filters are washed with another 4 x 3 ml of buffer A, and radioactivity bound to the filters is determined by scintillation counting at an efficiency of 35-40% for 3 H. In filters that are not pretreated with 0.33% PEI, it was found that 87% of the 3 H-ligand was bound to the filter.
Presoaking with 0.33% PEI reduces the nonspecific binding to 0.5 1.0% of the total ligand added.
A saturation curve is constructed by resuspending SPMs in buffer A. The assay buffer (500 1i) contains 60 .g of protein. Concentrations of [3H]arylalkylamine are used, ranging from 1.0 nM to 400 uM in half-log units. A saturation curve is constructed from the data, and an apparent K. value and value determined by Scatchard analysis (Scatchard, The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51: 660, 1949). The cooperativity of binding of the [3H]arylalkylamine is determined by the construction of a Hill plot (Hill, A new mathematical treatment of changes of ionic concentrations in muscle and nerve under the action of WO 97/46511 PCT/US96/20697 129 electric currents, with a theory to their mode of excitation. J. Physiol. 40: 190, 1910).
The dependence of binding on protein (receptor) concentration is determined by resuspending SPMs in buffer A. The assay buffer (500 s1) contains a concentration of P3H]arylalkylamine equal to its KD value and increasing concentrations of protein. The specific binding of 3 Hlarylalkylamine should be linearly related to the amount of protein (receptor) present.
The time course of ligand-receptor binding is determined by resuspending SPMs in buffer A.
The assay buffer (500 1i) contains a concentration of [PH]arylalkylamine equal to its KD value and 100 jug of protein. Duplicate samples are incubated at 0°C for varying lengths of time; the time at which equilibrium is reached is determined, and this time point is routinely used in all subsequent assays.
The pharmacology of the binding site can be analyzed by competition experiments. In such experiments, the concentration of [1H]arylalkylamine and the amount of protein are kept constant, while the concentration of test (competing) drug is varied. This assay allows for the determination of an ICso and an apparent KD for the competing drug (Cheng and Prusoff, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (ICs 0 of an enzymatic reaction. J. Biochem.
Pharmacol. 22: 3099, 1973). The cooperativity of binding of the competing drug is determined by Hill plot analysis.
WO 97/46511 PCT/US96/20697 130 Specific binding of the [3H]arylalkylamine represents binding to a novel site on receptor-operated Ca 2 channels such as those present within NMDA-, AMPAand nicotinic cholinergic receptor-ionophore complexes.
As such, other arylalkylamines should compete with the binding of ~PHarylalkylamine in a competitive fashion, and their potencies in this assay should correlate with their inhibitory potencies in a functional assay of receptor-operated Ca 2 channel antagonism inhibition of NMDA receptor-induced increases in [Ca 2 in cultures of rat cerebellar granule cells).
Conversely, compounds which have activity at the other known sites on receptor-operated Ca 2 channels MK-801, Mg 2 polyamines) should not displace [H]arylalkylamine binding in a competitive manner.
Rather, complex allosteric modulation of PH]arylalkylamine binding, indicative of noncompetitive interactions, might be expected to occur. In preliminary experiments, MK-801 did not displace 3 H]arylalykylamine binding at concentrations up to 100 4M.
Studies to estimate the dissociation kinetics are performed by measuring the binding of [H]arylalkylamine after it is allowed to come to equilibrium (see above), and a large excess of nonradioactive competing drug is added to the reaction mixture. Binding of the [PH]arylalkylamine is then assayed at various time intervals. With this assay, the association and dissociation rates of binding of the [3H]arylalkylamine are determined (Titeler, Multiple Dopamine Receptors: Receptor Binding Studies in WO 97/46511 PCT/US96/20697 131 Dopamine Pharmacology. Marcel Dekker, Inc., New York, 1983). Additional experiments involve varying the reaction temperature (0°C to 370C) in order to understand the temperature dependence of this parameter.
Example 25: Radioligand binding in cerebellar granule cells Primary cultures of cerebellar granule neurons are obtained from 8-day-old rats and plated onto squares of Aclar plastic coated with poly-L-lysine. The plastic squares are placed in 24-well culture plates, and approximately 7.5 X 10 5 granule cells are added to each well. Cultures are maintained in Eagles' medium (HyClone Laboratories) containing 25 mM KC1, 10% fetal calf serum (HyClone Laboratories), 2 mM glutamine, 100 4g/ml gentamicin, 50 U/ml penicillin, and 50 4g/ml streptomycin at 37 0 C in a humid atmosphere of 5% CO 2 in air for 24 hr before the addition of cytosine arabinoside (10 jtM, final). No changes of culture medium are made until the cells are used for receptor binding studies 6-8 days after plating.
To perform a binding assay with 3 H]arylalkylamine, the reaction mixture consists of 200 Al of buffer A (20 mM K-HEPES, 1 mM K-EDTA, pH in each well of the 24-well plate. The PH]arylalkylamine is added to this reaction mixture.
Nonspecific binding is determined in the presence of 100 kM nonradioactive arylalkylamine. Triplicate samples are incubated at 0°C for 1 hour. Assays are terminated by manually scraping the cells off the Aclar squares and placing them into polypropylene test tubes.
WO 97/46511 PCT/US96/20697 132 The membranes prepared from whole cells in this manner are suspended in 10 ml of ice-cold buffer A, and filtered over glass-fiber filters (Schleicher Schuell No. 30) that are presoaked in 0.33% PEI. The filters are washed with another 3 x 3 ml of buffer A, and radioactivity on the filters is determined by scintillation counting at an efficiency of 35-40% for 3
H.
The assay may be terminated by centrifugation rather than filtration in order to minimize nonspecific binding.
Specific experiments to characterize and validate the assay are performed essentially as above, except that cells are used in place of membranes for the initial binding. The binding assay allows for the determination of an IC 5 s value and an apparent KD for the competing drug as described by Scatchard analysis (The attractions of proteins for small molecules and ions.
Ann. N.Y. Acad. Sci. 51: 660, 1949) Cooperativity of binding of the competing drug is determined by Hill plot analysis (A new mathematical treatment of changes of ionic concentrations in muscle and nerve under the action of electric currents, with a theory to their mode of excitation. J. Physiol. 40: 190, 1910). The specific binding of the [3H]arylalkylamine represents binding to a novel site on receptor-operated calcium channels.
Example 26: Recombinant receptor binding assay The following is one example of a rapid screening assay for useful compounds of this invention.
In this assay, a cDNA or gene clone encoding the WO 97/46511 PCT/US96/20697 133 arylalkylamine binding site (receptor) from a suitable organism such as a human is obtained using standard procedures. Distinct fragments of the clone are expressed in an appropriate expression vector to produce the smallest polypeptide(s) obtainable from the receptor which retain the ability to bind Compound 1, Compound 2 or Compound 3. In this way, the polypeptide(s) which includes the novel arylalkylamine receptor for these compounds can be identified. Such experiments can be facilitated by utilizing a stably transfected mammalian cell line HEK 293 cells) expressing the arylalkylamine receptor.
Alternatively, the arylalkylamine receptor can be chemically reacted with chemically modified Compound 1, Compound 2 or Compound 3 in such a way that amino acid residues of the arylalkylamine receptor which contact (or are adjacent to) the selected compound are modified and thereby identifiable. The fragment(s) of the arylalkylamine receptor containing those amino acids which are determined to interact with Compound 1, Compound 2 or Compound 3 and are sufficient for binding to said molecules, can then be recombinantly expressed, as described above, using a standard expression vector(s).
The recombinant polypeptide(s) having the desired binding properties can be bound to a solid phase support using standard chemical procedures. This solid phase, or affinity matrix, may then be contacted with Compound 1, Compound 2 or Compound 3 to demonstrate that those compounds can bind to the column, and to identify conditions by which the compounds may be removed from WO 97/46511 PCT/US96/20697 134 the solid phase. This procedure may then be repeated using a large library of compounds to determine those compounds which are able to bind to the affinity matrix, and then can be released in a manner similar to Compound i, Compound 2 or Compound 3. However, alternative binding and release conditions may be utilized in order to obtain compounds capable of binding under conditions distinct from those used for arylalkylamine binding conditions which better mimic physiological conditions encountered especially in pathological states). Those compounds which do bind can thus be selected from a very large collection of compounds present in a liquid medium or extract.
Once compounds able to bind to the arylalkylamine binding polypeptide(s) described above are identified, those compounds can then be readily tested in the various assays described above to determine whether they, orsimple derivatives thereof, are useful compounds for therapeutic treatment of neurological disorders and diseases described above.
In an alternate method, native arylalkylamine receptor can be bound to a column or other solid phase support. Those compounds which are not competed off by reagents which bind other sites on the receptor can then be identified. Such compounds define novel binding sites on the receptor. Compounds which are competed off by other known compounds thus bind to known sites, or bind to novel sites which overlap known binding sites.
Regardless, such compounds may be structurally distinct from known compounds and thus may define novel chemical classes of agonists or antagonist which may be useful as WO 97/46511 PCTIUS96/20697 135 therapeutics. In summary, a competition assay can be used to identify useful compounds of this invention.
Example 27: Patch-clamp electrophysiology assay The following assay is performed for selected compounds identified in the above-mentioned radioligand binding assays as interacting in a highly potent and competitive fashion at the novel arylalkylamine binding site on receptor-operated Ca 2 channels, such as those present in NMDA-, AMPA- or nicotinic cholinergic receptor-ionophore complexes. This patch-clamp assay provides additional relevant data about the site and mechanism of action of said previously selected compounds. Specifically, the following pharmacological and physiological properties of the compounds interacting at the arylalkylamine binding site are determined, utilizing the NMDA receptor-ionophore complex as an example of receptor-operated Ca 2 channels: potency and efficacy at blocking NMDA receptor-mediated ionic currents, the noncompetitive nature of block with respect to glutamate and glycine, use-dependence of action, voltage-dependence of action, both with respect to onset and reversal of blocking, the kinetics of blocking and unblocking (reversal), and open-channel mechanism of blocking. Such data confirm that the compounds interacting at the arylalkylamine binding site retain the unique biological profile of the arylalkylamines, and do not have their primary activity at the known sites on the NMDA receptor-ionophore complex (glutamate binding site, glycine binding site, WO 97/46511 PCT/US96/20697 136 MK-801 binding site, Mg 2 binding site, Zn 2 binding site, sigma binding site, polyamine binding site).
Patch-clamp recordings of mammalian neurons (hippocampal, cortical, cerebellar granule cells) are carried out utilizing standard procedures (Donevan et al., Arcaine blocks N-methyl-D-aspartate receptor responses by an open channel mechanism: whole-cell and single-channel recording studies in cultured hippocampal neurons. Molec. Pharmacol. 41: 727, 1992; Rock and Macdonald, Spermine and related polyamines produce a voltage-dependent reduction of NMDA receptor single-channel conductance. Molec. Pharmacol. 42: 157, 1992).
Alternatively, patch-clamp experiments can be performed on Xenopus oocytes or on a stably transfected mammalian cell line HEK 293 cells) expressing specific subunits of receptor-operated Ca 2 channels. In this manner, for example, potency and efficacy at various glutamate receptor subtypes NMDAR1, NMDAR2A through NMDAR2D, GluRl through GluR4) can be determined. Further information regarding the site of action of the arylalkylamines on these glutamate receptor subtypes can be obtained by using site-directed mutagenesis.
Example 28: Synthesis of arylalkylamines Arylalkylamines such as Compound 1, Compound 2 and Compound 3 are synthesized by standard procedures (Jasys et al., The total synthesis of argiotoxins 636, 659 and 673. Tetrahedron Lett. 29: 6223, 1988; Nason et al., Synthesis of neurotoxic Nephila spider venoms: WO 97/46511 PCT/US96/20697 137 NSTX-3 and JSTX-3. Tetrahedron Lett. 30: 2337, 1989).
Specific examples of syntheses of arylalkylamine analogs 4-18 are provided in co-pending application U.S. Serial No. 08/485,038, filed June 7, 1995, and co-pending International Patent Application No. PCT/US94/12293, published as W095/21612,filed October 26, 1994, hereby incorporated by reference herein in their entirety.
Example 29: Synthesis of simplified arylalkylamines Synthesis of Compound 20 was accomplished as follows.
A solution of sodium hydride (1.21 g, 50 mmol) in dimethoxyethane was treated with diethyl cyanomethylphosphonate (8.86 g, 50 mmol) and the reaction stirred 4 hr at room temperature. To this was added 3,3'-difluorobenzophenone (10 g, 46 mmol) in DME. The reaction was stirred 24 hr at room temperature, quenched with H 2 0, and partitioned between diethyl ether and water. The ether fraction was dried over Na 2
SO
4 and concentrated. GC/MS of this material showed 90% of the product A and 10% starting benzophenone.
A solution of this material in ethanol with a catalytic amount of Pd(OH) 2 was hydrogenated at 55 psi hydrogen for 4 hr at room temperature. The reaction was filtered and the catalyst washed with ethanol The filtrate and ethanol washes were combined and concentrated. GC/MS of this material showed 90% of the product B and 10% of the starting benzophenone.
A solution of this material in THF was treated with 70 ml 1 M B 2
H
6 (70 mmol) in THF and refluxed 1 hr.
After cooling the reaction was treated with 6 N HC1 WO 97/46511 PCTfUS96/20697 138 ml) and refluxed an additional hour. After cooling the reaction was basified to pH 14 with 10 N NaOH and equilibrated with ether. The ether layer was removed and washed with 10% HC1 The acidic washes were combined, basified to pH 14 with 10 N NaOH and extracted with dichloromethane The organic washes were combined, dried over Na 2
SO
4 and concentrated to yield an oil. GC/MS of this material showed 100% Compound GC/EI-MS =7.11 min) m/z (relative intensity) 247 31), 230 (100), 215 201 183 (63) 134 (23), 121 101 95 77 (15) This material in diethyl ether was filtered and treated with 35 ml 1 M HC1 in ether. The precipitate was collected, dried, and recrystallized from water-ethanol to afford 1.045 g of Compound 20, as the hydrochloride salt. 'H-NMR (CDC13) d 8.28 (3H, br 7.28-7.17 (2 H, 7.02-6.86 (6 H, m), 4.11 (1H, t, J=8 Hz), 2.89 (2H, br t, J=8 Hz), 2.48 (2H, br t, J=7 Hz); 13 C-NMR (CDC13) d 164.6, 161.3, 144.8, 144.7, 130.4, 130.3, 123.3, 123.2, 114.7, 114.5, 114.1, 113.8, 47.4, 38.4, 32.7.
WO 97/46511 PCTUS96/20697 139 OH i ho p 0 Li (H 2 CCN)- F CN H-/Ni-AI FN A B HCF- NHCI H 2 /caialyst F NHICI C Compound (hydrochloride salt) Synthesis of Compound 21, Compound 33 and Compound 34 was accomplished as follows.
A 100 ml round-bottomed flask equipped with stir bar, septa, and argon source was charged with Compound 1 (2.43 g, 10 mmol) in 30 ml THF. The solution was cooled to -78 0 C and treated dropwise with 11 ml lithium bis(trimethylsilyl)amide (lM in THF) (11 mmol). The reaction was stirred at -78 0 C for 30 min and treated dropwise with excess iodomethane (3.1 ml, mmol). The reaction was stirred 30 min at -58 0
C.
GC/EI-MS analysis of an aliquot from the reaction showed consumption of the starting nitrile 1. The reaction was quenched with water, diluted with diethyl ether and transferred to a separatory funnel. The ether layer was washed with 10% HC1 brine dried with anhydrous MgSO 4 and concentrated to a brown oil. This material was distilled (Kugelrohr, 100 0 C) at reduced pressure to afford 1.5 g of a clear oil. GC/EI-MS of this material showed it to contain the desired product 2, (R,=7.35 min) m/z (rel. int.) 257 3), 203 (100), 183 170 133 109 'H-NMR WO 97/46511 PCT/US96/20697 140 (CDC13) d 7.4-6.9 (8H, 4.01 (1H, d, J=10 Hz), 3.38 (1H, dq, J=7, 10 Hz), 1.32 (3H, d, J=7 Hz); 3
C-NMR
(CDC1 3 d 19.4, 30.5, 54.2, 114.5, 114.6, 114.7, 114.9, 115.0, 115.3, 123.3, 123.4, 123.6, 123.7, 130.5, 130.6, 131.7.
Product 3 was synthesized by the catalytic reduction of 2 using Raney nickel in 95:5 EtOH:aqueous sodium hydroxide (2 Eq.) under 60 psi hydrogen.
GC/EI-MS (Rt=7.25 min) m/z (rel. int.) 261 20), 244 229 215 201 183 (100), 133 (42), 115 109 95 'H-NMR (CDC1 3 d 7.3-6.8 (8H, 3.62 (1H, d, J=10 Hz), 2.70 (1H, 2.40 (2H, 1.73 (2H, 0.91 (3H, d, J=7 Hz). Note that product 3 in this reaction sequence corresponds to Compound 21.
Product 2 in 10% IPA-hexane (100 mg/ml) was chromatographed, in 500 1l aliquots, through Chiral Cel OD (2.0 x 25 cm) using 10% IPA-hexane at 10 ml/min measuring optical density at 254 nm. This afforded the two optically pure enantiomers 4 and 5 (as determined by analytical chiral HPLC; Note, the stereochemistry of these two compounds has not been assigned at this time).
These two compounds were identical in their GC/EI-MS and 'H-NMR spectra as product 2 (data above).
Each of the enantiomers 4 and 5 was reduced separately using dimethyl sulfideborane complex in the following manner. A solution of compound (4 or 5 in THF was heated to reflux and treated with excess (2 Eq.) 1M (in THF) dimethyl sulfideborane complex and the WO 97/46511 PCT/US96/20697 141 reaction refluxed 30 min. After this time the reaction was cooled to 0 C and treated with 6 N HC1. The reaction was set to reflux for 30 min. After this time the reaction was transferred to a separatory funnel, basified to pH 12 with 10N NaOH, and the product (6 or 7) extracted into ether. The ether layer was washed with brine, dried over anhydrous MgSO 4 and concentrated to an oil. The product was purified by prep-TLC using methanol-chlorform. Each of the individual enantiomers (6 and 7) were found to be identical in their GC/EI-MS and 'H-NMR spectra as product 3 (data above). Note that products 6 and 7 in this scheme correspond to Compounds 33 and 34. Compound 33-HCl: mp 260-270 0 C (dec), [-136s26 +6.6 (c 1.0 in EtOH), []D26 +0.4 (c 1.0 in EtOH). Compound 34-HC1: 36 523 (c 1.0 in EtOH), [o]D23 +0.1 (c 1.0 in EtOH) Compound 33-HI: The free base of Compound 33 was dissolved in EtOH and 47% hydriodic acid (1.1 equivt.) was added. The solvent was evaporated under vacuum and the resulting solid hydroiodide was recrystallized twice from heptane/EtOAc by slow evaporation: mp 195-197 0
C.
The absolute configuration of Compound 33-HI was determined to be R by single-crystal (monoclinic colorless needle, 0.50 x 0.05 x 0.03 mm) X-ray diffraction analysis using a Siemens R3m/V diffractometer (3887 observed reflections).
WO 97/46511 PCT/US96/20697 142 I1) (MeS.))NLi Nf C H Raney nickel
CHI
F CN 2) Mel CN H, F. NHI
SF-F
Compound 21 Chirl Ccl OD CH N 10% IPA I Hexane F CN F vCN p N N I) Me)S.BH) 2) HCI r CHHI NHI Nil n F 6 2 (Compound 33) Compound 34) Synthesis of Compound 22 was accomplished as described below. Compound 23 was synthesized in a similar manner.
Triethyl phosphonoacetate (17.2 g, 76.8 mmol) was slowly added to a suspension of sodium hydride (3.07 g, 76.8 mmol) in N,N-dimethylformamide (350 ml). After minutes 3,3'-difluorobenzophenone (15.2 g, 69.8 mmol) was added to the solution and stirred an additional 18 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give 19.7 g of ethyl 3,3-bis(3-fluorophenyl)acrylate as a yellow oil.
To a solution of ethyl 3,3-bis(3-fluorophenyl) -acrylate (19.7 g, 68.4 mmol) in 200 ml of ethanol was added palladium hydroxide on carbon (3.5 The mixture was shaken under 60 psi of hydrogen for 3 hours, WO 97/46511 PCTIS96/20697 143 then filtered and evaporated in vacuo to give 19.5 g of product A as a colorless oil.
The ethyl ester A (19.2 g) was hydrolyzed by stirring for 6 days with 50 ml of 10 N sodium hydroxide.
The reaction mixture was then diluted with 50 ml of water and acidified to pH 0 with concentrated HC1. The aqueous mixture was extracted 3 times with ether and the ether extracts dried over magnesium sulfate and evaporated to give 3,3-bis(3-fluorophenyl)propionic acid as a white powder.
3,3-bis(3-fluorophenyl)propionic acid (13 g, 49.6 mmol) was dissolved in 50 ml (685 mmol) of thionyl chloride and stirred overnight at room temperature. The excess thionyl chloride was removed in vacuo on a rotary evaporator to give 13.7 g of product B as a yellow oil.
To acid chloride B (13.7 g, 49 mmol) dissolved in 100 ml of dry THF was added iron(III) acetylacetonate (0.52 g, 1.47 mmol). Methylmagnesium chloride (16.3 ml, 49 mmol) was then added over a period of 1 hr by syringe pump. The reaction was stirred for an additional hour, then quenched by pouring into ether/5% HC1. The ether layer was separated, washed with 5% HC1 and saturated NaC1, and dried over sodium sulfate. The solvent was evaporated in vacuo to give 4,4-bis(3-fluorophenyl)-2-butanone as a yellow oil. The crude oil was purified on silica gel using heptane/ethyl acetate as the elutant.
To 4,4-bis(3-fluorophenyl)-2-butanone (5.7 g, 21.9 mmol) in 25 ml of ethanol was added pyridine WO 97/46511 PCTIUS96/20697 144 (1.91 g, 24.1 mmol) and methoxylamine hydrochloride (2.01 g, 24.1 mmol). The reaction was stirred overnight at room temperature, then poured into ether/5% HC1. The ether layer was separated, washed with 5% HC1 and saturated NaCI, and dried over sodium sulfate. The solvent was evaporated in vacuo to give 6.26 g of the O-methyl oxime of 4,4-bis(3-fluorophenyl)-2-butanone.
To sodium borohydride (4.1 g, 108.3 mmol) in 15 ml of THF was slowly added zirconium tetrachloride (6.31 g, 27.1 mmol). This mixture was stirred for 15 min, then the oxime (6.26 g, 21.7 mmol) in 6 ml of THF was added over 5 min. After 3 hours of stirring at room temperature, the reaction was worked up by slowly adding mM sodium hydroxide followed by ether. The aqueous layer was extracted 4 times with ether, and the combined ether extracts were dried over sodium sulfate. The solvent was evaporated in vacuo to give 5.3 g of Compound 22.
WO 97/46511 PTU9/09 PCT[US96/20697 145 0 EEO C00Et F NaH DMF F COOEt
H
2 Pd(OH) 2 Ethianol
FN
F
A
N Cl 1 NaOH/MeQH/H 2 0
F
2. SOCI 2 0
F
B
1. Fe(Acac) 3 MeMgBr F NH- 2 2. H 2 N-OMe, pyridine CH 3 3. NaBH 4 /ZrC1 4
THF
F
Compound 22 Synthesis of Compound 24 was accomplished as described below. Compounds 25-29, 52-53, 65, 76-78, 83, 96-97, 115, and 135-136 were prepared in a similar manner.
A suspension of magnesium turnings (0.95 g, 39.2 mmol) in 150 ml anhydrous diethyl ether was treated with 1-bromo-3-fluorobenzene (6.83 g, 39.2 mmcl) dropwise via syringe. After 1.5 hr the solution was transfered via cannula to a flask containing o-anisaldehyde (5.0 g, 36.7 mmcl) in 100 ml anhydrous diethyl ether at 0 0 C and stirred 2hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were WO 97/46511 PCT/US96/20697 146 washed with brine and dried over anhydrous magnesium sulfate to afford 7.90g (93% yield) of product A.
Pyridinium dichromate (16.0 g, 42.5 mmol) was added to a solution of the alcohol A (7.90 g, 34.0 mmol) in dichloromethane (100 ml), and the reaction was stirred 12 hr. Diethyl ether (300 ml) was added to the reaction mixture and the black solution was filtered through a silica gel plug (30 cm) and washed with an additional 500 ml ether. After evaporation of the solvent in vacuo, the solid was recrystallized from acetone to give 7.45 g (95% yield) of product B.
Diethyl cyanomethylphosphonate (7.0 g, 39.5 mmol) was slowly added to a suspension of sodium hydride (1.58 g, 39.5 mmol) in 100 ml N,N-dimethylformamide. After 30 minutes the ketone B was added to the solution and stirred an additional 2 hr. The reaction mixture was quenched with water, and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give a pale yellow oil.
In a glass bomb, the oil was dissolved in 100 ml ethanol and 20 ml 10N NaOH. A catalytic amount of Raney Nickel suspened in water (ca. 15 mol percent) was added to the solution. The reaction mixture was shaken under 60 psi H 2 for 12 hr on a Parr Hydrogenator.
After filtering off excess Raney Nickel, the solution was extracted with chloroform. The combined organic layers were washed with brine and dried over anhydrous WO 97/46511 PCTIUS96/20697 147 magnesium sulfate. After filtration, the oil was run through a silica gel column in chloroform and methanol.
The solvent was evaporated in vacuo to give a pale yellow oil. GC/EI-MS (R,=8.10 min) m/z (rel. intensity) 259 (100), 242 213 183 136 109 91 77 The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether afforded a pale yellow solid that was recrystallized in hot acetonitrile to afford 3.45 g (42.1% yield) white needles of Compound 24, as the hydrochloride salt.
WO 97/46511 PCT/US96/20697 148 1) Mg, ether OCH 3 F' Br PCC or PDC CH2CI-h EtO CN, NaH-DMF EtO' 2) Raney Ni, EtOH, NaOH
H
2 60 p.s.i.
3) HCl-ether
.OCH
3 Compound 24 (HC1 salt) Compounds 101 and 103 were synthesized from Compounds 25 and 24, respectively, by cleavage of their O-methyl ethers with borane tribromide in the normal manner.
Synthesis of Compound 30 was accomplished as described below. Compound 31 was prepared in a similar manner.
A suspension containing magnesium turnings (0.95 g, 39.1 mmol) in 150 ml anhydrous diethyl ether was treated with 1-bromo-3-fluorobenzene (6.85 g, WO 97/46511 PCT/US96/20697 149 39.1 mmol) dropwise via syringe. After 1.5 hr the solution was transfered via cannula to a flask containing 3-chlorobenzaldehyde (5.0 g, 35.6 mmol) in 100 ml anhydrous diethyl ether at 0°C and stirred 2 hr.
The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anyhydrous magnesium sulfate to afford 8.40 g (>99% yield) of product A.
Pyridinium chlorochromate (15.0 g, 39.8 mmol) was added to a solution of the alcohol A (8.40 g, 35.5 mmol) in 100 ml dichloromethane and stirred 18 hr.
Diethyl ether (300 ml) was added to the reaction mixture and the black solution was filtered through a silica gel plug (30 cm), and washed with an additional 500 ml ether. After evaporation of the solvent the solid was recrystallized from acetone to give 6.31 g (76% yield) of product B.
Diethyl cyanomethylphosphonate (5.2 g, 29.6 mmol) was slowly added to a suspension of sodium hydride (1.2 g, 29.6 mmol) in N,N-dimethylformamide (100 ml). After 30 minutes the ketone B was added to the solution and stirred an additional 6 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give a yellow oil.
WO 97/46511 PCT/US96/20697 150 In a glass bomb, the oil was dissolved in ethanol (100 ml) and 10N NaOH (20 ml). A catalytic amount of rhodium suspended on alumina (ca. 35 mol percent) was added to the solution. The reaction mixture was shaken under 60 psi H2 for 24 hr on a Parr Hydrogenator. After filtering off excess catalyst, the solution was extracted with chloroform. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. After filtration and evaporation of the solvent in vacuo, the oil was taken up in tetrahydrofuran (100 ml). Diborane (23.4 ml, M) was added and the solution was refluxed for hr. The solvent was evaporated in vacuo and 6N HC1 ml) was added carefully. The solution was refluxed for 1 hr. After cooling, the mixture was basified with NaOH to pH 14 and partitioned between dichloromethane and water. The combined organic layers were dried over anhydrous magnesium sulfate and filtered. After evaporation of the solvent, the yellow oil was run through a silica gel column in chloroform and methanol. The solvent was evaporated in vacuo to give a yellow oil. GC/EI-MS (R,=8.15 min) m/z (rel.
intensity) 263 246 211 196 183 (100), 165 133 The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether afforded 0.96 g of a white solid, Compound as the hydrochloride salt.
PCT/US96/20697 WO 97/46511 151 1) Mg, ether 2) H CI 0 C
F
PCC-CH
2
C
2
CI
1L 0 Et" CN, NaH-DMF EtO" P C 2) Rh/Alumina, EtOH
H
2 60 p.s.i.
3) B 2
H
6
-THF
4) 6N HCI HCl-ether
NH
3
CI
Compound 30 (HC1 salt) Synthesis of Compound 35 was accomplished as described below. Compounds 36-37 were prepared in a similar manner.
A solution of 3-fluorobenzaldehyde (3.0 g, 24.2 mmol) at 0°C in 150 ml diethyl ether was treated with 3.0 M ethyl magnesium chloride (12.7 ml, 25.4 mmol) in tetrahydofuran (THF) via syringe. After 4 hr, the reaction mixture was quenched with water and partitioned LO between water and ether. The combined organic layers WO 97/46511 PCT/US96/20697 152 were washed with brine and dried over anyhydrous magnesium sulfate to afford 4.25 g of product A.
Pyridinium chlorochromate (6.53 g, 30.3 mmol) was added to a solution of A in dichloromethane (100 ml) and stirred 18 hr. Diethyl ether (300 ml) was added to the reaction mixture and the black solution was filtered through a silica gel plug (30 cm) and washed with an additional 500 ml ether. After evaporation of the solvent the solid was recrystallized from acetone to give 3.05 g of product B. The solvent was evaporated in vacuo to give a pale yellow oil.
Diethyl cyanomethylphosphonate (4.7 g, 26.4 mmol) was slowly added to a suspension of sodium hydride (1.1 g, 26.4 mmol) in 100 ml N,N-dimethylformamide. After 30 minutes the ketone B was added to the solution and stirred an additional 6 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give a yellow oil.
In a glass bomb, the oil was dissolved in 100 ml ethanol and 20 ml 10N NaOH. A catalytic amount of Raney Nickel suspended in water (ca. 15 mol percent) was added to the solution. The reaction mixture was a shaken under 60 psi H 2 for 24 hr on a Parr Hydrogenator.
After filtering off excess catalyst, the solution was extracted with chloroform. The combined organic layers were washed with brine and dried over anhydrous WO 97/46511 PCT/US96/20697 153 magnesium sulfate. After filtration, the oil was run through a silica gel column in chloroform and methanol.
The solvent was evaporated in vacuo to give a pale yellow oil. GC/EI-MS (R,=3.45 min) m/z (rel. intensity) 167 150 135 109 (100), 96 (53), The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether left a pale yellow solid that was recrystallized in hot acetonitrile to afford.2.2 g of Compound 35, as the hydrochloride salt.
OH
O
H
3 C
H
3
C
CH
3
CH
2 MgBr, ether
PCC-CH
2
CI
2
F
0 F
F
A B 1) 0 EtOlP CN NaH-DMF EtO' V 2) Raney Ni, EtOH, NaOH
H
2 60 p.s.i.
3) HCl-ether
H
3 C NH 3
C
Compound 35 (HC1 salt) WO 97/46511 PCT/US96/20697 154 Synthesis of Compound 38 was accomplished as described below.
To a solution of 3,3-bis(3-fluorophenyl) -propionitrile (1.5 g, 6.17 mmol) in 250 ml of THF at -700C was added butyl lithium (4.25 ml in hexanes, 6.8 mmol) by syringe over 5 minutes. The solution was stirred for 5 min then methyl iodide (1.75 g, 12.3 mmol) was added over 1 min. The reaction mixture was then allowed to warm up to room temperature and worked up by diluting with ether and washing with 5% HCl and water.
The ether layer was dried over sodium sulfate and evaporated to give 1.5 g of the methylated nitrile as a yellow oil.
To the 3,3-bis(3-fluorophenyl)- 2-methyl-propionitrile (1.46 g, 5.7 mmol) in 50 ml of dichloromethane at 0°C was 'added diisobutylaluminum hydride (1.02 ml, 5.7 mmol) by syringe over a 10 min period. The reaction was stirred for 30 min at 0 C followed by 2 additional hours at room temperature. The reaction was worked up by adding 200 ml of 10% HC1 and stirring at 40 0 C for 30 min followed by extraction of the product with dichloromethane. The organic layer was dried over sodium sulfate and evaporated to give 1.36 g of the product A.
To a solution of the aldehyde A (1.36 g, 5.23 mmol) in 40 ml of ether at 0°C was added methylmagnesium bromide (5.23 ml in ether, 5.23 mmol).
The reaction was stirred for 3 hr at room temperature, and then quenched with dilute HC1. The ether layer was WO 97/46511 PCT/US96/20697 155 separated, dried over sodium sulfate and evaporated to give 1.48 g of 4,4-bis(3-fluorophenyl) -3-methylbutan-2-ol.
To a solution of the alcohol (1.4 g, 5.07 mmol) in 300 ml of dichloromethane was added pyridinium chlorochromate (1.2 g, 5.58 mmol), and the mixture was stirred overnight. The reaction was then diluted with 100 ml of ether and filtered through a silica plug. The solvent was evaporated to give 1.39 g of product B.
The ketone B (1.3 g, 4.9 mmol) was added to a solution of methoxylamine hydrochloride (0.45 g, 5.38 mmol) and pyridine (0.44 ml, 5.38 mmol) in 30 ml of ethanol, and stirred overnight. The ethanol was then evaporated, and the residue taken up in ether and HC1. The ether layer was separated, washed once with HC1, dried over sodium sulfate and evaporated to give 1.4 g of the O-methyl oxime.
To a suspension of sodium borohydride (0.87 g, 23.1 mmol) in 5 ml of THF was added zirconium tetrachloride (1.35 g, 5.8 mmol), and the solution was stirred for 15 min followed by the addition of another ml of THF. The O-methyl oxime (1.4 g, 4.6 mmol) in ml of THF was then added, and the mixture stirred overnight. The THF was removed by evaporation in vacuo, and the residue treated with 10% sodium hydroxide.
After the bubbling ceased ether was added and the layers separated. The aqueous layer was extracted four times with ether, and the combined ether extracts were dried WO 97/46511 WO 9746511PCTJIUS96/20697 156 over sodium sulfate. The ether was evaporated to give 1.25 g of Compound 38.
CN L* BuLi, Mel
CHO
2. DIBAH,
CH-
2 c1 2 I. MeMgBrF 2. PC0
C"
2 C1 2 1. H2N-Oflvf pyridine
F
Compound 38 WO 97/46511 PCT/US96/20697 157 Compound 32 and Compounds 39 53 were synthesized according to standard procedures as described above.
Compounds 107, 116, 139, and 143 were prepared as synthetic intermediates used in the preparation of Compounds 32, 115, 20, and 25, respectively.
Compound 50 was also prepared using the chiral synthesis described below.
To an ice-cold solution of N-benzyl-(S)-a-methylbenzylamine (18.0 g, 85.2 mmol) in THF (75 ml) was added butyl lithium (2.5 M in hexane; 37.5 ml, 93.8 mmol) via a syringe over a period of min at such a rate as to keep the reaction temperature below 10 0 C during the addition. The reaction was then stirred at 0°C for 15 min. The reaction was cooled to -78 0 C in a dry ice/isopropanol bath and then a solution of benzyl crotonate (15.0 g, 85.2 mmol) in THF (100 ml) was added dropwise over a period of 45 min. The reaction was stirred at -78 0 C for 15 min, and then saturated NH 4 C1 (50 ml) was added. The reaction mixture was then quickly transferred to a separatory funnel containing saturated NaCl (500 ml) and ether (200 ml). The layers were separated and the aqueous layer extracted with ether (200 ml). The S 25 combined organic layers were dried, evaporated, and chromatographed on silica gel (50 mm x 30 cm) (hexaneethyl acetate to yield 21.0 g, 63.7% of product A. IH-NMR showed that the diastereoselectivity of the reaction is WO 97/46511 PCT/US96/20697 158 A mixture of magnesium (2.58 g, 106 mmol), THF (200 ml), and l-bromo-3-fluorobenzene (18.60 g, 106.3 mmol) was refluxed for 45 min. While still under reflux, product A (16.45 g, 42.45 mmol) was added via syringe with THF (25 ml) over a 2 min period. The reaction was refluxed for 1 hr, and then allowed to cool to room temperature. Saturated NHCl(aq., 200 ml) was added. The reaction mixture was then transferred to a separatory funnel containing saturated NaCl(aq) (500 ml) and diethyl ether (200 ml). The layers were separated and the aqueous layer extracted with ether (200 ml).
The combined organic layers were dried over sodium sulfate and evaporated to give 21.41 g of product B as a yellow liquid.
Product B (20.02 g, 42.45 mmol, theoretical) was dissolved in acetic acid (120 ml) and sulfuric acid ml). The reaction was stirred at 90 0 C for 1 hr.
The acetic acid was rotary evaporated giving a brown sludge. This material was placed in an ice bath and cold water (400 ml) was added. The product immediately precipitated. To the reaction was slowly added 10 N NaOH (150 ml) to neutral pH. Diethyl ether (200 ml) was added to this mixture. The mixture was shaken until there was no undissolved material. The ether layer was separated, washed with water (2 x 100 ml), dried over sodium sulfate, and rotary evaporated yielding 13.14 g (68.2% based on ester) of a thick brown oil. This oil was taken up in ether and converted to the hydrochloride WO 97/46511 PCT/US96/20697 159 salt with hydrogen chloride in diethyl ether to give product C as a yellow-white solid.
Product C (7.17 g, 14.6 mmol) was taken up in absolute ethanol (200 ml). Pearlman's catalyst (Pd(OH) 2 2.00 g) was added. The reaction was shaken under 70 psi hydrogen gas at 70 0 C for 20 hr, and the reaction mixture was filtered through Celite. The filtrate was rotary evaporated to give 3.54 g of a light yellow glass. This material was taken up in diethyl ether (100 ml) and was basified with 1 N NaOH (25 ml).
The ether layer was washed with water (1 x 25 ml), dried over sodium sulfate, and rotary evaporated to give 2.45 g of a light yellow oil. This material was Kugelrohr distilled (90-1000C, 1 mm Hg) to give 1.17 g of a colorless liquid. This material was taken up in diethyl ether and converted to the hydrochloride salt with ethereal hydrogen chloride. After rotary evaporation, the salt was recrystallized from 0.12 N HC1 (200 mg/ml). The crystals were filtered off and were washed with cold 0.12 N HCI yielding 0.77 g of Compound 50 as silvery white crystals (as the hydrochloride salt).
Compound 51 was synthesized in a similar manner to Compound 50 utilizing N-benzyl-(R)-amethylbenzylamine as a chiral starting material.
WO 97/46511 PCTIUS96/20697 160
-I
Br H 2 Nc CR3 KF/CeiLC
DMPU
CH
3 TH-F. reflux 1) BuLi, THE, -78-C 0 ACOH, H 2 S0 4
CH
3
CH-
3
B
1) Pd(OH) 2 EtOHF 2) HCI;Et 2 0
,NH
2
-HG!
compound 50 at (HCl salt) WO 97/46511 PCT/US96/20697 161 Synthesis of Compound 54 was accomplished as described below.
To a solution of 3,3'-difluorobenzophenone g, 22.9 mmol) and methyl cyanoacetate (3.4 g, 34.4 mmol) in 15 ml of ether was added titanium isopropoxide (16.9 ml, 57.25 mmol). This solution was stirred for 6 days at room temperature then quenched with 0.5 mol of HC1 in 300 ml of water. The mixture was diluted with 100 ml of ether, and the layers separated.
The ether layer was washed with 5% HC1 and saturated brine, then dried over sodium sulfate. The solvents were evaporated in vacuo to give 8 g of product A.
Compound A was dissolved in 50 ml of isopropanol, followed by the addition of a small amount of bromocresol green. Sodium cyanoborohydride (1.52 g, 24.2 mmol) was added all at once followed immediately with the dropwise addition of concentrated HC1, added at such a rate as to keep the solution yellow. After 2 hours the reaction was worked up by partitioning between ether and water. The ether layer was washed with water and saturated brine, dried over sodium sulfate, and concentrated to give the product B.
To a solution of lithium aluminum hydride (30.4 ml, 30.4 mmol) in THF was added product B (1 g, 3.04 mmol) in 2 ml of THF over a period of 30 seconds.
This solution was stirred overnight at room temperature, then quenched with the addition of 20 ml of ethyl acetate. The solvents were then removed in vacuo, and the resulting oil was dissolved in aqueous HC1 and WO 97/46511 PCT/US96/20697 162 acetonitrile. The product was then purified on a C-18 column with a gradient of 0.1% HC1 to acetonitrile to give 82 mg of Compound 54, as the hydrochloride salt.
EI-MS m/z (relative intensity) 277 100), 260 242 229 215 204 183 133 124 109 30 (22).
r CN F O NC.COOMe F .O YCH 3 0 CH3 Ti(i-OPr) 4 Ether F
F
A
OH
N
N H 3 C I NaCNBH 3 F YCH3 I.LA F Isopropano, CH 3 2. Chromatography Isopropanol. HCI in HCl/AcCN
F
F
B Compound 54 (HC1 salt) Compound 55 was synthesized analogously to Compound 21 except that ethyl iodide was used in the alkylation step. GC/EI-MS 7.43 min) m/z (relative intensity) 275 100), 258 229 204 (57), 201 183 134 124 109 72 (72).
The synthesis of Compound 56 was accomplished as follows.
The alcohol A was synthesized from 3-fluorobromobenzene and 3-fluoro-2-methylbenzaldehyde WO 97/46511 PCT/US96/20697 163 as described for product A in the synthesis of Compound 24.
The alcohol A (8.4 g, 36.2 mmol) was stirred with manganese dioxide (12.6 g, 144.8 mmol) in 100 ml of dichloromethane for 4 days. The reaction mixture was then diluted with ether and filtered through a 0.2 micron teflon membrane filter. The filtrate was concentrated to give 7.6 g of the ketone B.
The substituted acrylonitrile C was synthesized as described for product A in the Compound 20 synthesis.
To the nitrile C (4 g, 15.7 mmol) in 240 ml of ethanol was added 2 g of 10% palladium dihydroxide on carbon. This mixture was hydrogenated at 60-40 psi for 3 days. The reaction mixture was then filtered and concentrated. The resulting oil was dissolved in chloroform and chromatographed on silica gel isopropylamine in chloroform) to give the amine. This amine was dissolved in aqueous HCl/acetonitrile and purified via HPLC on C-18 acetonitrile/0.1% HC1 to 50% acetonitrile/0.1% HCL over min) then lyophilized to give 800 mg of Compound 56, as the hydrochloride salt. GC/EI-MS (Re 7.39 min) m/z (relative intensity) 261 64), 244 229 (57), 215 (100), 203 183 133 (39) 122 109 (32).
WO 97/46511 PCT/US96/20697 164 1) Mg, ether 2) H OF OH O F F 0 H 3 MnO 2
H
3 F Br F
CH
2 C12 F F A B EtO NHCI E P CN F H CN 1) Pd(OH) 2
H
2 Ethanol F
NH
3
C
EtO
H
3 C
H
3 NaD F 2) Chromatography in NaH-DMF HCl/AcCN F
F
C Compound 56 (HCl salt) The synthesis of Compound 57 was accomplished as follows.
To a solution of 5-fluoro-2-methylbenzonitrile g, 37 mmol) in 50 ml of THF was added 3-fluorophenylmagnesium bromide (46 ml, 40 mmol) and copper cyanide (0.072 g, 0.8 mmol). This solution was refluxed for 4 hours, then poured into ether/20% HC1 and stirred for a further 2 hours. The layers were separated, and the ether layer washed with water and saturated brine. The solution was dried over sodium sulfate and concentrated. The crude oil was purified on silica (hexane to 50% dichloromethane in hexane over min) to give 6.7 g of the ketone A.
The ketone A was converted to Compound 57 as described for Compound 56. GC/EI-MS 7.35 min) m/z (relative intensity) 261 52), 244 229 (67), 215 (100), 203 201 183 133 122 109 (26).
WO 97/46511 WO 9746511PCTIUS96/20697 165 i) Mg, ether F
H
F Br 2) F A EtO F NH 3
CI
E t P 1 1 C N F N 1 P d O H 2 H 2 E t h a n o l
C
NaH.DMFT 2) Chromatography in t HCI/AcCN
F
Compound 57 (HCi salt) The synthesis of Compound 58 was accomplished as follows.
To a solution of 5-f luoro-2-methylbenzoyl chloride (2.24 g, 13 minol) in 10 ml of dry TH-F was added iron III acetylacetonate (0.16 g, 0.44 mmol) The solution was cooled to QoC, and a TI-F solution of luoro-2-methylphenylmagnesium bromide (20 ml, 15.5 mmol) was added by syringe over a period of 30 min.
The reaction was stirred for another 30 min, then poured slowly into ether/50i HCl. The ether layer was separated, washed with saturated brine, dried over sodium sulfate, and concentrated to give 3.2 g of ketone A.
Dry THF (30 ml)*-was cooled to -78 0 C followed by the addition of butyl lithium (5.85 ml, 14.6 mmol, M solution in hexanes) Acetonitrile (0.76 ml, 14.62 mmol) was then added over a period of 2 min, then allowed to stir at -78 0 C for 15 min. To this solution WO 97/46511 PCTIUS96/20697 166 was added ketone A (3 g, 12.2 mmol) in 5 ml of THF. The solution was stirred for 30 min at -780C then allowed to warm to room temperature and stirred overnight. The reaction mixture was partitioned between ether and HC1. The ether layer was separated, washed with saturated brine, dried over sodium sulfate, and concentrated to give 2.2 g of the nitrile B.
The nitrile B (1 g, 3.48 mmol) was dissolved in 30 ml of ethanol and 3 ml of 10 N sodium hydroxide.
To this solution was added 1 g of a 50% aqueous slurry of Raney nickel, and the mixture was hydrogenated at psi for 20 hours. The reaction was filtered and concentrated to a white solid. This residue was taken up in ether/water and the ether layer separated. The ether solution was dried over sodium sulfate and concentrated to give 0.96 g of the hydroxyamine C.
The hydroxyamine C (0.96 g, 3.3 mmol) was taken up in concentrated HC1 and heated to 70 0 C which caused brief solution, and then precipitation of the alkene D. The alkene was collected by filtration and dissolved in 30 ml of ethanol and 1 ml of conc. HC1.
Palladium dihydroxide on carbon (0.4 g) was added to the solution-:and the mixture hydrogenated at 60 psi for 24 hours. The product was isolated by filtering off the catalyst and evaporating the solvent. The residue was dissolved in 0.1% HC1 and acetonitrile, and purified on C-18 (15% acetonitrile/0.1% HC1 to acetonitrile) to give 0.6 g of Compound 58, as the hydrochloride salt.
GC/EI-MS 7.82 min) m/z (relative intensity) 275 WO 97/46511 PCTfUS96/20697 167 100) 258 (20) 243 (74) 229 (38) 214 (65) 201 (31) 196 (32) 183 (20) 148 (35) 138 (42) 133 (48), 122 (69) 109 (41).
F~aMgBr BuLi, AcCN
THIF
CH Fe(Acac) 3
F""
F- ;C THF 0
CH
3
IH
CH
3 Raney Ni, H 2 NaOH N Ethanol
B
.CH
3
.CH
3 conc. HCI ,heat
.NH
3
CI
H
3 Pd(OH) 2 /C H 2
HCI
Ethanol F NNH 3
CI
F
Compound 58 (HC1 salt) WO 97/46511 PCTIUS96/20697 168 Synthesis of Compound 59 was accomplished as follows.
Compound 20 (2.0 g, 7.05 mmol) was dissolved in abs. EtOH (200 ml) and cooled to 5-10 0 C in an ice bath. Acetaldehyde (0.395 ml, 7.05 mmol, cooled to was added followed by nickel-aluminum alloy (200 mg, Fluka Chemika), and the reaction was hydrogenated on a Parr apparatus at 50 psi for 2 hr.
GC/MS showed 75% yield of the product and 2% of the N,N-diethyl side-reaction product. The reaction mixture was filtered through diatomaceous earth and the filtrate was evaporated under reduced pressure. The crude product was dissolved in isopropanol (5 ml)/ether ml)/ethereal HC1 (1 and then hexane (5 ml) was added to the cloud point. The cloudy mixture was filtered through paper, then hexane (10 ml) was added to the cloud point, and the solution was filtered again. The filtrate was stoppered and the product was allowed to crystallize at room temperature. The crystals were collected and dried to provide 0.325 g (14.8% yield) of Compound 59, as the hydrochloride salt (colorless needles).
:The synthesis of Compound 60 was accomplished as follows. Compounds 66, 69, 108, 123, 142, and 145 can be synthesized in a similar manner starting from Compounds 33, 50, 32, 60, 25 and 119, respectively.
Compound 20 (as the free base) (1.0 g, mmol) was refluxed in ethyl formate (150 ml) for 2 hr. The solvent was then removed under reduced WO 97/46511 PCT/US96/20697 169 pressure to provide 1.1 g, 99% yield of formamide A as a colorless oil. GC/MS showed the product to be 100.0% pure and was used in the following step without further purification.
The formamide A (1.1 g, 4.0 mmol) was dissolved in dry THF (100 ml) and heated to reflux (no condenser). Borane-methyl sulfide complex (1.2 ml, 12 mmol, 10.5 M) was added dropwise over a period of 3 min to the refluxing solution. Reflux was maintained for approximately 15 min, open to the air, until the reaction volume was reduced to approximately 30 ml. The reaction was then cooled in an ice bath, and ice (5 g, small pieces) was carefully added followed by H 2 0 (25 ml) and conc. HC1 (25 ml). The acidic solution was refluxed for 30 min. The reaction mixture was then cooled in an ice bath, basified with NaOH (10N), extracted with ether (3 X 100 ml), dried (Na 2 SO, anhydrous), and evaporated under reduced pressure. The crude product was dissolved in ether (10 ml)/hexane (50 ml) and ethereal HCL (1 M) was added dropwise to precipitate the hydrochloride salt. The salt was collected and recrystallized from isopropanol (3 ml)/ether (40 ml) to provide 0.5 g of as the hydrochloride salt.
WO 97/46511 PCT/US96/20697 170 Ethyl formate
H
SNH retlux F N 0 F
F
Compound 20 (as free base)
A
1) Borane-methyl sulfide, THF
CH
3
NH
2
CI
2)HCI
F
F
Compound 60 (HC1 salt) Alternatively, Compound 60 was synthesized from commercially available starting materials in the following four step reaction sequence. The first intermediate in this synthetic route, ethyl-N-benzyl-N-methyl-3-aminopropionate, was prepared by conjugate addition of N-benzylmethylamine to ethyl acrylate. The ester functionality of the first intermediate was then reacted with two equivalents of Grignard reagent (prepared from 1-bromo-3-fluorobenzene) to provide N-benzyl-N-methyl-3-hydroxy- 3 (bis-3-fluorophenyl) propylamine. The Grignard reaction product was then dehydrated in a mixture of 6N HCl/acetic acid to yield N-benzyl-N-methyl-3-(bis-3-fluorophenyl)-2-propenamine.
Catalytic hydrogenation of this material as its hydrochloride salt in ethanol over Pearlman's catalyst provided, after recrystallization from ethyl WO 97/46511 PCTIUS96/20697 171 acetate, colorless, needles of Compound 60 as the hydrochloride salt.
In a 500-rnL, 3-necked flask equipped with thermometer, reflux condenser, and a 125-mL addition funnel [charged with ethyl acrylate (88.3 mL, 81.5 g, 0.815 mol)] was placed N-benzylmethylamile (100 mL, 94.0 g, 0.776 mol) The ethyl acrylate was added dro-owise to the stirring reaction mixture over a period of 80 min. After stirring for 18 h at room temperature, the product was vacuum distilled and the fraction containing product was collected at 78-95 0
C
(0.12-0.25 mm Hg), (138 g, 80% yield) Bp 78-95 0
C
(0.12-0.25 mm Hg); TLC, Rt 0 0. 23 hexane -EtOAc 1)] Rf= 0.57 [MeOH-CHC1 3 (100:5)1; GC, 6.06 min; MS, 221 206 192 (M-C 2
H
5 176 (M-0C 2
H
5 144 (M-C 6
H
5 134 [CH 2 N (CH 3
CH
2 PhI 12 0 [N (CH3)CH 2 Ph1 91 77 (C 6
H
5 42 (CH 2
CH
2 N) H NMR (f ree base, CDCl3) d 1.25 ppm J 7.1, 3H-, CH 2
CH
3 2.20 3H,
NCH
3 2.51 J 7.3, 2H, COCH 2 2.74 J 7.2, 2H, CH 2 3.51 2H, NCH 2 Ph) 4. 13 J 1, 2H,
OCH
2
CH
3 7.18-7.35 (in, 5H, ArH) 1 3 C NYR (free base, CDCl3) d 15 .2 (CH 2 QH 3 3 4 .0 (COCH,) 4 2 .9 (NCH 3 3. 8 (NCH 2 6 1. 4 (O-CH 2
CH
3 6 3. 1 (QH 2 Ph) 12 8. 0 (CH) 129.2 (CH) 130.0 (CHI), 139.9 173.7 In a 5-L, four-necked, round-bottom flask, under nitrogen, were placed Mg [51.5 g, 2.12 mol, turnings, washed with THF (2 x 300 mL)] and THE (2 L).
An addition funnel was charged with 1-bromo-3-fluorobenzene (neat, 392.8 g, 2.24 mol).
WO 97/46511 PCTIUS96/20697 172 One-twentieth of the bromide was added to the magnesium suspension followed by one crystal of iodine. After initiation of the Grignard reaction the remaining 1-bromo-3-fluorobenzene was then added to the refluxing mixture over a period of 50 min. The reaction was refluxed for an additional 45 min. To the refluxing solution of Grignard reagent was added a solution of ethyl N-benzyl-N-methyl-3-aminopropionate (187.5 g, 0.847 mol) in THF (100 mL) over a period of 20 min.
After the ester addition was complete, the reaction was refluxed for 1h. The reaction was then cooled in an ice bath. Saturated NHC1 400 mL) and H,0 (400 mL) were added and the mixture was transferred to a separatory funnel. The organic layer was separated and the aqueous layer was extracted once with THF (400 mL).
The combined organic layers were washed with satd. NaC1 (2 x 200 mL, dried (anh. NaS0 4 filtered through paper, and rotary evaporated vacuum to yield 281.6 g of crude product as an orange, viscous oil. This material (281.6 g, 0.766 mol) was dissolved in acetonitrile (1.4 Concentrated hydrochloric acid (65.0 mL, 0.786 mol, 12N) was added to the stirring filtrate..- The crystallizing mixture was then cooled to OC for 17 h. The product was collected, washed with cold acetonitrile (800 mL), and dried to provide a white solid, 235.6 g (69% yield from the ester). For analytical purposes, the hydrochloride salt was further purified by recrystallization from acetonitrile: mp 194-197 0 C (uncorr.); TLC, R 0.23 [hexane-EtOAc WO 97/46511 PCT/US96/20697 173 Rf 0.85 [MeOH-CHC13 R, 0.72 [MeOH-CHC1 3 GC, t, 10.93 min; MS, 367 272 (M-CsH4F) 258 (M-CH 2 Ph-H 2 0) 219 (C 6
H
4
F)
2
CH],
148 [CH 2
CH
2
N(CH
3
)CH
2 Ph] 134 [CH 2
N(CH
3
)CH
2 Ph] 91 (C7H7), 42 (CHCH 2 N) H NMR (free base, CDC13) d 2.18 3H,
NCH
3 2.41 2H, CHCH 2 2.58 2H, CHN) 3.42 (s, 2H, CH 2 Ph) 6.86 (dt, J 8.5, J 2 1.8, 2H, Ar-H), 7.18-7.30 10H, Ar-H), 8.33 (bs, 1H, OH); 3 C NMR (free base, CDC13) d 35.6 (CHCH 2 41.5 (CH3, NCH 3 54.3 (CH 2 CH2N) 62.6 (CH2, CH 2 Ph) 113.1 J 23, CH, Ar-Cs,) 113.5 J 23, CH) 121.2 J 3, CH), 127.5 128.5 129.2 129.5 (CH) 129.6 137.0 150.2 162.8 J 243, q, Ar-C 3 3 In a 5-L, 3-necked reaction vessel, equipped with an overhead mechanical stirrer, reflux condenser, and thermometer, was placed N-benzyl-N-methyl-3-hydroxy-3-bis (3-fluorophenyl)propylamine hydrochloride (225.4 g, 0.559 mol), 6N HC1 (1392 mL) and glacial HOAc (464 mL).
The suspension was heated in a water bath (80-85 OC) and stirred for 18 h. After 18 h of heating, the reaction mixture was cooled in an ice/MeOH bath. Ethyl acetate (500 mL) was added to the cooled reaction mixture. NaOH (10N, 1.7 L) was then added to the cooled mixture over a period of 25 min at such a rate as to keep the temperature below 40 The mixture was transferred to a 6-L separatory funnel. The organic layer was separated and the aqueous layer was extracted with ethyl WO 97/46511 PCT/US96/20697 174 acetate (2 x 500 mL). The combined organic layers were washed with satd. NaCl (2 x 100 mL, dried Na 2
SO,
(250 rotary evaporated, and then dried under vacuum to provide 185.6 g (95% yield) of the free base as a fluid, brownish-colored oil.
The material above was stirred with hexane The resulting solution was filtered through paper. 4M HC1 in dioxane (146 mL) was added dropwise with stirring to the filtrate over a period of 5 min.
The semi-translucent solvent was then decanted away from the light-yellow colored, semisolid precipitate. The crude hydrochloride salt was dissolved in refluxing ethyl acetate (600 mL) and was filtered. The filtrate was then thoroughly cooled in an ice bath, and hexane (110 mL) was slowly added, with vigorous stirring.
After cooling in an ice bath for 2 h, the entire flask filled with a white crystalline solid. This material was collected on a filter funnel, washed with ice-cold hexane/ethyl acetate 400 mL], and dried to yield 128.7 g, 59.7% of a white solid. On standing the mother liquor precipitated another 14.8 g of an off-white solid. Total yield 128.7 g 14.8 g 143.5 Mp 141-142 °C (uncorr.); TLC, R, 0.20 [hexane-EtOAc Rf 0.75 [MeOH-CHC1 3 Rf 0.49 [MeOH-CHC1 3 GC, tR 10.40 min; MS, 349 330, 301, 281, 258 (M-CH 2 Ph) 240, 229 [M-N(CH)
CH
2 Ph] 201, 183, 146, 133, 109, 91 (CHI 2
C
6 H) 65, 42 (CH 2
NHCH
3 1 H NMR (free base, CDC1 3 d 2.20 ppm 3H, NCH 3 3.08 J 6.8, 2H, CH 2 N) 3.47 J 1, 2H, CHPh), WO 97/46511 PCT/US96/20697 175 6.29 J 6.8, 1H, CH), 6.85-7.04 6H, ArH), 7.19-7.35 7H, ArH).
N-Benzyl-N-methyl-3-bis(3-fluorophenyl)allylamine hydrochloride (120.0 g, 0.311 mol) was dissolved in abs.
EtOH (1250 mL). Pd(OH),/charcoal (10.0 g, -20% Pd, Fluka Chemical) was added. The reaction mixture was stirred under a steady flow of hydrogen gas for 18 h at 25 °C (atmospheric pressure). The mixture was then filtered through Celite'/fritted glass, the catalyst was washed with EtOH (2 x 50 mL), and the solvent was removed under reduced pressure to yield 95.4 g, 103% of crude product.
This material was dissolved in refluxing ethyl acetate (300 mL) with vigorous stirring and filtered. The flask was allowed to stand for 2 h at 25 OC, during which time the hydrochloride salt began to crystallize as needles.
The flask was then cooled, the product was collected, washed with ice-cold ethyl acetate (20 mL), and dried to yield 73.7 g, 80%, of Compound 60 as a white, crystalline solid. Mp 129-130C; UV/Vis, e 2.1 x 103 L-mol-cm- (264 nm, EtOH, 25 linear range: 0.05-0.20 mg/mL); TLC, R, 0.00 [hexane-EtOAc Re 0.07 [MeOH-CHCI 3 (100:5)1, Re 0.19 [MeOH-CHC13-NH4OH (100:5:1) GC, tR 7.45 min; MS, 261 229, 215, 201, 183, 164, 150, 138, -122, 101, 83, 75, 57, 42 [CHNHCH3 H NMR (HC1 salt, CDC1, 1 gtt MeOD) 6 2.56 2H, NCH 2 2.60 3H, NCH3), 2.85 J 2H, CHCH 2 4.11 J 8.0, 1H, CH) 6.87-6.98 4H, ArH), 7.06 J 7.7, 2H, Ar22.H) 7.25 (dd, J, 6, J 2 WO 97/46511 PCT/US96/20697 176 ArH); 'IC NMR (HCJ. salt, CDC1 3 I gt MeOD) 5 30.9
(CH
2
CH-CH
2 32. 7 (CH- 3
NCH
3 4 7. 6 (CH, £:HCH 2 4 7. 8
(CH-
2
CH
2 N) 113 .9 (J 2 1, ArC 2 2 or ArC 4 4 114. 5
T
-22, ArC 2 2 or ,123.2 J Ar-C, 6 130.3 J 9, Ar 14 4. 7 J 7, Ar 16 2.9 (d, J 245, Ar-C 3 3 ;IR: KBr pellet (cm- 1 3436.9, 2963.4, 2778.5, 2453.7, 1610.6, 1589.3, 1487.0, 144S.3, 1246.0, 764.5; solubility: 2 g/rnL (1-120) 1 g/ML (EtOH) anal. calcd. for C 16 Hl 7 NF,.HC1 (Karl Fischer: 0 .2 6 -0620) C, 64.37; H, 6.11; N, 4.69; found: C, 64.14;
H,
6.13; N, 4.69.
CHs~y-,3-F4HMgqr 025~l~
H~"CH
3 HC3H (2 equvt.) 0 OH IF ANHCH3.HCI A HCH 2 .HCI F NHCH3-HCI H Pd(OH)I/C Coomund so (HCI salt) WO 97/46511 PCT/US96/20697 177 Compound 105 was prepared by selective reduction of its corresponding alkene by catalytic hydrogenation over Pd/C.
Compound 61 was prepared from 2-bromo-4-fluoroanisole and 3-fluorobenzaldehyde as described for Compound 24. GC/EI-MS (Re 9.22 min) m/z (relative intensity) 277 74), 260 245 231 229 217 203 201 183 154 133 109 (100).
Compound 62 was prepared from 2-bromoanisole and 2-methoxybenzaldehyde as described for Compound 24.
GC/EI-MS 9.30 min) m/z (relative intensity) 271 100), 254 240 225 (40) 223 207 181 165 136 121 91 (83).
The synthesis of Compound 63 was accomplished as follows.
Alcohol A was obtained from 3-fluorobenzaldehyde as described for product A of the Compound 24 synthesis.
To alcohol A (10.275 g, 47 mmol) in 200 ml of ethanol was added 1.6 g of 10% Pd/C and 1 ml of concentrated HC1. This mixture was hydrogenated for 3 hi--at-60 psi, then filtered and concentrated to give the diphenylmethane B.
Product B (2.01 g, 9..86 mmol) was dissolved in ml of THF and cooled to -78 0 C. Butyl lithium (4.4 ml, 10.8 mmol, 2.5 M in hexanes) was added slowly by syringe, and then the reaction stirred for another 30 min at -78OC. To this orange solution was added cyclopentene oxide (0.9 ml, 10.3 mmol). The reaction was allowed to stir 3 hours while warming slowly to room temperature.
WO 97/46511 PCT/US96/20697 178 The reaction was quenched with 150 ml of 10% HC1 and extracted 3 times with ether. The ether layer was dried over sodium sulfate and concentrated to give 2.5 g of the alcohol C.
To the alcohol C (1 g, 3.5 mmol) in 10 ml of dry THF was added triphenylphosphine (1.37 g, 5.2 mmol) in 5 ml of THF and p-nitrobenzoic acid (0.87 g, 5.2 mmol) in 5 ml of THF. This solution was cooled to 0 C followed by the addition of DEAD (0.82 ml, 5.2 mmol), and allowed to stir overnight. The reaction was partitioned between water and ether. The ether was removed in vacuo and the resulting oil was chromatographed on silica gel in hexane/ethyl acetate to yield 365 mg of the cis-ester. This ester was hydrolyzed in methanol with potassium carbonate by stirring overnight. After removal of the methanol, the residue was taken up in ether, washed with water, dried over sodium sulfate and concentrated to give 250 mg of the cis alcohol
D.
To the alcohol D (.25 g, 0.9 mmol) in 5 ml of dry THF was added triphenylphosphine (342 mg, 1.3 mmol) in 5 ml of THF and phthalimide (191.3 mg, 1.3 mmol) in ml of THF. This solution was cooled to 0°C followed by the addition of DEAD (0.205 ml, 1.3 mmol), and allowed to stir overnight. The reaction was partitioned between water and ether. The ether was removed in vacuo and the resulting oil was chromatographed on silica gel in hexane/ethyl acetate to yield 100 mg of the phthalimide
E.
To a solution of the phthalimide E (100 mg) in ml of ethanol was added 8.8 mg of hydrazine hydrate.
WO 97/46511 PCT/US96/20697 179 The solution was refluxed for 5 hours then stirred at room temperature overnight. The reaction was worked up by adding 1 ml of conc. HC1 and filtering off the white solid. The resulting solution was concentrated to dryness and the solid taken up in ether and aqueous sodium hydroxide. The ether layer was dried over sodium sulfate and concentrated to a white solid. This was taken up in a small amount of ether and treated with drops of IM HCl in ether. After stirring overnight, the white solid was collected by filtration and dried to give 50 mg of Compound 63, as the hydrochloride salt.
GC/EI-MS 9.22 min) m/z (relative intensity) 287 (M 45), 270 201 183 133 (38), 109 83 56 (100), 43 (37).
WO 97/46511 PCT/US96/20697 180 1) Mg, etner 2%/H F
O
l- F Br Pd/C, H 2 EtOH HCI 1) BuLi THF 2) Cyclopentene Oxide Phthalimide, Ph 3 P, F DEAD, THF 1) p-Nitrobenzoic Acid, Ph3P, DEAD HF 2) Na 2 CO3 MeOH 1) Hydrazine, EtOH 2) HCI, Ether Compound 63 (HC1 salt) The synthesis of Compound 64 was done as described for Compound 63 except that the inversion step (product C to D) was omitted in order to obtain the cis amine as the final product. GC/EI-MS 8.28 min) m/z (relative intensity) 287 (M t 15), 270 201 183 133 109 (16) 84 (43) 56 (100) 43 (32) The synthesis of Compound 65 was accomplished as follows.
The ketone A was synthesized similarly to ketone B in the Compound 24 synthesis using 2-methylphenylmagnesium bromide and 2-methylbenzaldehyde as starting materials. This ketone was converted to the final product using the procedure outlined for Compound 58. GC/EI-MS (Re 7.84 min) m/z (relative intensity) WO 97/46511 PCTIUS96/20697 181 239 88) 222 (14) 207 (100) 193 (46) 178 (71) 165 (60) 130 (39) 120 (40) 115 (51) 104 91 (38) 77 (21).
1) Mg, ether 2)Q H 1 C; -Br
CH
3 Pcc
CH
2 Cl 2
CH
3 0
H
3
NH
2 BuLi AcCN
THF
Raney Ni H 2 NaOH Ethanol conc. HCI heat
.NH
3 Cl Pd(OH) 2 /C H 2
HCI
Ethanol
CH
3
NH
3
CI
H
3 Compound HC1 salt) WO 97/46511 PCT/US96/20697 182 Compound 119 was synthesized in a seven-step reaction sequence starting from commercially-available trans-3fluorocinnamic acid. This synthetic route is conceptually similar to that reported in the literature Patent 4,313,896 (1982)] for related analogs.
However, the three final steps were performed using a significantly different reaction sequence than that reported. The cinnamic acid was reduced and chlorinated in three steps to the corresponding 3-(3-fluorophenyl)propylchloride. This compound was brominated with NBS (N-bromosuccinimide) and the resulting trihalide was then reacted with 3-fluorophenol. The resulting ether was converted to the final product using a Gabriel synthesis.
Trans-3-fluorocinnamic acid (25.0 g, 150.4 mmol) was dissolved in abs. EtOH (250 mL) and hydrogenated over Pd/C (2.5 g) in a Parr apparatus at 60 psig, 50 0 C, for 1 h (hydrogen uptake: calcd. 245 psig; found 260 psig). The reaction mixture was filtered and evaporated to yield a crystalline product (23.0 g, GC, t, 4.43 min; MS, 168 Under a stream of dry nitrogen, at 0-10 0 C, a solution of 3-fluorohydrocinnamic acid (22.0 g, 131 mmol) in THF (100 mL) was added dropwise, over a period of 15 min, to a suspension of LiAlH, (4.23 g, 111 mmol) in THF (200 mL) The reaction was heated to reflux for a period of 1 h and then worked-up according to Fieser Fieser's Reagents for Organic Synthesis (Vol. 1, 1967) to provide a white solid (20.1 g, GC, t, 3.74 min; MS, 154 A solution of 3-(3-fluorophenyl)-1-propanol (15.0 g, 97.4 mmol) and triphenylphosphine (36.0 g, WO 97/46511 PCT/US96/20697 183 137.3 mmol) in CC1 4 (150 mL) was refluxed for 19 h.
Additional
P(CH,)
3 (3 x 3.0 g, 3 x 11.4 mmol) was added periodically over a period of 24 h. The resulting precipitate was removed by filtration and the solids were washed with hexane. The filtrate was evaporated under vacuum and the residue was suspended in hexane (200 mL) and then filtered. Evaporation of the filtrate provided 16.0 g of crude product which was purification by silica gel flash chromatography, elution with hexane, to provide 14.7 g of a colorless liquid. GC, tR 3.63 min; MS, 172/174 A solution of the above chloride (12.0 g, 69.5 mmol), N-bromosuccinimide (17.3 g, 97.2 mmol), and dibenzoyl peroxide (0.06 g) in CC1, (75 mL) was refluxed for 1 h. The reaction mixture was then cooled in an ice bath, filtered, and the solids were washed with hexane. The filtrate was evaporated to provide 17.9 g (100%) of product.
GC, t, 5.21 min; MS, 251/253 A mixture of 3-bromo-3-(3-fluorophenyl) -1-propylchloride (4.0 g, 15.9 mmol), 3-fluorophenol (1.98 g, 17.7 mmol), and K 2 CO, (2.65 g, 19.2 mmol) suspended in acetone (80 mL) was refluxed for 15 h. The volatiles were ther--removed under vacuum and the resulting residue was suspended.in a mixture of hexane (200 mL) and NaOH (0.1N, 100 mL). The layers were separated and the organic layer washed, 0.1N NaOH (100 mL) and H,0 (100 mL), dried (anh. Na 2 and evaporated in vacuuo. The resulting residue was chromatographed on silica gel, elution with hexane followed by hexane/EtOAc [100:1] then [40:1] to provide 1.64 g of product as a colorless oil. GC, tR 7.28 min; MS, 282/283 TLC rf 0.3, hexane/EtOAc WO 97/46511 PCT/US96/20697 184 [40:1].
A solution of 3-(3-fluorophenyl)-3- (3-fluorophenoxy)-1-propylchloride (1.52 g, 5.38 mmol) and potassium phthalate (1.20 g, 6.48 mmol) was heated to 90 0
C
in DMF (30 mL) for a period of 2 h in a nitrogen atmosphere.
The reaction mixture was then cooled and poured into H 2 0 (100 mL). The resulting solution was extracted with Et 2
O
(2 x 100 mL). The organic extract was washed, sat.
NaCI (100 mL) and H 2 0 (2 x 100 mL), dried (anh. ?a,SO 4 and evaporated under vacuum to provide 2.17 g of crude product.
The material was chromatographed on silica gel, elution with hexane/EtOAc [40:1] and then [20:1] to provide after evaporation 1.81 g of product as a glass.
A solution of N-phthaloyl-3-(3-fluorophenyl)-3 -(fluorophenoxy)-1-propylamine (1.74 g, 4.42 mmol) and anh. hydrazine (1.43 g, 44.6 mmol) in abs. EtOH '30 mL) was refluxed for 1 h. The reaction was cooled and evaporated under vacuum. The resulting material was suspended in Et 2
O
mL) and washed with 0.2N NaOH (2 x 25 mL). The organic layer was dried (anh. Na 2
SO
4 and evaporated under vacuum to provide 1.04 g which was purified by reverse-phase chromatography [Vydac Prep. C18; 264 nm; 50 mL/min; gradient elution ACN/0.1% HC1 aq., 10%-50% over 20 min; re 17.4 min], to yield 0.89 g of Compound 119 as a hygroscopic hydrochloride salt.
PCT/US96/20697 WO 97/46511 185 0 0 Cl
F'
BF
CI
N
F-O
__F
0
Q
F F -NH3CI y 0
F-
Comound 119 (HCI at) Compounds 118, 120-122 and 137 were prepared in a manner similar to the procedures used for the preparation of Compound 119.
Compound 113 was synthesized from commercially available .4,4-diphenylcyclohexenone in three steps. First, the alkene in the starting material was reduced by means of catalytic hydrogenation. Methoxylamine formation followed by reduction using standard procedures.
The synthesis of Compounds 188 and 189 was accomplished as follows.
PCTfUS96/20697 WO 97/46511 186 Compounds 188 and 189 The enantiomers of Compound 136 were separated by analytical chiral HPLC. Aliquots (20 tg) were injected onto a Chiralcel-OD-R (Chiral Technologies, Inc., Exton, PA) reversed-phase HPLC column (0.46 x 250 mm) using the following conditions: gradient elution, 40%-70% ACN 0.5N KTFA) over 30 min; flow rate, 1 mL/min; detector, 264 nm. Two identically-sized peaks were collected at 21.0 and 24.4 min. GC/MS analysis of the two samples indicate that both materials have identical GC retention times as well as identical mass spectra.
The synthesis of Compound 151 was accomplished as follows.
NH,
Compound 151 WO 9746511PCTIUS96/20697 187 3,3 -Bis (3 -flucrophe12Yl)Propanamide (Compound 2.51) A solution of liquid anh. ammonia (10 mL) in
CH
2 Cl 2 (50 mL) at -780C was treated with a solution of 3 3 -bis(3-fluorOphenyl)Propionyl chloride (2.19 g, 7. 81 mmol) in CH2Cl2 (25 mL) The reaction was then stirred at ambient temperature for 15 min and was then diluted with diethyl ether (500 mL) washed three times with 10% HCi, three times with 1N NaOH, and finally once with H, 2 0. The organic layer was dried (anh. Na 2
SO
4 and evaporated to give the primary amide as a white solid (2.01 9, 98%).
The synthesis of Compound 156 was accomplished as follows.
0 NCCIA'0(Et C. N H,/Ni (Rev) NH2 Compound 156 5-Cyanomethyid2.fo-10,11-~dihydrodibelzo fa, dicycloheptene To a solution of diethyl cyanomethylphosphonate (9.66 g, 54.5 mmol) in dry 1\,N-dimethylformamfide
(DMF,
mL) was added NaHl (60% dispersion, 2.20 g, 55.0 mmol) over a period of 2 min. The reaction was stirred for 10 min and then a solution of dibenzosuberone (10.3 g, 49.6 mmol) WO 97/46511 PCT/US96/20697 188 in dry DMF (10 mL) was added over a period of 2 min. The reaction was stirred at 80 0 C for 4 h under Water (200 mL) was added and the reaction mixture was extracted with EtO2 (2 x 100 mL). The combined organic layers were rotary evaporated to less than 50 mL. The resulting crystals were collected and washed with cold EtO (2 x 50 mL) to yield 7.48 g (65.3%) 5-(2-Aminoethyl)-5H-10,11-dihydrodibenzo[a,d]cycloheptene hydrochloride (Compound 156) 5-Cyanomethylidino-10,11-dihydrodibenzo[a,d] cycloheptene was dissolved in EtOH (100 mL). 1N NaOH (10 mL) and Raney® nickel (aq. suspension, 0.50 g) were added. The reaction mixture was shaken under 60 psig H 2 at 500C for 22 h, and was then filtered through Celite®. The filtrate was rotary evaporated and the residue was dissolved in Et20 (100 mL), washed with satd. aq. NaCl (50 mL) and H,O (50 mL) The Et,O layer was dried (anh. Na 2 SO,) and rotary evaporated to give the crude product (850 mg) as a colorless oil. This oil was dissolved in EtOAc (5 mL) and filtered. 1.OM HC1 (5 mL) in EtO was added to the filtrate and a white, crystalline solid precipitated. This material was recrystallized from EtOH mL)-EtO (12 mL) to yield 600 mg of product as a white powder.
The synthesis of Compound 167 was accomplished as follows.
SCH-I
3 ,CO, O O Ti(i-PrO OCHa OCH3 2) NaBCN Compound 167 WO 97/46511 PCT/US96/20697 189 2-Methoxypropiophenone A mixture of 2-hydroxypropiophenone (3.00 g, 20.0 mmol), iodomethane (3.40 g, 24.0 mmol), and K 2
CO
3 (granular, anh.; 13.8 g, 99.9 mmol) was refluxed in acetone (75 mL) for 18 h. The reaction mixture was cooled to room temperature and the inorganic salts were removed by filtration. The filtrate was evaporated under vacuum to give an oil which was subsequently dissolved in diethyl ether (200 mL) and then washed with 0.1N NaOH (3 x 50 mL) followed by H 2 0 (50 mL). The organic layer was dried (anh.
Na 2
SO
4 filtered, and evaporated to an orange oil (3.17 g, This material was used in the following step without further purification. TLC, Rf 0.55 MeOH:l% IPA:CHC1 3 GC, tr 4.58 min; MS, m/z 164 S)-N-1 (2-methoxyphenylpropyl)-3,3 -diphenylpropylamine (Compound 167) A solution of 2-methoxypropiophenone (0.848 g, 5.17 mmol), 3 ,3-diphenylpropylamine (1.00 g, 4.70 mmol), and titanium(IV) isopropoxide [Ti(OCH(CH3),) 4 (1.76 mL, 5.88 mmol, 1.25 equiv)] was stirred at room temperature for 6 h. EtOH- (2 mL) was then added, followed by sodium cyanoborohydride (0.295.g, 4.70 mmol) in portions over a period of 10 min, and the reaction was then stirred for 18 h. The reaction mixture was then poured into diethyl ether (200 mL) and the resulting suspension was centrifuged to remove the titanium precipitate. The supernatant was collected and the pellet was rinsed with diethyl ether (200 mL). The combined organic washings were evaporated under vacuum to give a crude oil which was chromatographed on silica gel (elution with 4% MeOH-CHC12) to provide 647 mg of product. The material was then dissolved in PCTIUS96/20697 WO 97/46511 190 diethyl ether (50 mL) filtered, and excess ethereal 1-id was added to precipitate the hydrochloride salt (125 mg, 7.4%) as a white solid; TLC, Rf 0.25 (4*1 MeOH-CH 2 Cl 2
GC,
tr 11.2 min; MS, rn/z 359 The synthesis of Compounds 172 -,176 was accomplished as follows.
CHO4 m.FC 6
H
4 MgBr F4 OCH3
F
OCH
3
CH
3
CN
1) 81-3 S(Ci) 2 2) HCI
NH
2
HCI
F-
Pd/C
FK
B8C CH Compound 173 Compound 174 Compound 176 Compound 175 R, S) -Dif2.uoro-4-mfethoxybenzhYdro1 A mixture of MgO-turnings (2.45 g, 101 mo~l), 1-brorno-3-fluorobelzee (17.6 g, 100 rnmol), and dry THE WO 97/46511 PCT/US96/20697 191 (200 mL) was carefully heated to reflux for 30 min. While still refluxing, 3-fluoro-p-anisaldehyde (15.3 g, 99.3 mmol) in THF (100 mL) was added over a period of 5 min. The reaction temperature was maintained for 30 min, cooled to room temperature, and then the reaction was quenched with satd. aq. NH 4 Cl (200 mL). The organic layer was separated, washed with satd. aq. NaCi (2 x 200 mL), dried (anh. Na 2
SO
4 and rotary evaporated to yield 23.5 g of product as an orange-brown oil.
3,3'-Difluoro-4-methoxybenzophenone Pyridinium chlorochromate (22.3 g, 103 mmol) was added to a solution of 3,3'-difluoro-4-methoxybenzhydrol- (23.5 g, 93.8 mmol) in CH 2 C12 (300 mL) and the reaction mixture was stirred for 16 h. Diethyl ether (500 mL) was added and the reaction mixture was filtered through Celite'.
The filtrate was rotary evaporated and the resulting oil was flash chromatographed (gradient elution of hexanes to 1:1 hex-EtOAc). The TLC-pure fractions were rotary evaporated to yield 1.58 g of a white solid. The rest of the impure fractions containing product were combined and rotary evaporated to the point where crystals began to form.
Additional hexane (300 mL) was added and the crystallizing solution was allowed to stand. The resulting crystals were collected and washed with hexanes (2 x 50 mL) to yield 6.81 g of product. The two batches were combined to afford a total yield of 8.39 g -a-Cyanomethyl-3,3' -difluoro-4-methoxybenzhydrol To dry THF (100 mL) was added butyllithium (2.6M in heptane; 16.0 mL, 41.6 mmol) at -780C. Acetonitrile (2.20 mL, 42.1 mmol) was added over a period of 1 min and WO 97/46511 PCT/US96/20697 192 the reaction was stirred at -78 0 C under N 2 for 30 min. A solution of 3,3'-difluoro-4-methoxybenzophenone (8.38 g, 33.8 mmol) in anh. THF (50 mL) was added to the reaction over a period of 5 min and the solution was stirred at -78 0
C
for 30 min. The cold bath was removed and the reaction was allowed to warm for 30 min. Satd. aq. NH 4 C1 (100 mL) was added to quench the reaction. The THF layer was separated, washed with satd. aq. NaCl (2 x 25 mL), dried (anh. Na 2
SO
4 rotary evaporated, and dried under vacuum to yield 10.1 g (103%) of product as a yellow oil.
and (Z)-3-(3-Fluoro-4-methoxy)-3- (3-fluorophenyl)allylamine hydrochloride (Compound 172) -a-Cyanomethyl-3,3' -difluoro-4-methoxybenzhydrol (9.77 g, 33.8 mmol) was dissolved in dry THF (200 mL) and heated to boiling (no condenser). Under a stream of nitrogen, borane-dimethyl sulfide complex (BH3-S(CH 3 10.1M; 16.8 mL, 170 mmol) was added carefully over a period of 2 min to the boiling solution. Boiling was then maintained for 15 min until most of the THF was gone. The reaction mixture was then cooled in an ice bath. Ice (10 g) was carefully added, followed by H 2 0 (50 mL) The reaction was then heated to near boiling and 12.1N HC1 (100 mL) was added. The reaction was boiled (no condenser) for 30 min and was then cooled in an ice bath, basified with 10N NaOH (100 mL), and extracted twice with EtO (200 mL, 100 mL) The combined ether layers were washed with IN NaOH (50 mL) and H 2 0 (50 mL), dried (anh. Na 2
SO
4 and rotary evaporated.
The resulting oil was flash chromatographed (CHC13; 1:100 MeOH-CHC1 3 1:10 MeOH-CHC13) through flash silica gel to afford 6.83 g of a yellow oil. This oil was dissolved in WO 97/46511 PCT/US96/20697 193 EtOH (2 mL) and Et20 (10 mL) 1.OM HCI in Et20 (27 mL) was added and the solution was rotary evaporated to yield 7.10 g of product as a solid, yellow foam.
(R,S)-3-(3-Fluoro-4-methoxy)-3-(3-fluorophenyl)propylamine maleate (Compound 173) The mixture of and (Z)-3-(3-fluoro-4methoxy)-3-(3-fluorophenyl)-allylamine hydrochlorides (7.10 g, 22.8 mmol) was dissolved in EtOH (200 mL) and a suspension of palladium on charcoal (10% Pd; 0.71 g) in (3.5 mL) was added. The reaction mixture was then shaken under 60 psig H 2 for 18 h and subsequently filtered through Celite". The filtrate was rotary evaporated, the residue was dissolved in EtOAc (25 mL) and EtO2 (100 mL), and was basified with sat. aq. NaHCO 3 (25 mL). The organic layer was separated, dried (anh. NaSO 4 and rotary evaporated to yield 6.28 g of an oil. This oil and maleic acid (2.59 g) were dissolved into hot EtOAc (100 mL). Diethyl ether mL) was added and crystals soon began to form. The crystals were collected and dried to yield 2.45 g of a white powder. The combined filtrate and washings afforded more crystalline product out upon standing. The second crop was filtered, washed with 1:1 EtOAc-Et2O (2 x 25 mL) and Et 2 O-41-x 25 mL), and dried to provide 3.69 g of a white powder. The total yield was thus 6.14 g (R,S)-3-(3-Fluoro-4-methoxy)-3- (3fluorophenyl)propylformamide (R,S)-3-(3-Fluoro-4-methoxy)-3- (3fluorophenyl)propyl amine maleate (3.12 g, 7.93 mmol) was free-based in a mixture of EtOAc (25 mL), Et20 (100 mL), and satd. aq. NaHCO 3 (25 mL) The organic layer was separated, dried (anh. Na 2
SO
4 and rotary evaporated. A solution of WO 97/46511 PCTIUS96/20697 194 the amine in ethyl formate (75 mL, 930 mmol) was refluxed for 17 h. The reaction solution was rotary evaporated to yield 2.38 g of formamide as a light-orange, viscous oil.
(R,S)-N-Methyl-3-(3-fluoro-4-methoxy) fluorophenyl)propyl amine maleate (Compound 174) (R,S)-3-(3-Fluoro-4-methoxy)-3-(3fluorophenyl)propyl formamide (2.27, 7.43 mmol) in THF (100 mL) was heated to boiling (no condenser). Boranedimethyl sulfide complex (10.1M; 2.30 mL, 23.2 mmol) was added carefully over a period of 2 min to the boiling solution. Boiling was then maintained for 15 min. The reaction was then cooled in an ice bath. Ice (10 g) was carefully added, followed by H 2 0 (30 mL), followed by 12.1N HC1 (50 mL). The reaction was then boiled (no condenser) for 30 min. The reaction was subsequently cooled in an ice bath, basified with 10N NaOH (50 mL), and extracted with Et 2 o (200 mL). The ether layer was washed with satd. aq. NaCI (100 mL), dried (anh. Na 2
SO
4 and rotary evaporated to yield 2.03 g of a yellow oil. This material was purified by RP- HPLC (20-60% acetonitrile-0.1% aq. HC1 over 20 min). The collected fractions were frozen and lyophilized to yield 1.28 g of a white solid. The free-base of the purified amine was dissolved in EtOAc. Maleic acid (305 mg) was added and the mixture was heated until everything had dissolved. The product was crystallized by adding mL). The crystals were filtered and washed with WO 97/46511 PCT/US96/20697 195 1:1 EtOAc-Et 2 O (10 mL) followed by EtO (10 mL) to yield 967 mg of product as a white, finely crystalline solid.
(R,S)-3-(3-Fluoro-4-hydroxy)-3- (3-fluorophenyl)propylamine maleate (Compound 175) (R,S)-3-(3-Fluoro-4-methoxy)-3-(3fluorophenyl)propyl-amine maleate (2.45 g, 6.23 mmol) was free-based in the normal manner and dissolved in CH 2 C1 2 mL). The resulting solution was cooled to -78 0 C. Under
N
2 flow, boron tribromide (1.OM in CH 2 C12; 15 mL, 15 mmol) was added over a period of 5 min. The cold bath was removed and the reaction mixture was allowed to warm to room temperature. After 30 min at 25 0 C, the reaction was hydrolyzed with 12.1N HC1 (10 mL). The aqueous layer was neutralized (pH 7) by the careful addition of 10N NaOH (14 mL). Satd. aq. NaHCO 3 (50 mL) was added along with Et 2 0 (100 mL) and EtOAc (20 mL). This mixture was shaken vigorously and the organic layer was separated. The aqueous layer was extracted with EtOAc (20 mL). The combined organic layers were dried (anh. Na,SO,) and rotary evaporated. The resulting oil was dissolved in EtOH, 1.OM HC1 in Et 2 O (7 mL) was added, and the solution was rotary evaporated. This material was then purified by RP-HiP-L&- [20-60% acetonitrile-0.1% HCl over 20 min] The collected fractions were frozen and lyophilized, affording 716 mg of a white solid. The free-base of the purified amine (315 mg) was dissolved in EtOAc. Maleic acid (138 mg) was added and the mixture was heated until everything dissolved. The EtOAc was rotary evaporated to give a hard glass which was dissolved in MeOH (5 mL). Water (100 mL) was then added and the solution was subsequently frozen and lyophilized. The above procedure yielded 445 mg WO 97/46511 PCT/US96/20697 196 of product as a white solid.
-N-Me thyl 3 (3 fluoro-4-hydroxy) 3 (3fluorophenyl)propyl amine hydrochloride (Compound 176) A solution of (R,S)-N-methyl-3-(3-fluoro-4methoxy)-3-(3-fluorophenyl)propylamin e (703 mg, 2.41 mmol) in CH 2 C12 (10 mL) was cooled to -78 0 C. Under nitrogen, boron tribromide (1.OM in CH 2 C1,; 6.0 mL, 6.0 mmol) was added over a period of 5 min. The cooling bath was then removed and the reaction was allowed to warm to room temperature. After 1 h, the reaction was quenched with 12.1N HC1 (5 mL). The aqueous layer was then neutralized (pH 7) by the careful addition of 10N NaOH mL). Satd. aq. NaHCO 3 (25 mL) was added along with Et2O (50 mL), EtOAc (15 mL), and CHC13 mL). This mixture was shaken vigorously, and the organic layer was separated, dried (anh. Na 2
SO
4 and filtered through paper. The crude product was then purified by RP-HPLC (20-60% acetonitrile-0.1% aq. HCl gradient over min). The fractions were frozen and lyophilized to afford 602 mg of product as a white solid.
The synthesis of Compound 185 was accomplished as follows.
S CI NHOH pFC D A D F F
(C
6 1i 3 P. DED Compound 185 (3-Fluorophenoxy) -3 -phenylpropylchloride Following a similar procedure for the chiral synthesis of fluoxetine [Srebnik, M. et al., J. Org. Chem.
53(13), 2916-20 (1988), hereby incorporated by reference herein], a solution of (S)-(-)3-chloro-l-phenyl-l-propanol WO 97/46511 PCT/US96/20697 197 (4.00 g, 23.4 mmol), 3-fluorophenol (2.63 g, 23.4 mmol), and diethyl azodicarboxylate (4.00 g, 23.4 mmol) were dissolved in THF (200 mL). The mixture was cooled to 0°C and triphenylphosphine (6.77 g, 25.8 mmol, 1.1 equiv) was added slowly over 10 min. The reaction mixture was then stirred at room temperature for 18 h. The THF was subsequently evaporated under vacuum to afford a gel which was washed with pentane (3 x 50 mL). The pentane washings were filtered and the filtrate was evaporated under vacuum to give a clear oil. This oil was dissolved in diethyl ether (150 mL) and washed with 1% HCl-satd. NaC1 (25 mL), 0.1N NaOH-satd. NaCl (2 x 25 mL), and finally H 2 0 (2 x 25 mL).
The organic layer was then dried (anh. Na 2 filtered, and evaporated to dryness under vacuum to give an orange oil.
The crude product was chromatographed on silica gel x 180 mm, gravity column), elution with 40:1 hexane-EtOAc, to provide 971 mg of product as a colorless oil.
-3-(3-Fluorophenoxy)- 3-phenylpropylamine (Compound 185) A solution of (R)-3-(3-fluorophenoxy)-3phenylpropyl chloride (0.971 g, 3.96 mmol), conc. NH 4
OH
and EtOH (20 mL) were shaken at 90 0 C on a Parr' apparatus.(50-90 psig) for 18 h. The mixture was then evaporated under vacuum and the residue was dissolved in (100 mL) and washed with H20 (2 x 25 mL) The organic layer was dried (anh. Na 2
SO
4 filtered, and evaporated under vacuum to provide a yellow oil. This material was then dissolved in EtOAc (50 mL) and filtered. A solution of maleic acid (0.272 g, 2.6 mmol, 0.93 equiv) dissolved in hot EtOAc (5 mL) was added to precipitate the maleate salt WO 97/46511 PCT/US96/20697 198 (519 mg, 53.5%) as a white solid: TLC Rf 0.25 (1% MeOH-CHC1 3 GC, tr 7.37 min; MS, m/z 245 The synthesis of Compound 187 was accomplished as follows.
0 CN CN 2 NCCHPO(OEt Al(H) CN LAHM S0 0 Compound 187 11-Cyanomethylene- 1, 11 -dihydrodibenzo c]oxepine To a solution of diethyl cyanomethylphosphonate (5.06 g, 28.6 mmol) in dry DMF (15 mL) was added NaH mineral oil dispersion; 1.14 g, 28.5 mmol) over a period-of 2 min. The reaction was stirred for 10 min and then a solution of 6,11-dihydrodibenzo[b, c]oxepin-11-one [Kurokawa M. et al., Chem. Pharm. Bull. 39(10), 2564-2573 (1991), hereby incorporated by reference herein] (4.00 g, 19.0 mmol) in dry DMF (5 mL) was added. The reaction mixture was stirred under argon for 21 h. Water (100 mL) was then added and the product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with satd. aq. NaCI (2 x 50 mL dried (anh. Na 2
SO
4 and rotary evaporated. The resulting solid was recrystallized from hot EtOAc (10 mL)hexanes (40 mL) to provide 2.43 g of product.
11- Cyanomethyl -1H-0, 11- dihydrodibenzo[b, c]oxepine Following a procedure described in Great Britain Patent 1,129,029 (1968) (Chem. Abstr. 27:37664), hereby incorporated by reference herein], for the preparation of aluminum amalgam, A10 granules (2.00 g, 74.1 mmol) were first etched with 0.5N NaOH (100 mL) and then washed with H 2 0 (100 mL) followed by EtOH (100 mL). A solution of HgC12 (2.00 g, 7.37 mmol) in Et20 (100 mL) was added. The reaction WO 97/46511 PCTIUS96/20697 199 mixture was stirred for 5 min and the supernatant was decanted. The solid Al(Hg) amalgam was washed with H 2 0 (100 mL), EtOH (100 mL), and then Et 2 O (100 mL). The amalgam was covered with Et20 (100 mL) and a solution of 1l-cyanomethylene-10,11-dihydrodibenzo[b,c]oxepine (2.00 g, 8.57 mmol) in EtOAc (30 mL) and EtOH (20 mL) was added.
Water (2 mL) was added and the reaction mixture was stirred for 18 h and then filtered. The filtrate was rotary evaporated to yield 1.65 g of product as a white, crystalline solid.
Il-(2-Aminoethyl)-11H-10,11-dihydrodibenzo[b,c]oxepine hydrochloride (Compound 187) To a stirring suspension of lithium aluminum hydride (0.67 g, 18 mmol) in anh. Et.O (30 mL) was added a solution of ll-cyanomethyl-11H-10,11-dihydrodibenzo[b,c] oxepine (1.65 g, 7.01 mmol) in dry THF (5 mL)/anh. Et 2
O
mL) over a period of 2 min. The reaction was stirred for 30 min. In the following order, H.O (0.7 mL), 5N NaOH (0.7 mL), and H 2 0 (2.1 mL) were added to the reaction mixture. Diethyl ether (30 mL) was added and the mixture was filtered. The filtrate was rotary evaporated and the resulting oil was dissolved in EtOH (10 mL)-Et20 (65 mL).
1.0M4.-HC in EtO2 (10 mL) was added and the solution was allowed to crystallize, giving 1.42 g (73.4 of the title compound.
ComDounds 67-68, 70-75, 79-82, 84-89, 91-95, 98- 100, 102, 104-106, 109-114, 117, 124-134, 138, and 140-150 were synthesized by standard procedures known to those skilled in the art, as described above.
Gas Chromatography of Simplified Arylalkylamines Gas chromatographic and mass spectral data were WO 97/46511 PCT/US96/20697 200 obtained on a Hewlett-Packard 5890 Series II Gas Chromatograph equipped with a 5971 Series Mass Selective Detector [Ultra-2 Ultra Performance Capillary Column (crosslinked 5% phenyl methyl silicone); column length, 25 m, column 0.20 mm; The flow rate, 60 mL/min; injector temp., 2500C; gradient temperature program, 20oC/min from 125 to 3250C for 10 min, then held constant at 3250C for 6 min].
Compound 19. (Rt 7.40 min), m/z (rel. int.) 211 195 194 (100), 193 180 179 178 (19), 168 167 166 165 (72) 164 153 152 117 116 115 (26) 106 104 (14), 103 102 91 78 77 63 51- (17) Compound 20. (Rt 7.34 min), m/z (rel. int.) 247 231 230 (100), 229 215 214 204 (43), 203 202 201 184 183 181 151 135 134 133 124 122 (16), 121 109 101 96 (18) 95 83 (11) 57 42 (9) Compound 21. (Rt 7.53 min), m/z (rel. int.) 261 262 245 244 (100), 230 229 216 (11), 215 214 204 203 202 201 (63), 184-(-12), 183 148 136 135 133 (36), 124 (21) 115 109 83 74 58 57 (11) Compound 22. (Rt 7.37 min), m/z (rel. int.) 261 244 229 204 203 201 183 (16), 138 133 109 101 75 58 57 44 (100), 42 (7) Compound 24. (Rt 8.21 min), m/z (rel. int.) 259 (M+,122), 260 242 241 228 227 216 WO 97/46511 PCT/US96/20697 201 213 (56) 212 (16) 211 (55) ,199 (32) ,196 (22) ,185 (34) 184 (19) 183 (67) 171 (16) ,170 (38) ,165 (44) ,151 150 (16) ,146 (13) 136 (46) ,134 (17) 133 (37) ,123 121 12 0 (13) 10 9 (100), 91 (34) 77 (29) 51 Compound 25. (Rt 8.49 min), m/z (rel. int.) 259 243 (16) 242 (95) 241 (25) 227 (27) 217 (15) 216 (100), 215 212 211 201 200 199 196 (15) 185 (20) 184 (19) 183 (50) 171 (24) 170 (28), 165 (15) 146 (10) 136 (11) 134 (12) 133 (23) 121 (21), 77 (9) Compound 26. (Rt 8.69 min), m/z (rel. int.) 259 243 (17) 242 (100) 241 (69) 227 (10) 215 (31) 212 (11), 211 184 183 172 171 170 (23), 165 (13) 147 (21) 146 (12) 134 (19) 133 (23) 121 (13), 91 77 Compound 27. (Rt 8.80 min), m/z (rel. int.) 243 226 (36) 212 (12) 211 (69) 200 (14) 199 (16) 198 197 (100) 196 (39) 185 (35) 184 (30) 183 (50) 179 (13), 178 (14) 165 (13) 134 (15) 133 (19) 120 (29) 117 (16), 115 (27) 104 (13) 101 (11) 91 (23) 77 (13) Compound 2S8. (Rt 8.77 min), m/z (rel. int.) 243 227 (15) 226 (85) 225 (26) 212 (19) 211 (100) 200 (22), 199 (17) 197 (18) 196 (29) 185 (46) 184 (35) 183 (64), 179 .165 134 133 121 120 (18), 117 (14) 115 (24) 101 (12) 91 (25) 77 (12) 65 (11) 51 (9) Compound 29. (Rt 7.89 min), m/z (rel. int.) 243 227 226 (52) 225 (17) 212 (19) 211 (100) 199 (13), 197 (12) 196 (21) 185 (19) 184 (24) 183 (43) 179 134 (11) 133 (15) 120 117 (10) 115 (17) 91 (14) Compound 30. (Rt 8.36 min), m/z (rel. int.) 263 WO 97/46511 PCTIUS96/20697 202 246 (26) 220 (13) 212 (17) 211 (100) 197 (10) 196 185 (43 184 (30) 183 (69) 181 165 (12) 133 (18), 115 (14) 101 (15) 75 Compound 31. (RL 9. 31 min), rn/z (rel. int. 279 18) 281 (11) 262 (10) 236 (10) 229 (33) 228 (17) 227 (100), 203 201 (33) 199 (15) 192 (15) 178 (19) 166 (18), 165 (53) 164 (13) 163 (16) 140 (12) 115 (13) 103 (9) Compound 32. (Rt 7.30 min), m/z (rel. int.) 229 213 (16) 212 (100) 211 (61) 197 (33) 196 (19) 194 (14), 186 (26) 185 (30) 184 (19) 183 (69) 170 (17) 166 (16), 165 (77) 134 (25) 133 (23) 116 (17) 115 (17) 103 (18), 101 (11) 78 (13) 77 (23) 75 (13) 51 (18) 4 3 (13) 42 (13) Compound 33. (Rt 7.56 min), m/z (rel. int.) 261 245 (18) 244 (100) 229 (43) 215 (16) 214 (15) 204 (57), 203 (43) 202 (15) 201 (64) 184 (14) 183 (73) 148 (16), 136 (13) 135 (46) 133 (60) 124 (51) 115 (27) 111 (14), 109 (96) 107 (16) 96 (14) 83 (27) 75 (20) 58 (96) 57 (33) 56 (23) 41 Compound 34. (Rt 7.39 min), m/z (rel. int.) 261 262 (14) 245 (18) ,244 (100) 229 (42) 216 215 214 (14) ,204 (52) ,203 (38) 20Q2 (14) 201 (54) 184 (12) 183 C 6 181 (10) ,148 (13) 136 135 (31) 133 124 115 109 107 83 (13) 58 (21) 57 (11) Compound 35. (Rt 4.45 min), m/z (rel. int.) 181 165 (10) 164 (76) 138 136 (11) 135 (63) 133 (12), 123 (22) 122 (22) 121 (11) 110 (21) 109 (100) 101 (13), 96 83 75 56 (15) 45 (21) 44 (4 0) 42 41 Compound 37. (Rt 4.87 min) m/z (rel. it.) 196 WO 97/46511 PCT1US96/20697 203 195 (17) 178 (76) 163 (20) 152 (41) 150 (22) 137 (12) 136 (29) 135 (60) 133 (19) 124 (13) 123 122 (49), 121 (17) 110 (78) 109 (100) 101 (17) 96 (29) 83 (17), (12) 56 (29) 55 45 (53) 44 (45) 43 (39) 41 Compound 38. (RL 7.68 min), m/z (rel. int.) 275 203 201 183 135 133 109 71 45 44 (100), 42 (4) Compound 39. (Rt 7.67mmn), m/z (rel. int.) 289 203 201 183 135 133 109 85 59 58 (100) Compound 40.. (Rt 7.63mmn), m/z (rel. int.) 289 (M+,19)1 203 201 (13) 183 (17) 152 135 133 109 85 70 58 (100) Compound 41. (Rt 7.93 min), m/z (rel. int.) 275 258 203 (27) 202 (14) 201 (52) 184 183 (59), 181 (10) 150 (11) 149 (18) 147 135 (24) 134 (14), 133 (40) 124 (12) 123 (19) 109 (76) 107 103 83 (15) 75 (10) 72 (100) 71 (12) 57 (18) 56 (21) (41) Compound 4-3. (Rt 9.18 min), m/z (rel. int.) 293 276 (10) 243 (11) 241 (31) 236 (11) 235 (16) 201 (18), 199-(-22,) 179 (11) 178 (25) 176 (10) 166 (16) 165 164 (19) 163 (24) 103 102 75 (11) 44 (100) 43 (11) 42 Compound 46. (Rt 9.34 mmi), m/z (rel. int.) 293 295 (28) 276 (16) 243 (24) 242 (15) 241 (75) 237 (12), 236 (18) 201 (33) 199 (31) 178 (26) 176 (13) 166 (31), 165 (100) 164 (32) 163 (43) 152 (11) 151 (13) 149 (12), 140 (30) 139 (11) 129 (12) 127 (20) 125 (31) 117 (26), 116 (26) 115 (64) 91 (12) 89 (17) 77 (13) 75 (22) 63 WO 97/46511 PCTIUS96/20697 204 (14) 58 (51) 57 (15) 56 (19) 41 (19) Compound 50. (Rt 7.37 min), m/z (rel. int.) 261 244 229 204 203 (11) 201 183 1 01 58 44 (100) 42 (7) Compound 51. (Rt 7.30 min) m/z (rel. int.) 261 244 (20) 229 204 (14) 203 (23) 202 201 183 (27) 133 121 101 75 58 44 (100), 43 42 (11) Compound 52. (Rt 7.24 min), m/z (rel. int.) 247 231 (13) 230 (81) 229 (47) 216 (12) 215 (32) 214 (16), 204 (29) 203 (31) 202 (16) 201 (63) 196 (21) 184 (20)4 183 (100) 182 (11) 181 (15) 170 151 (13) 150 (11), 135 134 133 124 122 121 (21), 109 101 (27) 96 (21) 75 (23) 43 (14) 42 Compound 53. (Rt 7.21 min), m/z (rel. int.) 247 248 (17) 231 230 (84) 229 (56) 215 (38) 214 203 (33) 202 (16) 201 (68) 2.96 (26) 184 (16) 183 (100), 182. (15) 151 (21) 150 (15) 135 (14) 134 (35) 133 (24), 124 (19) 122 (23) 121 (25) 111 (13) 101 (31) 96 (19), 75 (19) Compound 5-5. (Rt 7.86 min), m/z (rel. int.) 275 276 (20) 258 (59) 229 (58) 216 (31) 215 (22) 214 (19), 204 (A2,203 (41) 202 (21) 201 (82) 184 (18) 183 (100), 181 150 135 133 124 115 (13), 109 (90) 102. (15) 83 (20) 75 (16) 72 (23) 57 (13) 56 (24) Compound 56. (Rt 7.79 min), m/z (rel. int.) 261 262 (12) 244 (54) ,.229 (56) 218 (27) 217 (16) 216 (19), 215 (100) 214 (45) 203 (50) 202 (32) 201 (51) 197 (16), 196 (26) 2.83 (24) 138 (17) 135 (20) 134 (17) 133 (39), 122 121 109 101 96 83 WO 97/46511 PCTIUS96/20697 205 (13) Compound 57. (Rt 7.65min), m/z (rel. int.) 261 244 229 218 217 216 215 (100), 214 203 202 201 197 196 (19), 183 138 135 134 133 122 (29), 109 101 (13) Compound 58. (Rt 8.15 min), m/z (rel. int.) 275 (M+,134), 276 258 244 243 (100), 232 229 (53), 217 216 215 214 201 197 (21), 196 183 148 147 138 135 (46), 134 133 125 123 122 115 (27), 109 (54) 107 (17) 83 44 (19) 43 (19) Compound 59. (Rt 7.61 min), m/z (rel. int.) 275 204 203 (10) 201 183 (25) 109 101 58 (100), 57 56 44 (9) Compound 60. (Rt 7.34 min), m/z (rel. int.) 261 262 204 203 201 183 133 (11), 122 121 109 101 96 75 57 44 (100), 42 (11) Compound 61. (Rt 8.07min), m/z (rel. int.) 277 278 260 246 245 234 231 (32), 229 217 203 201 188 183 (22), 154 151 150 133 124 109 (100), 44 (14) Compound 62. (Rt 8.93 min), m/z (rel. int.) 271 (M+,115), 272 254 239 225 223 181 (33), 165 153 152 136 132 131 (16), 123 (20) 122 121 119 115 105 (17), 91 (100), 77 (22) Compound 63. (Rt 8.47min), m/z (rel. int.) 287 241 204 (27) 203 202 201 (30) 183 (38) WO 97/46511 PCTIUS96/20697 206 150 (13) 133 (20) 109 (27), (18) 56 (100) 43 Compound 64. (Rt 8.57 min), 288 (13) 270 (14) 242 (16), 204 (35) 203 (27) 202 (18), 147 146 135 (16), 83 82 75 57 Compound 65. (Rt 8.18 min), 240 (17) 222 (12) 208 (18), 192 (11) 181 (33) 180 (32), 165 (60) 152 (13) 130 (36), 116 115 107 (20), 91 (37) 77 (20) 65 (17) Compound 66. (RL 7.46 min), 84 (45) 83 (43) 82 (11) m/z (rel. init.) 287 241 (17) 215 (17) 214 (18), 201 (70) 183 (86) 150 (18), 133 (45) 109 (45) 84 (31), (21) 56 (100), 43 (44) m/z (rel. int.) 239 207 (100) 195 (24) 193 (48), 179 (57) 178 (72) 166 (16) 129 (17) 120 (40) 117 (34) 105 (19) 104 (42) 103 (11) m/z (rel. int.) 275 201 183 133 109 71 45 44 (100) 42 (3) Compound 67. (Rt 56 min), m/z (rel. int.) 225 24) 194 193 (12) 179 168 167 (12) 166 165 152 120 116 115 103 77 51 44 .(100) Compound 6B. (Rt 7.85 min), m/z (rel. int.) 239 194 193 (10) 168 (10) 167 (12) 166 165 (19), 152 134 116 115 91 77 59 58 (100), 44 (8) Compound 69. (Rt 7.35mn) m/z (rel. int.) 275 203 202 201 (23) 183 (35) 122 121 101 58 (100) 57 56 Compound 72. (Rt 7.90 min), m/z (rel. int.) 253 238 193 168 167 (14) 165 (17) 152 115 91 73 72 (100), 58 56 44 43 42 (8) WO 97/46511 PCTIUS96/20697 207 Compound 73. (Rt 7.29 min), m/z (rel. it.) 239 240 167 165 152 115 77 59 58 (100) 44 42 Compound 74. (Rt 8.01 min), m/z (rel. int.) 267 167 165 152 91 87 86 (100), 72 58 56 42 (4) Compound 79. (Rt .7.89 min) m/z (rel. int.) 230 214 (15) 213 (100) 212 (62) 201 (26) 200 (72) 198 (21), 195 (12) 188 (17) 187 (85) 186 (46) 18 5 (42) 184 157 (12) 135 133 (24) 109 (10) 107 (20) 106 (62), 79 78 51 Compound 81.' (Rt =7.40 min), m/z (rel. int.) 209 (M+,891, 210 (14) 208 (100) 193 (17) 192 (56) 191 (42) 189 (12), 178 (20) 166 (11) 165 (45) 152 (12) 132 (86) 131 130 .117 115 (48) 106 (22) 105 (10) 104 (12), 103 (16) 91 (16) 77 (22) 51 Compound 82. (Rt 7.93min), m/z (rel. int.) 275 (M+i,124), 276 (25) 232 (33) 215 (12) 214 (16) 204 (14) 203 (100), 201 (24) 196 183 (20) 150 (14) 138 136 (14), 135 (44) 133 (26) 125 124 (71) 123 (29) 121 (14), 115 (14) 111l (72) 110 109 (84) 101 (14) 83 (8) Compound 83. (Rt 7.22 min), m/z (rel. int.) 235 219 (17) 218 (100) 217 (62) 203 (20) 192 (10) 191 (38), 190 189 (14) 185 (17) 183 171 165 147 146 (11) 134 (12) 133 (17) 121 109 97 45 (7) Compound 85. (Rt =7.73 min), m/z (rel. int.) 239 222 (15) 179 ,178 168 (16) 167 (33) 166 (12), 165 (43) 161 152 (20) 146 (17) 129 120 118 117 (19) 115 (25) 91 (25) 77 72 44 WO 97/46511 PCTIUS96/20697 208 (100) 42 (6) Compound 86. (Rt =7.66 min), m/z (rel. int.) 239 222 168 167 166 165 152 120 117 115 91 72 44 (100) 42 (3) Compound 87. (Rt =7.33 min), m/z (rel. int.) 239 222 179 178 (11) 168 167 (27) 166 (13), 165 (48) 161 152 (22) 146 (14) 128 120 (11), 118 117 (21) 115 (31) 91 (29) 77 72 51 44 (100) 42 (9) Compound 88. (Rt 7.4 min), m/z (rel. int.) 227 183 (10) 168 (18) 167 (100) 166 (32) 165 (83) 164 163 153 152 139 115 105 77 (12) 51 45 (23) Compound 89. (RL 8.74 min), m/z (rel. it.) 260 (M+,220), 261 (39) 259 (89) 242 (18) 203 (17) 202 (16) 201 (61), 183 (58) 165 (100) 150 (20) 148 (25) 138 (24) 137 (61), 122 (73) 121 (3 1) i11 (47) 101 (23) 96 (16) 75 (16) 44 (17) 43 (29) Compound 90. (Rt =7.32mmn), m/z (rel. int.) 235 219 218 (100), 217 206 205 204 203 (21) 202 193 (12) 192 (71) 191 (62) 190 189 185 171 159 147 146 134 133 121 109 101 97 Compound 91. (Rt 10.67 min), m/z (rel. int.) 329 301 (20) 300 (81) 167 (18) 166 165 (18) 152 132 120 (45) 119 (21) 118 (11) 117 115 (11), 106 105 104 103 92 91 (100), 77 41 (6) Compound 92. (Rt 10.37mmn), m/z (rel. int.) 337 WO 97/46511 PCTIUS96/20697 209 338 204 203 201 183 (10) 133 121 120 (70) 106 92 91 (100) Compound 93. (Rt 10.25 min), m/z (rel. int.) 351 352 337 336 (39) 203 201 (11) 183 (17), 135 134 (20) 133 132 120 118 109 (18) 106 (12) 105 (100) 104 (13) 103 91 (14) 79 (11) 77 (12) Compound 94. (Rt 10.48 mini), m/z (rel. int.) 365 337 (25) 336 (100) 203 201 183 (14) 133 132 120 (14) 119 (13) 118 115 109 (20) 106 104 (10) 91 (52) Compound 95. (Rt 6.68min), m/z (rel. int.) 283 284 (11) 267 (11) 266 (71) 265 (19) 251 (24) 250 241 240 (100) 239 237 232 220 219 (65) 199 152 (12) 151 (18) 142 (20) 140 (13), 139 (20) 127 (22) 119 (24) 114 (12) 101 (10) 63 44 (9) Compound 96. (Rt =6.93 min), m/z (rel. int.) 265 249 (16) 248 (100) 247 (34) 233 (27) 232 (11) 223 222 (65) 221 (39) 220 (10) 219 (36) 202 (14) 201 (54), 152 (15) 151 (14) ,133 124 (12) 119 109 101 (14) 75 (9) Compound 97. (Rt 8.10 min), m/z (rel. int.) 241 101), 242 (18) 224 (50) 223 (19) 210 (11) 209 (37) 197 (12), 196 (10) 195 (55) 194 (16) 193 (60) 181 (29) 178 167 (38) 166 (16) 165 (52) 153 (12) 152 (36) 136 (27), 133 (12) 132 (14) 116 (12) 115 (25) 103 (13) 91 (100), 77 (18) Compound 98. (Rt 6.69 min), m/z (rel. int.) 232 204 (11) 203 (37) 202 (30) 201 (100) 188 184 (14), 183 (84) 182 (10) 181 (15) 170 109 (17) 107 (10) WO 97/46511 PCTIUS96/20697 210 83 75 57 (7) Compound 99. (Rt 6.75 min), m/z (rel. int.) 233 204 (12) 203 (68) 202 (26) 201 (100) 200 188 184 183 182 181 170 133 109 107 83 81 75 57 (9) Compound 100. (RL 7.66 min) m/z (rel. int.) 261 (M+,150), 262 (29) 217 (11) 216 (70) 215 (28) 214 (11) 203 202 (31) 201 (100) 196 (10) 184 (15) 183 (90) 181 (11), 133 (20) 124 (12) 122 (20) 109 (39) 101 (14) 83 75-(10) 45 (43) Compound 101. (Rt 7.72 min), m/z (rel. int.) 245 229 (16) 228 (100) 227 (36) 213 (21) 211 (22) 202 (57), 201 (30) 199 (21) 183 (50) 181 (14) 171 (15) 170 (26), 165 (12) 152 (21) 134 (19) 133 (35) 122 (28) 120 (19), 120 (13) 119 (12) 109 (20) 107 (20) 106 (18) 101 94 (15) 91 (20) 77 (18) 74 (15) 65 (20) 63 (14) (14) 51 (15) 44 (27) 43 (17) 42 (14) Compound 102. (Rt 8.33 min), m/z (rel. int.) 273 204 (16) 203 (16) 201 (15) 183 (18) 177 133 109 (13) 70 (41) 69 (100) 68 43 42 41 Compound 103. (Rt =8.59 min), m/z (rel. int.) 245 246-(-2- 229 228 (100), 227 213 211 (23), 209 (15),-_207 (12) 202 (19) 201 (32) 200 199 (84), 196 (10) 183 (38) 181 (15) 171 (13) 170 (23) 152 (19), 151 (15) 150 (10) 134 133 (32) 131 (12) 122 (36), 119 (15) 109 (24) 107 (10) 106 (12) 91 (19) 77 (12) Compound 104. (Rt 7.72 min) m/z (rel. int.) 261 262 (17) 217 (15) 216 (92) 215 (18) 204 (12) 203 (86), 202 (25) 201 (100) 184 (10) 183 (69) 148 (12) 133 (13), 122 109 (26) 101 83 45 (33) WO 97/46511 PCT1US96/20697 211 Comp~ound 105. (Rt 10. 24 min), m/z (rel.- int.. 351 7), 201 183 135 134 (79) 133 109 92 91 (100) 65 42 (7) Compound 106. (Rt 7.52 min), m/z (rel. int.) 259 260 (14) 258 244 (30) 228 (13) 227 214 (14), 201 (24) 165 (12) 164 (100) 162 (29) 133 (56) 109 (44), 44 42 (56) Compound 107. (Rt 7.45 min), m/z (rel. int.) 227 (M+,101), 228 (16) 226 (100) 211 (22) 210 (68) 209 (49) 207 (13), 196 (22) 1-84 (15) 183 (62) 150 (50) 148 (31) 133 (44), 132 (53) 130 (45) 117 (15) 115 (29) 106 (14) 77 (18), 51 (14) Compound 108. (Rt 7.46 min, m/z (rel. int.) 243 244 212 211 197 186 (12) 185 (10) 184 183 (19) 165 (15) 133 120 103 77 44 (100) 42 (6) Compound 109. (Rt 8.68 min), m/z (rel. int.) 285 (M+,110), 286 (22) 284 (27) 256 (16) 228 (37) 227 (27) 225 220 (11) 207 (15) 201 (27) 191 (14) 190 (100), 163 (11), 162 (85) 161 (10) 147 (11) 146 (11) 133 (32) 109 83 (12) 82 (36) Compound 110. 8.66 min), m/z (rel. int.) 285 286 (16) 284 (100) 243 (16) 227 (26) 225 (11) 221 220 (17) 214 (12) 207 (15) 201 (23) 147 (25) 146 (16), 133 (17) 2.09 (20) 42 Compound 111. (Rt =8.81 min), m/z (rel. int.) 287 214 204 (15) 203 (18) 202 201 (34) 183 (42), 135 3133 (28) 109 (28) 84 83 (100) 82 (19) 70 68 57 56 44 43 42 (14) Compound 112. (Rt 8.85 min), m/z (rel. int.) 287 (M+,141), WO 97/46511 PCT/US96/20697 212 288 (29) 286 (22) 202 (21) 201 (62) 183 (64) 133 (23), 109 (27) 84 (100) 83 (18) 82 (31) 57 (14) 56 (58) (53) 43 (14) 42 Compound 113. (Rt 9.08 min), m/z (rel. int.) 251 180 (38) 179 (36) 178 (39) 174 (15) 173 (100) 166 (11), 165 (53) 158 (12) 152 (10) 132 115 (28) 91 (31) 82 77 56 51 43 (23) Compound 114. (Rt 8.71 min), m/z (rel. int.) 237 (M+,197), 238 (37) 236 (67) 193 (15) 179 (30) 178 (40) 165 (41), 159 (43) 158 (26) 132 (24) 130 (16) 116 (17) 115 (37), 106 (21) 103 (34) 91 (50) 77 (48) 57 (68) 56 (100) 51 43 42 (34) Compound 115. (Rt 9.45 min), m/z (rel. int.) 271 255 (12) 254 (67) 253 239 (23) 229 (16) 228 (100), 227 (18) 224 (16) 223 (68) 213 212 (10) 211 197 (34) 196 (17) 195 (11) 181 (18) 169 (10) 165 (22), 153 (19) 152 (27) 146 (16) 145 (13) 141 (12) 139 136 (22) 134 (11) 133 (41) 122 (16) 121 (31) 115 91 77 65 63 44 Compound 116. (Rt 9.50 min), m/z (rel. int.) 269 268 (32) 254 253 (21) 252 (100) 251 (14) 238 (23), 237 (18) 221 (10) 209 178 165 (19) 162 (22), 160 (19) ,152 (18) ,147 (11) 146 145 (18) 139 (9) 130 (11) ,115 Compound 117. (RL 7.64 min), m/z (rel. int.) 212 183 (16) 182 (100) 180 167 152 104 (27) 91 78 77 (4 1) 51 (13) Compound 118. (Rt =7.46 min), m/z (rel. int.) 245 153 152 150 135 133 (10) 124 123 122 121 (17) 109 (16) 101 (14) 96 (24) (16) ,94 (100) ,93 83 77 (21) 75 (11) 66 WO 97/46511 PCTIUS96/20697 213 (30) 63 (10) 5 (14) ,50 (6) Compound 119. (Rt 7. 39 min), m/z (rel. int.) 263 7), 171 (14) 170 (14) ,152 (74) 151 (13) 150 141 135 (10) 133 (23) 123 (20) 122 (100) 121 (49) 120 (11), 113 112 (92) 111 109 (41) 107 (12) 103 (13) 102 (11) ,101 (40) 97 96 (66) 95 94 84 (28) 83 (88) 82 81 (16) 77 (14) 75 (54) 74 69 64 63 57 56 51 50 (12) 42 (8) Compound 120. (Rt =8.48 min), m/z (rel. int.) 279 159 (16) ,157 (49) ,153 (11) 152 (100) 150 (12) 133 (11j, 130 (27) 128 123 (12) 122 (57) 121 (23) 111 109 (25) 101 (23) 99 (16) 96 (26) 95 (10) 83 (28) 73 (10) 65 (12) 64 (11) 63 (22) 51 50 (8) Compound 121. (Rt 8.30 min), m/z (rel. int.) 275 152 (15) 125 124 (100) 122 (14) 121 109 96 95 81 77 65 52 (11) Compound 122. (Rt 7.39 min), m/z (rel. int.) 263 170 (12) 152 (66) 151 (10) 150 (18) 141 (68) 135 133 (19) 123 (16) 122 (76) 121 (39) 112 (100) 111 (18), 109 (36) -107 (11) 103 (11) 102 101 (33) 96 (56) (32) 92 (11) 83 (96) 81 (13) 77 (13) 75 (43) 64 6 3 4-26), 57 56 (14) 51 (14) 50 (11) Compound_123. (Rt 5.88 min), m/z (rel. int.) 275 276 202 201 (30) 183 (28) 133 109 101 71 59 (12) 58 .(100) 44 42 (26) Compound 124. (Rt 7.05 min), tn/z (rel. int.) 229 213 (15) 212 211 198 197 (100), 196 (24), 186 (12) 185 (21) 184 (29) 183 (87) 179 178 177 (13) 176 171 170 (18) 169 166 165 152 133 75 63 57 56 (4) WO 97/46511 WO 9746511PCTIUS96/20697 214 Compound 125.
226 (13) 209 178 (20) -165 104 (94) 103 (13) 51 (20), Compound 126.
244 (31) 152 133 (21) 122 83 (27), Compound 127.
208 (20) 207 178 (36) 167 130 (26) 129 65 (7) Compound 128.
212 (15) 194 179 (53) 178 152 (24) 120 (Rt =7.54 min), m/z (rel. int.) 225 (13) ,208 (75) ,193 (13) /180 (14) 179 (21), (22) 130 (34) ,117 (59) ,115 (28) 105 (18), (45) 91 (100) ,78 (30) 77 (38) 65 (36) ,63 45 (17) (Rt 7. 81 min), m/z (rel. int. 261 12) (27) 151 (17) 150 ,136 (11) 135 (100), (24) 115 110 (13) ,10 9 (90) 107 96 56 (7) (Rt 7.93 min), m/z (rel. int.) 225 193 (13) 181 180 (37) 179 (100), 166 (12) 165 (36) 152 134 117 (18) 115 (22) 104 91 (38) 77 (Rt (36) (60) (39) 7.42 min), m/z (rel. int.) 211 193 (18) 182 (62) 181 (20) 180 (17), 176 (11) 167 (57) 166 (44) 165 (100), 116 (12) 115 (28) 104 (22) 103 91 (46) 89 (16) 78 (10) 77 (20) 65 (15) 63 (12) 51 (12) Compound 1-29. (Pt 7.39 min), m/z (rel. int.) 229 (M+,104), 230 (19) 212 (28) 211 (14) 201 (13) 200 (85) 199 (22), 198 197 (50) 196 (58) 185 (73) 184 (45) 183 (100), 179 (43) 178 (55) 177 (17) 176 (17) 170 (18) 165 (33), 152 (12) 133 (22) 120 (57) 115 (17) 109 (44) 104 (23), 103 (17) 91 (32) 89 (16) 83 78 (12) 77 (22) 63 (16) 51 (13) Compound 130. (Rt 7.38 min), m/z (rel. int.) 229 (M+,133), 230 212 211 200 199 198 (16), 197 (53) 196 (64) 185 (49) 184 (43) 183 (100) 179 (28), 178 (29) 177 (14) 170 (19) 165 133 120 WO 97/46511 WO 9746511PCT/US96/20697 215 115 (19) 109 (32) 104 (17) 103 (18) 91 (38) 89 (17) 83 (18) 77 (24) ,63 (16) Compound 131. (Rt 7.40 min), m/z (rel. it.) 229 (M+,146), 230 (26) 212 (48) 211 (23) 200 (51) 199 (17) 198 (16), 197 (61) 196 (70) 185 (50) 184 (43) 183 (100) 179 (28), 178 (28) 170 (20) 165 (23) 133 (21) 120 (35) 115 109 (59) 104 (25) 103 (17) 91 (27) 89 (17) 83 (22) 77 (22) Compound 132. (Rt 7.03 min), m/z (rel. int.) 0 185 184 (100), 183 181 165 155 (12), 153 (14) 152 (12) 120 (85) 119 (67) 115 (10) 106 (16) 91 (19) 89 (14) 78 (12) 77 (25) 51 (16) Compound 133. (Pt 7.09 min), m/z (rel. int.) 211 195 (16) 194 (100) 181 (27) 180 (70) 179 (31) 178 (28), 166 (25) 165 (40) 152 120 (14) 119 (14) 118 (12), 115 (10) 104 (26) 103 (53) 102 (12) 91 (62) 89 (10) 78 77 (42) 65 51 (13) Compound 134. (Rt 7.45 min), m/z (rel. int.) 211 183 182 (100), 181 179 178 167 (27), 166 165 (46) 152 115 104 103 91 (29) 89 78 77 65 (7) Compound 135. (Rt =8.60 min), m/z (rel. int.) 273 257 (144) 256 (76) ,231 (16) 230 (100) 228 (18) 227 (57) 213 (14) 211 (37) 202 (30) 201 (40) 199 (26) 184 (13), 183 (50) 181 (12) 171 (17) 170 (20) 152 (15) 150 (19), 134 (15) 133 (31) 122 (14) 121 (29) 109 (16) 107 (13), 106 (17) 91 (12) 65 (12) Compound 136. (Rt 9.26 min), m/z (rel. int.) 275 277 260 259 258 257 243 234 (33) 233 (19) 232 (100) 231 (13) 229 (15) 227 (42), 224 (15) 223 (86) 208 (13) 197 (45) 196 (26) 195 (13), WO 97/46511 PCTJUS96/20697 216 182 (14) ,181 (33) ,179 (11) ,178 (18) ,166 (22) ,165 164 (12) ,163 (10) ,153 (32) ,152 (55) 15 (18) ,149 139 137 (17) ,136 (19) ,121 (13) ,115 (25) ,102 (11) 91 77 (17) Compound 137. (Rt =7.42 min), m/z (rel. it.) 245 153 152 141 (64) 135 (10) 134 (100) 132 (11), 117 115 (12) 112 (56) 105 (15) 104 (55) 103 (32), 91 84 83 78 77 -75 63 57 51 (9) Compound 138. (Rt= 9.24 min), m/z (rel. int.) 289 (M+,77) 290 (16) 230 (20) 229 (21) 215 (15) 203 (22) 201 (32) 183 134 (10) 133 124 121 109 101 (10) 73 (100) 43 (23) Compound 139. (Rt =7.25 min), m/z (rel. int.) 245 246 244 229 228 227 225 224 (15) 214 (13) ,201 183 (13 151 (13) 150 (100) 149 (14) 148 (58) ,135 133 (54) 124 (14) 122 (12) 109 (18) 101 (15) ,75 (13) Compound 140a. (Rt =8.64 min), m/z (rel. int.) 271 272 (14) 270 255 254 (100) 242 (19) 227 (14), 226 -225 199 197 (30) 196 (25) 183 (32) 176 (27) 170 (20) ,150 (44) 148 (34) 146 (14) 133 (32), 131 121 (11) (Rt =8.68 min), m/z (rel. int.) 271 272 (10) 270 (33) 255 (20) 254 (100) 242 (15) 227 (12), 226 (54) 225 (40) 209 199 (14) 197 (22) 196 (19), 183 (25) 176 (21) ,170 (16) ,150 (33) 148 (22) 146 133 (20) 131 Compound 141. 8 .44 min), m/z (rel. int.) 257 258 256 241 240 (100) 239 (19) 226 (22) 225 209 197 (14),'196 183 170 (16), WO 97/46511 PCTIUS96/20697 217 162 (19) ,160 (10) ,150 (28) 148 (26) ,147 146 (8) 145 (13) ,133 (20) ,130 121 Compound 142. 8.4 7 min), m/z (rel.- t. 273 14) 217 216 (31) ,215 183 170 ,150 121 58 45 44 (100) Compound 14 3. CR, 9. 39 min), m/ z (re1. int.) 2 73 47) 275 (16) 274 (19) 272 (36) 258 (39) 257 (26) 256 (100), 255 (17) 242 (25) 241 (15) 221 (23) 178 (25) 177 (11), 176 (14) 168 (14) 167 (11) 166 (54) 165 (34) 164 (34), 163 (16) 162 (45) 160 (19) 152 (28) 151 (22) 149 (19), 147 (18) 145 (24) 139 (11) 136 (15) 131 (15) 130 121 (15) 115 (14) 111 103 (13) 102 (19) 89 (ilY, 77 75 63 51 (12) Compound 145. (Rt =7.35 min), m/z (rel. int.) 277 122 109 96 95 83 75 63 57 44 (100) 4 2 Compound 148. (Rt 8.43 min), m/z (rel. int.) 261 3), 170 (14) 169 168 (44) 153 151 140 139 138 (15) 132 125 123 (40) 115 103 102 101 95 94 (100), 89 77 (22), 66- 65 63 51 50 Compound 149. (Rt =9.28 min), m/z (rel. int.) 295 170 (.3221, 169 (12) 168 (100) 166 159 (22) 157 (66), 152 (11) 140 (16) 139 (11) 138 132 130 (32), 129 128 (82) 127 (10) 125 (16) 115 (12) 111 103 (55) 102 (18) 101 (15) 99 (19) 89 (10) 77 (26) 76 75 73 65 64 63 51 (11).
Compound 150. (Rt 8.32 min), m/z (rel. int.) 279 171 170 (37) 169 (13) 168 (100) 166 ,.142 141 (88) 140 (19) 139 (12) 138 (42) 132 (12) 130 125 (16) 115 (12) 113 (10) 112 (89) 111 (11) 104 WO 97/46511 PCTJUS96/20697 218 103 (60) 102 (19) 101 (12) 95 (14) 89 (11) ,84 (11) 83 (24) 77 (29) 76 75 (24) 63 (13) 57 (17) 51 (11).
Compound 151. (Rt 7.68 min), m/z (reil. init.) 261 244 216 (79) 203 (65) 201 (82) 183 (100) 121 101 (40) 75 (35) 44 (52).
Compound 152. (Rt 8.097 min), m/z (rel. int.) 42 43 44 (42) 56 (13) 57 (10) 58 (72) 71 72 (74), 73 (14) 74 (14) 75 (14) 86 (15) 95 96 (10) 100 (42) 101 (31) 114 (90) 115 120 (10) 121 (20) 122 123 138 (10) 149 164 170 181 183 (100) 184 (15) 188 194 195 196 201 (64) 202 (21) 203 (63) 204 (10) 214 (12) 215 (12), 216 (12) 317 (92) 318 Compound 153. (Rt 7.88 min), m/z (rel. int.) 42 43 44 46 72 75 86 95 96 101 (20) 109 (14) 121 (30) 122 (14) 123 139 149 (10) 170 181 183 (59) 184 188 194 (11) 195 196 (10) 201 (51) 202 (17) 203 (56), 204 214 (10) 215 (18) 216 (52) 217 (13) 289 (100), 290 Compound 154. (Rt 7.74 min),'m/z (rel. int..) 42 44 (23) 45 (35) 46 (15) 58 (20) 72 (59) 73 (17) 75 (12), 86 96 101 (18) 121 (22) 183 (52) 194 201 (44) 202 (15) 203 (41) 214 215 (11) 216 (20) 217 (10) 289 (100) 290 Compound 155. (Rt 7.67 min), M/z (rel. int.) 58 95 96 (11) 101 (22) 109 (16) 121 (33) 122 125 (12) 149 183 (62) 184 (10) 196 (12) 201 (57) 202 (19) 203 (53) 214 215 (19) 217 (13) 275 (100) 276 (18).
Compound 156. (Rt 8.93 min), m/z (rel. int.) 237 WO 97/46511 PCTIUS96/20697 219 220 (41) 219 (30) 219 (30) 206 205 (39) 204 194 (28) 193 (100) 192 (21) 191 190 189 (17), 179 (15) 178 (50) 177 176 165 (20) 152 128 116 115 (39) 91 (11).
Compound 157. (Rt 10.88 min), m/z (rel. int.) 343 3.00 (100) 167 (16) 166 166 165 (16) 152 133 120 118 117 115 104 92 9 1 (62) 77 Compound 158. (Rt 10.74 min, m/z (rel. int.) 342 300 (100) 167 (13) 166 165 (13) 152 120 (22), 118 -115 106 104 91 (31).
Compound 159. (Rt 11.41 min), m/z (rel. int.) 363 336 (33) 335 (24) 334 (95) 182 (10) 181 168 (14), 167 (40) 166 (18) 165 (36) 156 (27) -155 (15) 154 153 (27) 152 (29) 140 139 138 (14) 127 (32), 126 125 (100) 117 (19) 116 115 (24) 103 (11), 91 (43) 77 (15) 72 41 (12).
Compound 160. (Rt =11.48 min), m/z (rel. int.) 363 336 (35) 335 (25) 334 (100), 182 181 (11) 168 167 (29) 166 (13) 165 (29) 156 155 (11) 154 (37), 153 (26) ,,152 (23) 140 139 138 (12) 127 (26), 126 125 (81) 125 (81) 117 (13) 115 (17) 103 91 Compound-161. (Rt 11.83 min), m/z (rel. init.) 408 407 (12) 381 (24) 380 (98) 379 (25) 378 (100) 200 (77), 199 (31) 198 (87) 197 (24) 184 (17) 182 (15) 181 (16), 171 (75) 169 (77) 168 (18) 167 (60) 166 (22) 165 (58), 152 (32) 118 (27) 117 (47) 116 115 (37) 104 (13), 103 (19) 91 (64) 90 (17) 77 Compound 162. (Rt 12.02 min), m/z (rel. int.) 408 380 (100) 379 (25) 378 (99) 200 (40) 199 (32) 198 (48), WO 97/46511 PCTIUS96/20697 220 197 (30) ,184 (18) ,182 181 (23) 171 169 168 (16) ,167 (49) ,166 (18) ,165 (50) 152 (28) ,119 (11) 118 (32) ,117 (46) ,116 (12) ,115 (34 104 103 (17), 91 (63) 90 (16) 89 (10) 77 (23) Compound 163. (Rt 10.58 min), m/z (rel. int.) 347 318 (100) 181 168 167 (24) 166 (17) 165 (26), 152 (16) 150 139 138 (66) 137 (23) 137 (23), 136 (10) 124 122 (13) 117 115 (14) 110 109 (100) 103 91 (22) 77 Compound 164. (Rt 10.59 min), m/z (rel. it.) 347 318 (100) 181 178 168 167 (27) 166 (17), 165 (28) 152 (16) 150 139 138 (70) 137 (18); 136 (11) 122 (14) 117 115 (13) 110 109 (79), 103 91 (20) 91 (20) 77 Compound 165. (Rt =10.61 min), m/z (rel. int.) 347 318 (95) 181 167 (20) 166 (10) 165 (21) 152 (13) 138 (34) 137 (27) ,136 (11) ,136 (11) 122 (14) 117 (6) 115 (11) 110 109 (100) ,91 (22) 77 Compound 166. (Rt 11.62 min), m/z (rel'. int.) 359 330 (100) 167 165 (14) 152 150 149 (38), 148 1-35 134 (13) 122 122 121 (73) 117 115 91 (23) 77 ComppouRF 167. (Rt 11.18 min), m/z (rel. int.) 359 330 (100OL, 136 121 Compound 168. (Rt 10. 86 min), m/z (rel. int.) 343 6), 314 (100) 167 (16) 166 165 (16) 152 134 (17), 133 (13) 132 118 (14) 117 115 (10) 106 106 105 (59) 91 (20) 77 Compound 169. (Rt 10.94 min), m/z (rel. int..) 343 314 (100) 167 (14) 166 165 (15) 152 134 133 (16) 132 132 118 (14) 117 115 106 WO 97/46511 PCT1US96/20697 221 105 (62) 91 (18) 77 Compound 170. (Rt 12.52 min), m/z (rel. int.) 374 345 (50) 315 207 (12) 194 193 (16) 179 168 167 166 (16) 165 (100) 164 164 (15) 152 (12) 136 (45) 117 (13) 115 (11) 104 103 91 90 77 Compound 171. (Rt 11.16 min), m/z (rel. int.) 341 182 181 (53) 168 167 (18) 167 (18) 166 165 (21) 152 (11) 144 132 (18) 131 (100) 129 (10) 128 120 (12) 118 117 116 (10) 115 (15) 106 104 103 91 77 Compound 172.
274 (95) 260 244 (41) 243 189 (18) 188 165 (38) 163 139 (58) 135 Compound 173.
260 (80) 259 (19) 229 (100 189 (25), (14) 164 (23) 121 Compound 174.
260 (27) 259 203 (12) 202 170 (12) 169 138 (Rt (18) (46) (36) (28) (20) (Rt (34) ,21 188 154 109 (Rt (17) (10) 8.53 min), m/z (rel. int.) 275 (M+,165), 259 (24) 258 (87) 257 (28) 254 (17), 242 (18) 233 (30) 214 (26) 201 (46), 183 181 180 (100) 178 (24), 154 150 149 148 (82), 133 (35) 109 8.44 min) m/z (rel. int.) 277 245 241 234 233 (23) 230 4 203 (12) 202 (17) 201 (25) 190 (18) 183 (18) 171 170 (15) 165 152 151 134 (12) 133 (13) 101 8.49 min) m/z (rel. int.) 291 234 (18) 233 (14) 230 (10) 229 (55) 201 (18) 189 (20) 188 (14) 183 168 (13) 165 (14) 164 152 151 137 134 133 (13) 109 (12) 101 57 44 (100), 42 Compound 175. (RC 9.64 min), m/z (rel. int.) 303 123 (47) 109 96 95 (40) 85 (26) 84 (100) 82 WO 97/46511 PCTJUS96/20697 222 75 68 56 55 43 42 (16).
Compound 176. (Rt 8.35 min), m/z (rel. int.) 277 24), 245 220 219 183 171 170 (10) 1,51 138 109 57 44 (100) 42 Compound 177. (Rt 7.83 min)-, m/z (rel. int.) 241 134 (30) 109 108 (100) 107 (16) 104 (17) 103 91 (12) 90 79. (10) 78 (14) 77 (24) 65 51 Compound 178. (Rt =8.29 min), m/z (rel. int.) 257 134 (17) 125 124 (100) 109 (23) 104 (10) 103 95 91 81 78 77 65 52 51 (6) Compoound 179. (Rt =7.88 min), m/z (rel. int.) 255,(M+,61, 148 (12) 115 108 107 104 (12) 103 91 79 78 77 65 51 44 (100), 42 Compound 180. (Rt 7.28 min), m/z (rel. int.) 295 183 (10) 162 (22) 145 143 (28) 135 (10) 134 (100), 133 (11) 132 (13) ,117 115 (12) 114 113 112 105 (17) 104 (57) 103 (32) 102 95 91 (18), 89 83 79 78 (28) 77 (28) 75 65 63 Compound 181. (Rt =7.7 min), m/z (rel. int.) 259 137 (16) 135 122 (15) 121 109 (15) 108 (100), 107 96 91 79 78 77 65 51 Compound 182. (Rt 8.00 min), m/z (rel. int.) 225 208 (51) 207 (40) 182 (14) 181 (100) 165 152 (24), 151 74 Compound 183. (Rt 8.98 min), m/z (rel. int.) 241 224 (33) 223 (46) 199 198 (15) 197 (100) 178 165 (28) 152 (13) 150 WO 97/46511 PCTUS96/20697 223 Compound 184. (Rt 8.90 min), m/z (rel. int.) 235 218 217 203 202 193 (10) 192 (67), 191 (100), 190 189 178 165 152 Compound 185. (Rt 7.37 min), m/z (rel. int.) 245 152 141 135 134 (100), 132 115 (14), 112 105 104 103 102 95 91 89 84 83 79 78 77 (44), 65 64 63 57 56 52 51 50 Compound 186. (Rt 7.31 min), m/z (rel. int.) 245 152 141 135 134 (100), 132 117 115 112 77 75 65 64 63 57 52 51 50 Compound 187. (Rt 8.64 min), m/z (rel. int.) 239 221 220 207 196 195 194 (14), 193 192 191 181 179 178 (100), 168 167 166 165 164 153 152 139 128 115 91 89 77 63 51 44. Example 30: Biological properties of synthesized arylalkylamines Compounds synthesized as described in Example 28 and Example 29 were tested for various biological properties detailed in the examples.
WO 97/46511 PCTIUS96/20697 224 Table 1 Compound
IC
5 s (pM) ICso (4M) vs. NMDA a vs. [3H]MK-801c Compound 1 0.102 126 (4) Compound 2 0.192 not tested Compound 3 0.003 not tested Compound 4 0.184 89 (1) Compound 5 0.102 15.2 (2) 0.070 3 )b Compound 6 0.129 100 (1) at 100 gM)d Compound 7 0.163 129 (1) Compound 8 0.099 219 (1) Compound 9 1.2 100 (2) at 100 /M) Compound 10 0.082 80 (57% at 80 IM)d Compound 11 4.0 not tested Compound 12 6.0 (11) 98 (1) Compound 13 not tested not tested Compound 14 8.8 100 kM Compound 15 4.9 100 4M .Compound 16 5.1 28.8 (1) Compound 17 9.6 36.3 (1) Compound 18 5.1 34 (1) Compound 19 0:435 (11) 2.1 Compound 20 0.070 (15) 0.252 (9) Compound 21 0.038 0.457 (2) Compound 22 0.145 3.45 (2) Compound 23 0.267 5.4 (1) WO 97/46511 PCT/US96/20697 225 Compound 24 0.206 0.591 (6) Compound 25 0.279 0.871 (2) Compound 26 27 34 (2) Compound 27 0.071 0.180 (2) Compound 28 0.380 2.3 (3) Compound 29 1.9 5.8 (3) Compound 30 0.035 0.407 (2) Compound 31 0.052 1.3 (2) Compound 32 0.284 0.799 (3) Compound 33 0.060 0.181 (6) Compound 34 0.426 2.7 (3) Compound 35 6.2 25.1 (1) Compound 36 not tested not tested Compound 37 0.944 11.1 (2) Compound 38 0.407 2.3 (2) Compound 39 0.251 2.9 (3) Compound 40 0.933 18.1 (3) Compound 41 0.724 14.0 (3) Compound 42 not tested not tested Compound 43 0.232 7.5 (2) Compound 44 not tested not tested Compound 45 not tested not tested Compound 46 0.013 5.2 (2) Compound 47 not tested not tested Compound 48 not tested not tested not tested not tested Compound 49 Compound 50 0.089 0.762 (4) PCT/US96/20697 WO 97/46511 226 Compound 51 Compound 52 Compound 53 Compound 54 Compound 55 .1 1 4.5 (2) 0.102 (3) 0.380 (2) 0.217 (3) 4.2 (2)
I
I
0.036 (4) 0.046 (3) 0.035 (3)
I
0.153 (2)
I
Compound 56 0.218 0.955 (2) Compound 57 0.028 0.063 (2) Compound 58 0.028 0.203 (3) Compound 59 0.272 0.453 (3) Compound 60 0.416 (11) 0.641 (9) Compound 61 0.134 0.324 (2) Compound 62 0.177 0.617 (1) Compound 63 0.093 0.245 (3) Compound 64 0.309 0.851 (2) Compound 65 0.167 2.0 (1) Compound 66 0.236 1.2 (2) Compound 67 10.95 2.9 (1) Compound 68 2.9 not tested Compound 69 0.224 0.366 (1) Compound 70 1.7 not tested Compound 71 6.35 not tested Compound 72 7.4 not tested Compound 73 12.6 not tested Compound 74 27.5 not tested Compound 75 0.94 not tested Compound 76 0.73 not tested Compound 77 5.5 not tested Compound 78 10.2 not tested PCT/US96/20697 WO 97/46511 227
I
Compound 79 Compound 80 Compound 81 Compound 82 Compound 83 Compound 84 Compound 85 Compound 86 Compound 87 12.6 (4) 10.2 (2)
I.
28 (1) 182 (1) 1.4 (1) 6.1 (2) 0.106 (5) 0.794 (1) 0.342 (4) 0.794 (1) I i 7.9 (2) 23.4 (1) 1.2 (3) 3.5 (1)
I
1.2 (3) 6.0 (1) I 0.657 (4) 3.0 (1) Compound 88 2.5 10.6 (2) Compound 89 0.240 1.2 (2) Compound 90 0.270 1.4 (2) Compound 91 0.162 14.1 (2) Compound 92 1.3 20.2 (2) Compound 93 0.486 26.9 (2) Compound 94 0.248 22.6 (2) Compound 95 0.311 3.0 (2) Compound 96 0.187 1.1 (2) Compound 97 0.410 2.6 (1) Compound 98 7.9 52.5 (2) Compound 99 100 105 (2) Compound 100 0.602 3.2 (1) Compound 101 0.912 2.0 (1) Compound 102 1.01 3.3 (1) Compound 103 0.380 (4) Compound 104 7.983 (3) Compound 105 1.03 (1) 0.661 (2) 10 (1) 3 (1) 1.31 (1) Compound 106 0.767 (1)
I
PCTIUS96/20697 WO 97/46511 228 Compound 107 Compound 108 Compound 109 2.67 (1) 3.83 (1) 1.06 (1) 1.95 (1) 0.942 (1) 1.08 (3) Compound 110 42.7 13.3 (1) Compound 111 0.645 0.167 (2) Compound 112 28.0 21.0 (1) Compound 113 13.5 not tested Compound 114 3.4 not tested Compound 115 1.4 1.0 (1) Compound 116 3.6 not tested Compound 117 19.6 6.0 (2) Compound 118 0.409 0.240 (3) Compound 119 0.115 0.087 (3) Compound 120 0.101 0.074 (3) Compound 121 0.656 0.670 (3) Compound 122 0.209 0.342 (2) Compound 123 9.6 3 (2) Compound 124 3.5 14.3 (3) Compound 125 1.7 6.7 (2) Compound 126 0.398 6.0 (1) Compound 127 1.2 17.5 (2) Compound 128 0.646 5.5 (1) Compound 129 1.26 not tested Compound 130 0..851 not tested Compound 131 1.23 not tested Compound 132 1.3 6.4 (1) Compound 133 0.760 3.0 (1) Compound 134 2.5 (1) 10 (1) .1 PCT/US96/20697 WO 97/46511 229- Compound 135 0.244 1.185 (2) Compound 136 0.139 0.706 (1) Compound 137 0.232 0.074 (2) Compound 138 107 100 (1) Compound 139 1.97 5.6 (2) Compound 140 20.8 not tested Compound 141 4.26 8.97 (1) Compound 142 1.013 1.54 (2) Compound 143 2.82 not tested Compound 144 not tested not tested Compound 145 0.098(1) 0.626(1) Compound 146 0.829 0.372 (1) Compound 147 0.894 not tested Compound 148 0.549 0.373 (2) Compound 149 0.085 0.150 (3) Compound 150 0.195 0.351 (2) Compound 151 54.9 100 (1) Compound 152 not tested not tested Compound 153 not tested not tested Compound 154 not tested not tested Compound 155 not tested not tested Compound 156 0.069 0.090 (2) Compound 157 0.142 23.16 (2) Compound 158 0.351 39.64 (1) Compound 159 0.185 10.41 (1) Compound 160 7.35 48.94 (1) Compound 161 0.247 5.62 (1) Compound 162 1.138 76.41 (1) PCTIUS96/20697 WO 97/46511 230 Compound Compound Compound Compound Compound Compound Compound 163 0.326 (2) 10.34 (1) 164 0.475 18.30 (1) L65 0.337 171 (1) 166 0.619 36.7 (1) 167 0.080 14.5 (1) 168 0.092 17.4 (1) 169 0.298 (2) 26.7 (1) 57.0 (1) i Compound 170 0.238 (2) Compound 171 0.310 39.6 (1) Compound 172 38.0 37.3 (1) Compound 173 22.9 24.1 (1) Compound 174 not tested 57.0 (1) Compound 175 not tested 5.1 (1) Compound 176 not tested 10.0 (1) Compound 177 not tested 0.754 (1) Compound 178 not tested 1.25 (1) Compound 179 not tested 1.67 (1) Compound 180 <100 1 0( 1 Compound 181 0.081 0.632(1) Compound 182 2.6 7.05(1) Compound 183 0.676 5.01(1) Compound 184 1.5 1.51(1) Compound 185 0.646 0.639(1) Compound 186 0..155 0.123(1) Compound 187 1.78 (1) Compound 188 not tested Compound 189 not tested Compound 190 not tested 12.01(1) not tested not tested not tested WO 97/46511 PCT/US96/20697 231 Compound 191 Compound 192 Compound 193 Compound 194 Compound 195 Compound 196 Compound 197 not tested not tested not tested not tested .1.
I
not tested
I
not tested not tested not tested not tested not tested not tested not tested not tested not tested Compound 198 not tested not tested Compound 199 not tested not tested Compound 200 not tested not tested Compound 201 not tested not tested Compound 202 not tested not tested Compound 203 not tested not tested Compound 204 not tested not tested Compound 205 not tested not tested Compound 206 not tested not tested Compound 207 not tested not tested Compound 208 not tested not tested Compound 209 not tested not tested Compound 210 Compound 211 Compound 212 not tested not tested not tested I not tested not tested not tested not tested
I
Compound 213 r not tested
I
Compound 214 not tested not tested Compound 215 not tested not tested a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example in parentheses WO 97/46511 PCT/US96/20697 232 indicates the number of experiments).
b:TFA salt.
c:Inhibition of [PH]MK-801 binding in rat cortical/ hippocampal washed membrane preparations (see Example 4).
d:ICsO study incomplete. inhibition at the stated concentration.
A comparison of the IC, 0 values in the RCGC assay with the IC 5 values in the 3 H]MK-801 binding assay (Table 1) illustrates that the arylalkylamines of the invention inhibit NMDA receptor activity by a mechanism different than that of binding to the MK-801 binding site; the concentration of the compound that inhibits NMDA receptor function is several orders of magnitude less than the concentration that competes at the site labeled by [3H]MK-801. This is not the case, however, with the simplified arylalkylamines exemplified by Compounds 19 215. Such compounds bind to the site labeled by [IH]MK-801 at concentrations ranging approximately 1 to 400-fold higher than those which antagonize-NMDA receptor-mediated function in the rat cerebellar granule cell assay.
Some of the simplified arylalkylamines disclosed have structural features similar to portions of other compounds which are utilized as, for example, anticholinergics, antiparkinsonians, antihistamines, antidepressants, calcium channel blockers, coronary vasodilators, opiate analgesics, and antiarrhythmics.
However, when certain of these compounds were evaluated for NMDA receptor antagonist potency (Example as can be seen in Table 2, none of the compounds tested, with PCTIUS96/20697 WO 97/46511 233 the exception of and (_a)-fendiline, nisoxetine, and the Eli Lilly compound, had IC5 0 values less than 1 u~M.
These data are summarized in Table 2.
Table 2 Compound Structure 1C 5 0 (riM) and vs. NMDAa Therapeutic utility (R)-fendiline -H -O 0.719 N (calcium channel blocker; coronary
C
vasodilator) (S)-fendiline HLI' H 0.686 (calcium channel blocker; coronary
CH
vasodilator) prenylamine -H (calcium channel blocker; coronary
C
vasodilator) pheniramine CH322 (antihistamine) N, CH PCTIUS96/20697 WO 97/46511 234 Table 2 chiorpheniranine C1 0-3 >100
II
brompheniramine Br 0-3 138 (antihistamine) CH3.
diphenhydranine 26 (antihistamine)
CHN
cH 3 doxylamine CHa- 3 62 (antihistamine; 0---C hypnotic) CH 3 chiorcyclizine NNCH3 (antihistamine) N~ N: C1 cyclizine N CH 3 28 (antiemetic) N N nor-cyclizine N"NH 23 (pharmaceutical
N
intermediate)7 PCTIUS96/20697 WO 97/46511 li do f la zir (calcium c blocker; c vasodi-atc pimozide ipsycl di sopyram (ant iarrh isopropal (antichol pridinol (anticho] ant ipark: chloropy: (antihis' :hannel :oroflary r)
NH
>100 ide zthxic) ide inergic) 10.7 i n~ergic; Lnsonian) *Ncf ram ine tarnine) trihexyphinidyl (ant ichol'riergic; ant iparkins onian) WO 97/46511 PCTIUS96/20697 236 f luoxetine (antidepressant) r
H
0T- ,C 00
F
3
C
13.4 zimeldine Br T> 26 (antidepressant) N..
methadone 0 H> 3 not tested (opiate analgesic) iH
OH
3 Astra compoundb (antidepressant) NH2 C H 3 00H 3 Novo-Nordisk <H3 not tested c ompoundc
CH
(calcium channel 0 blocker; 0 neuroprotectant)
F
3
C
No-vm-.erdisk NC,,i CH3 28.8 c ompoundd
NOH
3 (calcium channel0 blocker; Ca neuronrotectant) PCT1US96/20697 WO 97/46511 2 37 0 894 nisoxetifle (monoamine uptake inhibitor; antidepressant) terodiline (calcium channel blocker; anticholinergic; vasodilator) tomoxetine (monoamine uptake inhibitor; antidepressant) amitriptylile (serotonir' uptake inhibitor; antidepressant) irnipramne (serotonin uptake inhibitor; antidepressant) cdrmprarnine (serotonifi uptake inhibitor; antidepressant)
H
a r N-CH 3
(OCH
3 0.894 H CH3not tested O
H
3 C H 3
OCH
3
H
OH
3 0 aH3 not tested
I
not tested H 3 CH 3 not tested not tested I PCTIUS96/20697 WO 97/46511 238 a: Inhibition of NMDA/glycie-idu~ced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
WO97/46511 PCT/US96/20697 239 b: Disclosed as compound 2 in Table 4 in Marcusson et al., Inhibition of [3H]paroxetine binding by various serotonin uptake inhibitors: structure-activity relationships. Europ. J. Pharmacol. 215: 191-198, 1992.
c: Disclosed as compound 17 in Jakobsen et al., Aryloxy-phenylpropylamines and their calcium overload blocking compositions and methods of use. U.S. Patent No. 5,310,756, May 10, 1994.
d: Disclosed as compound 25 in Jakobsen et al., Aryloxy-phenylpropylamines and their calcium overload blocking compositions and methods of use. U.S. Patent No. 5,310,756, May 10, 1994.
e: Disclosed as Compound 1 in McQuaid et al., Inhibition of [PH]-MK801 binding and protection against NMDA-induced lethality in mice by a series of imipramine analogs Res.
Comm. in Pathol. and Pharm. 77:171-178, 1992.
Structure-activity relationship studies were initiated using Compound 19 as the lead structure. An examination of the side chain demonstrated that the propyl side.chain was optimal for NMDA receptor antagonist-potency (Table This finding was verified using Compound 20 as the lead structure (Table 3).
WO 97/46511 PCTIUS96/20697 24 0 Table 3 -diphenylpentylamine (Compound 71) 2,2-bis(3-flJuoropher1yl)-l- 7.9 ethylaine
NH
2 3,3-bis( 3-fluoropheflyl)-i- 0.070 propylamifle NH2 (Compound 4,4-.bis(3-fluoropheflyl)-l- -4.60 butylamine
-NH
(Compound 100) WO 97/46511 PCT/US96/20697 241 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
Further SAR studies examined the optimal pattern of phenyl ring substitution. Initial studies demonstrated that substitution of a halogen group (fluoro or chloro) at the meta position was optimal for NMDA receptor antagonist potency (Table Increasing the number of fluoro substituents led to an apparent decrease in potency (Table 4).
WO 97/46511 PCTIUS96/20697 2 42 Table 4 Compound Str-ucture 3,3 -dip'nenyl--propylaminfeN (Compound 19)
-NH
2 3-(2-fluoropohenyj)-3-(4-
F
fluorophenyl)
NH
propylamine (Compound 76)N
F
3, 3-bis (4-f luorophenyl) -1propylamine INH 2 (Compound 77)-
F
3, 3-bis (3-fluorophenyl) -1propylamine (Compound 3-(2-fluorophenyl)-3-(3-
F
fluoroptienyl)
INH
2 propylamine- (Compound 52)N WO 9746511PCTIUS96/20697 243 3, 3 -bis (2 fluoropnenyl) F0.217 propylamile (Compound 53) F 3, 3 -bis (3 -chloropnenyl) N0.052 propylamine cr
H
(Co~ound 31) 3-(3-fJluorophenyl)-3-(3- N0.035 chiorophenyl) clO NH 2 propylamine (Compound 3-(3-fJluorophenyl)-3- N0.284 phenyl-1 -propy2.amine e; NH 2 (Compound 32)
F
3- 5-difluorophenyl) F0.187 (3-fluorouheny,) -1-NH propoylarmine (Compound 96).
IN
b is 5, di.Jio.opheny) -I -IN propylamine
F
(Compound 97)N _F F_ 3,3-bis(3- 10.2 trifluoromethyl) phenyl- F -F 1-propylamine (Compound 78)N
CF
3 WO 97/46511 PCTIUS96/20697 244 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
Replacement of one of the fluoro groups on one phenyl ring with a methyl, methoxy or hydroxy group led to no change or a decrease in the in vitro NMDA receptor antagonist potency. The ortho position was optimal for this methyl, methoxy or hydroxy group, and the rank order of potency for this substitution was methyl methoxy hydroxy (Table Also illustrated in Table are those compounds possessing the 3,3-bis(3fluorophenyl) moiety with additional methyl or methoxy substitutions on the phenyl rings, often leading to an increase in NMDA receptor antagonist potency. Table also illustrates those compounds possessing the 3,3bis(2-methylphenyl) or 3,3-bis(2-methoxyphenyl) moiety in place of the 3,3-bis(3-fluorophenyl) moiety; these substitutions are acceptable, although a decrease in potency is noted.
PCTIUS96/20697 WO 97/46511 245 Table -5 Compound Structure ICS 0 (PJX) vs.
MDA&
3, 3-bis (3-fluorophenyl) -1-N007 propylamine NH (Compound 3-(3-fluorophenyl)-3-(2-
CH
3 0.071 methyiphenyl) IH propylamine (Compound 27)N 3-(3-fluorophenyl)-3-(3- N0.380 methyiphenyl) H 3 C NH 2 propylamine (Compound 28)N -fluorophenyl)-3-(4-
H
3 N1.9 methyiphenyl) -1-N 2 propylamine (Compound 29)N 3-(3-fluoropheriyl)-3-(2- OCH 0.206 methoxyphenyl)-l--
NH
2 ,p2opyJlamine (Compound 24) I PCTIUS96/20697 WO 97/46511 246 3-(3-fluoropheflyl)- 3 N0.279 metbhoxyphenyl)
H
3 CO
H
propyJlamine (Compound 3-(3-fluorophenyl)-3-(4-
H
3 C N 27 methoxyphenyl) NHi2 propylamine (Compound 26) 3-(2-methoxypheflyl)-3-
NOCH
3 .tt4_ phenyl-1 -propylamirie
H
(Compound 97) 3-(2-hydroxyphenyl)-3-(3- N0.380 f luorolphenyl) 1- F
H
propylamine (Compound 103)N 3-(3-hydroxyphenyl)-3-3- 0.912 fluorophenyl) -1-F propylamine (Compound 101)N 3-(3-fluotophenyl)-3-(2- I N- 0.218 tnethyJ-3-fJluorophenyl)-l -1
NH
2 _propylamine
H
3 (Compound 56)N 3-(3-fluorophenyl)-3-(3- N0.028 fJluoro-6-methyjlphenyl) F- NH 2 propylamine CH 3 (Compound 57)N WO 97/46511 PCTIUS96/20697 247 3,3-bis(3-fluoro-6- 0.028 methylphenyl)
N
propylamine S (Compound 58).
3-(3-fluorophenyl)-3-(3- H 0.134 fluoro-G--methox-ypheliyl)
NH
2 propylamnune (Compound 61) 3, 3-bis (2-metbyiphenyl)-i-
CH
3 propylamine (Compound 65) H 3,3-bis(2-methoxyphenyl)- OCH3 0.177 1-propyla.rrine Nli (Compound 62) H 3
C
3,3-bis(3-methoxyphenyl)-1.
1-propylamile
H
3 CO
H
(Compound 115)
H
3 WO 1 PCT/US96/20697 WO 97/46511 248 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
The next series of SAR experiments investigated the effect of alkyl chain substitutions (branching patterns) on NMDA receptor antagonist potency in vitro. The addition of a methyl group on either the a or 6 carbon on the propyl side chain led to a decrease or no change in potency, respectively (Table 6).
WO 97/46511 PCTIUS96/20697 249 Table 6 Compound Str~ucture
IC
50 (PIM) vs.
NHDA a 3, 3-bi s(3 fluoro-ohenyl) 1- 0.070 propylamine -a
NH
2 (Compound 3, 3-bis (3 fluorophey 1) -2 N CH3 I38 methyl-l-propylaminfe
H
(Compound 21) 3,3-bis(3-fluorophenyl)-2- N CH 3 0.060 methyl-l-propylamile F-NH 2 (Compound 33) 3,3-bis(3-fluorophenyl)-2- N H 3 0.426 methyl-1-propylamifle
NH
2 (Compound 34) 3,3-bis(3-fluarophenyl)-1- 0.145NH methyl -2.-propylaimine
H
(Compound 22)
CH
3 3, 3-bis (3-fluorophenyl) -1> methyl-i -propylamine (Compound 0.089 L WO 97/46511 250 3, 3-bis (3-fluorophel)- methyl-i -propylamile (Compound 51) 3, 3-bis (3-fluorophelyl) -2ethyl -1-propylamile (Compound 3, 3-bis (3-f luorophenyl) -1ethyl -1-propylamile (Compound 23) 3, 3-bis (3-fluorophelyl) -2hydroxyethyi -1-propylain~fe (Compound 54) 3, 3-bis (3-fluoropheflyl) -3ethyl-i -propylamifle (Compound 82) 3 ,3-bis (3-fluorophelyl) 1, 2 -imethyl-i-propylamile (Compound 38) 3, 3-bis fluorophelyl) 2, 2-dimethyl-l-propylalUife (Compound 41) 3, 3-bis (3-fluorophenyl) 2, 2-diethyl-l-propylanine (Compound 80) PCTIUS96/20697 F F Cc WO 9746511 PCTIUS96/20697 251 a:Inhibition of NMDA/glycifle-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
The next series of SAR experiments investigated the effect of incorporation of a double bond within the propyl chain on NMDA receptor antagonist potency in vi tro (Table As can be seen in Table 7, the incorporation of a double bond decreased potency in a consistent manner.
Table Compound Structure
ICS()
(M)vs.
3,3-bis(3-fluoropheflyl)-l- 0.070 propylamine
NH
2 (Compound 3,3-bis(3-fluoropheflyl)- 1.4 prop-2 -ene-l-arznineF-
H
(Compound 139) 3,3 -diphenyl-l-propyJlamifle N0.435 (Compound 19)
H
IN
PCTIUS96/20697 WO 97/46511 252 3, 3-diphenyl-prop-2-ene-1-1.
amine
NH
2 (Compound 81) 3- (3-f luorophenyl) -3phenyl -2.-propyl.amine (Compound 32)
NH
2
FI
0.284 i i* 3 (3 fluorophenyl) -3 phenyl-prop-2-ene---aU-ne (Compound 2.07) 2 .67 3, 3-bis (3-methoxyphelyl) 1 -propyJlamine (Compound 115) 3, 3-bis (3-methoxyphenyl) prop-2 -ene-1-amine (Compound 116) 1.9 1 4.47 WO 97/46511 PCT/US96/20697 253 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
The next series of SAR experiments investigated the effect of incorporation of the propylamine chain into a ring structure on NMDA receptor antagonist potency in vitro (Table 8).
WO 97/46511 PTU9109 PCTIUS96/20697 254 3, 3-bis (3-f luoroohenyl) -1propyl amine (Compound Compound 63 Compound 64 1.01 Compound 102 Compound 84 Compound III Compound 112 WO 97/46511 PCT/US96/20697 255 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
The next series of SAR experiments investigated the effect of simple alkyl substitution on the nitrogen on NMDA receptor antagonist potency in vitro (Table 9).
PCTIUS96/20697 WO 97/46511 256 Table 9 Compound Structure
ICS()
(jim) vs.
NMDA
3, 3-bis (3-f2.uoroheny2- NN 0.070 Oropyiaxrine F-
N
(Compound N-rehy-3, 3 -bis(> N H 0.416 f lucrop'nenyl) -1
NCHI
propylamine (CompDound N-ethyl-3, 3-bis (3 H 0.272 'Lluorophenyl) 1- F N 1-CH 3 propylamifle (Compound 59)FN N,N-dimet.y-3,3-bis( 3 NC 1 9.6 f1uoromhenyl) N, CHI propylanu~fle (Compound 123) 3-(3-fluorophenyl)- 3 0NH8 phenyl -2.-propylane
-Z
(Compound 32) F 1.06 N'-methyl 3- (3 fluorophenyl) -3 -phenyl-lpropylamnfe (Compound 108) 3 ,3-diphenylpropylaminfe (Compound 19) 0.435 I WO 97/46511 PCTIUS96/20697 257 N-met-hyl-3,3- H 10.95 ciiphenylpropylamine N CH (Compound 67) N-ethyl-3,3- IH 2.9 diphenylprocylami4ne N..C H, 3 (Compound 68) N,N-dimethyl-3,3- N, H-3 12.6 dliphenylpromylamine
H
(Compound 73) N-isopropyl-3, 3- NH 7.4 diphenylpropylamine _rH (Compound 72) CH *N,N-diethyl-3, 3diphenylprocylamiLne kCH (Compound 74)
K
WO 97/46511 PCTIUS96/20697 258 a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
Certain simplified arylalkylamine compounds were selected for evaluation of activity in a battery of neurotransmitter receptor binding assays, and for activity against the L-type calcium channel and delayed rectifier potassium channel. The compounds were inactive (less than 50% inhibition at concentrations up to 10 uM) in the following assays: nonselective a2 adrenergic receptor ([H]RX 821002 binding in rat cortex), H1 histamine receptor ([PH]pyrilamine binding in bovine cerebellum), nonselective sigma receptor ([RH]DTG binding in guinea pig brain), nonselective opiate receptor ([PH]naloxone binding in rat forebrain), monoamine oxidase (MAO) activity, both MAO-A (["C]serotonin metabolism in rat liver mitochondria) and MAO-B (["4C]phenylethylamine metabolism in rat liver mitochondria) As can be seen in Table 10, activity was noted for several compounds at concentrations below 10 tM in the following assays: L-type calcium channel, delayed rectifier potassium channel, central muscarinic cholinergic receptor binding, and monoamine (dopamine, norepinephrine, and serotonin) uptake binding assays.
This profile of activity in the central muscarinic cholinergic receptor and monoamine uptake binding assays is not unexpected,- given the chemical structures of our simplified arylalkylamines (refer to Table 2 above).
With the exceptions, however, of the activity of Compound 19 in the serotonin uptake binding assay, the WO 9746511PCTIUS96/20697 259 activity of Compound 34 in the dopamine uptake binding assay, the activity of Compound 50 in the serotonin uptake binding assay, the activity of Compounds 63 and 64 in the dopamine uptake binding assay, and the activity of Compound 60 in the dopamine and serotonin uptake binding assays, the simplified arylalkylamine compounds were most potent at the NMDA receptor.
Table Compound IC,O (MsM) L-type Delayed Central Monomine vs. NMDAI calcium rectifier muscarinic uptake channelb potassium cholinergic binddng channelc receptord assays- .0 Compound 0.435 10.2 1-10 4%-0 at 7%0 at 19 0.174% at 0. 11750- at 10131- at 0.1953*6 at 1091806 at 0.1h89*i at 1 Oh Compound 0.070 2.2 1-10 8%6 at at 0.190% at 0.1181l6 at at 0 1958% at 10g280- at 0 .1h 940- at 1 Qh Compound 0.060 1.6 >10 421 at 23%* at 33 0.199% at 0.1186%6 at 10120% at 0.1954*6 at 1091406 at 0 1h89% at lOh PCT/US96/20697 WO 97/46511 260 Compound 0.426 not 10 25%1 at 6001 at 34 tested 0.199%1 at 0.1199% at 10110'6 at 0.1964% at 10g12% at 0.1,790- at Compound 0.089 not 10 11% at 17%6 at so tested 0.184%1 at 0.1193% at at 0.1978% at 10975% at 0 .lh9701 at Compound 0.013 0.676 -3 33% at 40% at 46 0.189%1 at 0 .1i97%i at 101701 at 0.1964% at 10910'-. at 0 Jh75% at 1 Qh Compound 0.0 93 1.9 not 11%, at 64%6 at 63 tested 0. 181%-o at 0 1f98% at 1017% at 0.1g76% at.
10913% at 0.11,85% at Compound 0.309 not not 11% at 50%1 at 64 tested tested 0.183% at 0.lf9906 at lbf 8%6 at 0.1965% at 10929% at 0 .1h 68% at loh WO 97/46511 PCTIUS96/20697 261 Compound 0.028 1.6 not 1% at 0% at 58 tested 0.148% at 0.1'45% at 10'1% at 0.1967% at 10927% at 0.1"95% at Compound 0.272 not not 9% at 2% at 59 tested tested 0.187% at 0.1'78% at 1017% at 0. 151% at 10914% at 0.1"86% at Compound 0.416 2.3 not 13% at 0.914?16% tested 0.193% at at 0.1964% at 109 0.068" a:Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1).
b:Inhibition of KC1 depolarization-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGCs); estimated IC,, value in uM.
c:Inhibition of delayed rectifier potassium channel in cultured N1E-115 neuroblastoma cells; estimated ICs, value in 4M.
d:Inhibition of the binding of [3H]quinuclidinylbenzilate (QNB) to rat cortical membranes; percent block at indicated concentration in MM.
e:Inhibition of the binding of ['H]WIN-35,428 to guinea pig striatal membranes (dopamine uptake binding assay), ['H]desipramine to rat cortical membranes (norepinephrine uptake binding assay), or citalopram to rat forebrain membranes (serotonin uptake binding assay); percent WO 97/46511 PCT/US96/20697 262 block at indicated concentration in MM, or ICs when available.
':dopamine uptake binding assay 9:norepinephrine uptake binding assay h:serotonin uptake binding assay Advantageous properties of the arylalkylamine compounds of the present invention are illustrated by the fact that concentrations which suppress NMDA receptor-mediated synaptic transmission fail to inhibit LTP. Furthermore, while compounds such as Compound 9, and 11 do produce a hypotensive response following systemic administration in rats, the hypotensive effect produced by these compounds is of a relatively short duration (approximately 30 min). Additionally, Compounds 12 and 14 have no cardiovascular activity at doses up to 37.3 gmoles/kg i.v. and 15 gmoles/kg i.v., respectively.
PCT1US96/20697 WO 97/46511 263 Table 11 Compound Suppression of NMDA LTP Assayb Drop in Mean Receptor-Mediated Arterial Blood Synaptic Pressurec Transmissiona Compound 1 10 30 gM no block at 65 mm Hg at 300 gM 1.5 gmoles/kg 60 min duration 30 4M no block at 40 mm Hg at Compound 2 100 )M 1.5 pmoles/kg 120 min duration Compound 3 10 30 MM not tested 20 mm Hg at' mg/kg min duration Compound 4 10 100 AM no block at 40 mm Hg at 100 UM 1.5 pmoles/kg 120 min duration Compound 9 10 100 MM no block at 75 mm Hg at 300 4M 4.5 Amoles/kg 90 min duration Compound 11 not tested not tested 20 mm Hg atl mg/kg min duration not tested not tested no effect at Compound 12 doses up to 37.3 pmoles/kgi.v.
Compound 14 not tested not tested no effect at doses up to pmoles/kg i.v.
Compound 19 100 300 pM block at 100 not tested pM PCT/US96/20697 WO 97/46511 264 Compound 20 30 300 MM block at 100 no effect at 'M doses up to umoles/kg i.v.
Compound 22 not tested not tested no effect at doses up to moles/kg i.v.
a:Concentration which suppresses NMDA receptor-mediated synaptic transmission (see Example b:Concentration that does not block the induction of LTP (see Example 19).
c:Drop in systemic blood pressure produced by administration of compound in rats (see Example 22).
WO97/46511 PCT/US96/20697 265 Formulation and Administration As demonstrated herein, useful compounds of this invention and their pharmaceutically acceptable salts may be used to treat neurological disorders or diseases. While these compounds will typically be used in therapy for human patients, they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.
In therapeutic and/or diagnostic applications, the compounds of the invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton PA (18th ed. 1990).
Pharmaceutically acceptable salts are generally well known to those of ordinary skill in the art, and may include, by way of example but not limitation, acetate, benzenesulfonate, besylate, benzoate, bicarbonate, bitartrate, calcium edetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/disphosphate, polygalacturonate, WO97/46511 PCT/US96/20697 266 salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, or teoclate. Other pharmaceutically acceptable salts may be found in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA (18th ed. 1990).
Preferred pharmaceutically acceptable salts include, for example, acetate, benzoate, bromide, carbonate, citrate, gluconate, hydrobromide, hydrochloride, maleate, mesylate, napsylate pamoate (embonate), phosphate, salicylate, succinate, sulfate, or tartrate.
The useful compounds of this invention may also be in the form of pharmaceutically acceptable complexes. Pharmaceutically acceptable complexes are known to those of ordinary skill in the art and include, by way of example but not limitation, 8-chlorotheophyllinate (teoclate).
The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1).
It should be noted that the attending physician would know how and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunction. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical responses were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with WO 97/46511 PCT/US96/20697 267 the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
Depending on the specific conditions being treated, such agents may be formulated into liquid or solid dosage forms and administered systemically or locally. The agents may be delivered, for example, in a timed or sustained-release form as is known to chose skilled in the art. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA (18th ed. 1990). Suitable routes may include oral, buccal,. sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration; parenteral. delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.
For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated WO 97/46511 PCT/US96/20697 268 are used in the formulation. Such penetrants are generally known in the art.
Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
Agents intended to be administered intracellularly may be administered using techniques well known- to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external-microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be WO 97/46511 PCT/US96/20697 269 directly administered intracellularly.
Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, by means of conventional mixing, dissolving., granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid ester, such as ethyl oleate or triglycerides, or liposomes. Aqueous WO 97/46511 PCT/US96/20697 270 injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose (CMC), and/or polyvinylpyrrolidone (PVP: povidone). If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments may be added WO 97/46511 PCTIUS9620697 271 to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs). In addition, stabilizers may be added.
Other embodiments are within the following claims.

Claims (6)

1. A compound of the formula: R4 R NH 2 R 1 R 2 (X)m wherein: X is independently selected from the group consisting of-Br, -Cl, -CF 3 alkyl, -OH, -OCF 3 -0-alkyl, and -0-acyl; RI is independently selected from the group consisting of-H, lower alkyl and -0-acyl; R 2 is independently selected from the group consisting of alkyl, and hydroxyalkyl, or both R 2 s together are imino; R 4 is phenoxy which is optionally substituted with -Cl, -Br, -CF 3 alkyl, -OH, -OCF 3 -0-alkyl or -0-acyl; provided that when X is H, then R 4 is substituted with meta-fluoro, meta-chloro, ortho- methyl, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and 1 complexes thereof.
2. A compound of the formula: R 2 NR RNH2 R1 ,2 wherein: X is independently selected from the group consisting of-Br, -Cl, -CF 3 alkyl, 20 -OH, -OCF 3 -0-alkyl, and -0-acyl; RI is independently selected from the group consisting of-H, lower alkyl and -0-acyl; R 2 is independently selected from the group consisting of alkyl, and hydroxyalkyl, or both R 2 s together are imino; R 4 is phenoxy which is optionally substituted with -Cl, -Br, -CF 3 alkyl, -OH, -OCF 3 -0-alkyl or -0-acyl; R provided that when X is H, then R 4 is substituted with meta-fluoro, meta-chloro, ortho- methyl, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and [I:\DAYLIB\libaa]08021.DOC:kww 273 m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.
3. A compound of the formula: R 1 R4 aR 'NHR3 R 2 (X)m wherein X is independently selected from the group consisting of-F, Cl, -Br, -CF3, alkyl, -OH, -OCF 3 O-alkyl, and -O-acyl; R 1 is independently selected from the group consisting of lower alkyl, and alkyl; R 2 is independently selected from the group consisting of lower alkyl, and hydroxyalkyl, or both R 2 s together are imino; R 3 is selected from the group consisting of methyl and ethyl; R 4 is phenoxy which is optionally substituted with Cl, -Br, -CF 3 alkyl, -OH, -OCF 3 O-alkyl or -0-acyl; provided that when X is para-fluoro, R 4 is not meta-CF 3 -substituted phenoxy; and m is S '15 independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.
4. A compound of the formula: R 1 R4 R NHR 3 RI 2 R (X)nr wherein: S 20 (X)m is selected from the group consisting of meta-fluoro, meta-chloro, ortho-O-lower alkyl, ortho-methyl, ortho-fluoro, ortho-chloro, meta-O-lower alkyl, meta-methyl, ortho- OH, and meta-OH; RI is H; R2 is H; R 3 is selected from the group consisting of methyl and ethyl; [I:\DAYLIB\Iibaa]08021 .DOC:kww 274 R 4 is phenoxy which is optionally substituted with -Cl, -Br, -CF 3 alkyl, OH, -OCF 3 -O-alkyl, or -0-acyl; and pharmaceutically acceptable salts and complexes thereof. A compound of the formula R2 NHR 3 (X)m- wherein: X is independently selected from the group consisting of -Br, -Cl, -CF 3 alkyl, -OH, -OCF 3 -0-alkyl, -0-acyl; R 1 is independently selected from the group consisting of-H, alkyl, hydroxyalkyl, -OH, -0-alkyl, and -0-acyl; R 2 is independently selected from the group consisting of alkyl, and hydroxyalkyl, or both R 2 s together are imino; SR 3 is independently selected from the group consisting of-H, methyl, and ethyl; R 4 is phenylthio which is optionally substituted with -Cl, -Br, -CF 3 alkyl, 15 OH, -OCF 3 -0-alkyl, or -0-acyl; and m is independently an integer from 0 to 5; and pharmaceutically acceptable salts and complexes thereof.
6. A compound selected from the group consisting of Compound 118 NH2 e* 0 2 S*1i S K f^ [I:\DAYLIB\ibaa]08021.DOC:kww 275 Compound 119 NH 2 Compound 120 ,NH 2 Compound 121 S. S. S S 5 0 0*S S *0 55 S S S S egos 0000 Compound 122 NH 2 Compound 137 .NH 2 [I:\DAYLIB\libaa]08021 .DOC:kww 276 Compound 145 NH H Compound 148 ~NH 2 Compound 149 NH 2 Compound 150 NH 2 Compound 177 NH 2 A p p. p p p p p p. p. p.p. p a p p a a p ppp p [I:\DAYLIB\libaa]0802 I .DOC:kww Compound 181 ~.NH 2 Compound 185 Compound 186 NH 2 a* S S S S. S. S S S S 5* S S *SSSS S S
55.. S S S S S S *SSS i S S. S 555 S S Compound 191 [1:\DAYLIB\Iibaa]08021 .DOC:kww 278 Compound 192 NH 2 Compound 198 S. 5 S S S. S S p. 5 5 0 *S S S S *55p p S *5*S 9 S 5 9 *5*5 S S OS S S S *.SS Compound 199 F ~NH, H and pharmaceutically acceptable salts and complexes thereof. 7. The compound of claim 6, selected from the group consisting of Compound 118 [I:\DAYLIB\Iibaa]08021 .DOC:kww 279 Compound 119 NH 2 Compound 120 *1 9 9 9 *99 9 90 9 99 9 0* 9 6 9 0 9*9 9 99 99 9 9 9 9 'OCH 3 Compound 121 NH 2 Compound 122 NH 2 Compound 137 NH 2 9 9 9*9* 99*s 9 9 .9 9. 9 9 9 V.. 9 9. .9 9@9 9 [I:\DAYLIB\libaa]08021 .DOC:kww 280 Compound 145 NH H Compound 148 6O 0 0 000 0 00 0 00 00 0 60 0 0 0 0 *00 S 00 00 0 0 0 S S 000050 0 0000 0 0 0005 OSOS 0 0 *0*0 00 0 0 S S .54. 0000 0 S OSSO 00 0 OSO S OSOS 0 S 0@*0 Compound 149 Compound 181 ,NH 2 [1:\DAYLIB\libaa]0802 1. DOC:kww Compound 185 .NH 2 Compound 186 NH 2 0* 0* 0 0* 00 0 0 0*0**0 0 0000 0 0 000* 0 0 *000 0 0 0 0 0000 0 0 000 0 0 0000 Compound 191 Compound 192 NH 2 [I:\DAYLIB\ibaa]08021 .DOC:kww 282 Compound 198 C C Compound 199 z NH, F H 8. The compound of claim 6, selected from the group consisting of: Compound 119 Compound 137 [L:\DAYLLB\libaa]08021 .DOC:kww Compound 185 Compound 186 NH 2 0 9. A compound having the chemical structure: 00 9* .00. .0* .0.0 000. Compound 119 NH 2 and pharmaceutically acceptable salts and complexes thereof. A compound having the chemical structure: Compound 137 NH 2 [L:\DAYLIB\libaa]08021 .DOC:kww 284 and pharmaceutically acceptable salts and complexes thereof. 11. A compound having the chemical structure: SCompound 185 and pharmaceutically acceptable salts and complexes thereof. 12. A compound having the chemical structure: a a a, Compound 186 NH 2 0 F and pharmaceutically acceptable salts and complexes thereof. 13. A pharmaceutical composition, comprising a compound as in any one of claims 1 to 5 or 8 to 11, and a pharmaceutically acceptable carrier. 14. A pharmaceutical composition, comprising a compound of claim 6, and a 1i pharmaceutically acceptable carrier. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition is adapted for the treatment of a neurological disease or disorder. 16. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition is adapted to provide neuroprotection to a patient. 17. The pharmaceutical composition of claim 14, wherein said compound is a hydrochloride salt. 18. The pharmaceutical composition of claim 15, wherein said compound is a "hvdrochloride salt. [I:\DAYLIB\libaaI0802 1.DOC:kww 285 19. The pharmaceutical composition of claim 16, wherein said compound is a hydrochloride salt. A method for treating a patient having a neurological disease or disorder, the method comprising administering a compound as in any of claims 1 to 5 or 7 to 12. 21. A method for treating a patient having a neurological disease or disorder, the method comprising administering a compound as in claim 6. 22. The method of claim 21, wherein said neurological disease or disorder is selected from the group consisting of stroke, head trauma, spinal cord injury, epilepsy, anxiety, Alzheimer's disease, Huntington's disease, Parkinson's disease, and arnyotrophic lateral sclerosis. 23. The method of claim 22, wherein said neurological disease or disorder is a stroke. 24. The method of claim 22, wherein said neurological disease or disorder is head trauma. 25. The method of claim 22, wherein said neurological disease or disorder is spinal cord injury. 26. The method of claim 22, wherein said neurological disease or disorder is S: epilepsy. 27. The method of claim 22, wherein said neurological disease or disorder is anxiety. 28. The method of claim 22, wherein said neurological disease or disorder is Alzheimer's disease. 29. The method of claim 22, wherein said neurological disease or disorder is Huntington's disease. 25 30. The method of claim 22, wherein said neurological disease or disorder is Parkinson's disease. 31. The method of claim 22, wherein said neurological disease or disorder is amyotrophic lateral sclerosis. 32. The method of claim 23, wherein said stroke is global ischemic. 33. The method of claim 23, wherein said stroke is hemorrhagic. 34. The method of claim 23, wherein said stroke is focal ischemic. A method for providing neuroprotection to a patient, comprising administering a compound as in any one of claims 1 to 8. 36. The method of any one of claims 20 to 35 wherein the compound is S administered in the form of the pharmaceutical composition of any one of claims 13 to 19. [I:\DAYIBibaa]08021.DOC:kww [I:\DAYLIB\libaa]0802i .DOC:kww 286 37. A compound of any one of claims 1 to 12 or a pharmaceutical composition of any one of claims 13 to 19 when used for treating a patient having a neurological disease or disorder. 38. Use of a compound of any one of claims 1 to 12 in the manufacture of a medicament for treating a patient having a neurological disease or disorder. Dated 6 June, 2000 NPS Pharmaceuticals, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *r S S S.. [I:\DAYLIB\libaa]08021 .DOC:kww
AU13525/97A 1996-06-07 1996-12-11 Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases Ceased AU723349B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU71810/00A AU770292B2 (en) 1996-06-07 2000-11-24 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU2004202114A AU2004202114A1 (en) 1996-06-07 2004-05-18 Compounds Active at a Novel Site on Receptor-operated Calcium Channels Useful for Treatment of Neurological Disorders and Diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66301396A 1996-06-07 1996-06-07
US08/663013 1996-06-07
AU12837/97 1996-12-06
US9619525 1996-12-06
PCT/US1996/020697 WO1997046511A1 (en) 1996-06-07 1996-12-11 Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU71810/00A Division AU770292B2 (en) 1996-06-07 2000-11-24 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Publications (2)

Publication Number Publication Date
AU1352597A AU1352597A (en) 1998-01-05
AU723349B2 true AU723349B2 (en) 2000-08-24

Family

ID=24660155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13525/97A Ceased AU723349B2 (en) 1996-06-07 1996-12-11 Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Country Status (4)

Country Link
EP (1) EP0912494A1 (en)
JP (1) JP2002511835A (en)
AU (1) AU723349B2 (en)
WO (1) WO1997046511A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268166B2 (en) 1993-02-08 2007-09-11 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211245B1 (en) 1993-02-08 2001-04-03 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6750244B2 (en) 1993-02-08 2004-06-15 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) * 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP2001525390A (en) * 1997-12-10 2001-12-11 エヌピーエス ファーマシューティカルズ インコーポレーテッド Anticonvulsants and central nervous system active bis (fluorophenyl) alkylamides
EP1640359A3 (en) * 1997-12-10 2006-04-05 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
ATE355054T1 (en) * 1998-07-13 2006-03-15 Nps Pharma Inc METHODS AND COMPOUNDS FOR TREATING DEPRESSION
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
BRPI0411131A (en) 2003-06-11 2006-07-18 Merck & Co Inc compound, method of treating a cannabinoid receptor-mediated disease 1, method of preventing obesity in a person at risk for obesity, composition, and use of a compound
MXPA06014018A (en) 2004-06-01 2007-02-08 Hoffmann La Roche 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor.
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
BRPI0619247A2 (en) 2005-11-30 2011-09-20 Hoffmann La Roche Methods for Synthesis of 3-Amino-1-Aryl-Propyl Indoles
RU2008120141A (en) 2005-11-30 2010-01-10 Ф. Хоффманн-Ля Рош Аг (Ch) 3-AMINO-2-ARILPROPYLAZINDOLES AND THEIR APPLICATIONS
CN101316818B (en) 2005-11-30 2011-08-31 弗·哈夫曼-拉罗切有限公司 3-amino-1-arylpropyl indoles and aza-substituted indoles
RU2541430C2 (en) 2007-10-05 2015-02-10 Акусела Инк. Compositions and methods of treating neurodegenerative diseases
JP5860398B2 (en) 2009-07-02 2016-02-16 アキュセラ インコーポレイテッド Pharmacology of visual cycle modulators
CN111225901B (en) * 2017-10-16 2023-07-04 埃斯特韦制药股份公司 Propylamine derivatives for the treatment of pain and pain-related disorders
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1793735C3 (en) * 1967-02-18 1975-01-30 Boehringer Mannheim Gmbh, 6800 Mannheim Tricyclic amino alcohols and their nontoxic salts and processes for their preparation
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
PT743853E (en) * 1994-02-08 2001-10-31 Nps Pharma Inc ACTIVE COMPOUNDS IN A NEW LOCATION IN CALCIO CANIS ACTIVATED BY A UTEIS RECEIVER FOR THE TREATMENT OF NEUROLOGICAL DISTURBACTIONS AND DISEASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268166B2 (en) 1993-02-08 2007-09-11 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Also Published As

Publication number Publication date
AU1352597A (en) 1998-01-05
EP0912494A1 (en) 1999-05-06
WO1997046511A1 (en) 1997-12-11
JP2002511835A (en) 2002-04-16

Similar Documents

Publication Publication Date Title
EP0831799B1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
AU723349B2 (en) Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU710575B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6750244B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7268166B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6211245B1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU770292B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CA2257234C (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU2004202114A1 (en) Compounds Active at a Novel Site on Receptor-operated Calcium Channels Useful for Treatment of Neurological Disorders and Diseases
CA2560002A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)